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Abstract
Recent advances in genetics have resulted in the identification of mutations respon-
sible for a number of genetic disorders which, in turn, have led to the development
of genetic tests. The use of genetic testing raises the issue of who should be al-
lowed access to the results; in particular should insurers be allowed to use genetic
test results when calculating premium rates? At the moment there is a self-imposed
moratorium in the UK preventing insurers from using the results of presymptomatic
genetic tests until more investigation is carried out.
It is well-established that critical-illness (and sometimes life) insurance cannot be
offered to mutation carriers. However such conclusions have (necessarily) been based
on the published medical studies available, few of which include the detail needed
to reconstruct the data. At the same time, the Genetics and Insurance Committee
(GAIC) is setting out criteria that must be met if any genetic tests may be used
in underwriting. These criteria cover questions of reliability that from a statistical
point of view must include the estimation of insurance premiums from medical or
epidemiological data. This question is rarely addressed: we address it in this thesis
using pedigree data for Huntingon’s Disease and BRCA1-related breast and ovarian
cancer.
In particular, we study the extent to which ascertainment bias, long known to affect
pedigree analysis, affects the actuarial questions of pricing insurance. Having direct
access to pedigree data gives us a unique opportunity to analyse how the sampling
uncertainty inherent in the data translates into sampling uncertainty in actuarial
quantities such as premium rates; moreover, allowing for ascertainment bias and
adjustments to remove it. In particular, we are able to assess the validity of ad hoc
adjustments to onset rates used by other authors.
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Chapter 1
Introduction
In the past 20 years the study of human genetics has advanced considerably and
the genes responsible for many disorders have been identified. As a result presymp-
tomatic genetic tests have been developed that can determine whether a person
carries specific disease-related mutations and, subsequently, give a measure of the
risk of developing the disease.
Some rare genetic disorders, such as Huntington’s Disease, are purely genetic, and
the gene mutation that has been identified occurs in all people who have the dis-
order. There is a 50% chance that a person has the associated mutation if one of
their parents is a carrier, so a genetic test will inform an individual at 50% risk if
their actual risk of having the mutation is 100% or 0% and, therefore, if they have
a very significant risk of developing the disorder or no risk whatsoever.
For some other diseases, such as breast cancer, the genes that have so far been
identified do not explain all cases of the disorder. Therefore, although there is a
higher risk of breast cancer if a particular mutation is present, there is still a high
chance of developing breast cancer in the absence of a known mutation.
While genetic tests inform people of their risks of developing a disorder there are
worries that a result which reveals a high risk will disadvantage them, particularly
when buying life and critical illness insurance.
From this arises the question of whether insurance companies should have access to
the results of genetic tests when determining premium rates.
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Insurance companies are concerned that if they do not have access to genetic test
results they could experience adverse selection, where the applicant can take advan-
tage of information about risks to their future health that the insurer is not aware
of. Would a person with an adverse genetic test result buy more insurance than
they would have done before they knew the result?
Insurers already take account of family histories of certain disorders when determin-
ing premium rates. We want to find out what effect the extra information gained
through (possibly) being able to use genetic test results would have on premium
rates.
Premium rates are usually determined based on the insurers’ own experience of
certain factors, such as age and smoking habits. As yet, however, they do not have
information available from their own experience in respect of genetic testing.
Since 1999 the insurance industry in the UK has observed a self-imposed moratorium
on the use of genetic testing, enforced by the Association of British Insurers (ABI).
The moratorium states that genetic test results cannot be used by an insurer unless
the amount sought is over a certain threshold and even then the insurer can only
use existing test results if they have been approved for use by the Genetics and
Insurance Committee (GAIC).
Of the genetic disorders that are of interest to insurers we will investigate three,
Huntington’s disease (HD), BRCA1/2-related breast and ovarian cancer and Fa-
milial adenomatous polyposis (FAP). For both HD and BRCA1/2-related breast
and ovarian cancer we will investigate critical illness insurance for known mutation
carriers based on onset rates derived from real pedigree data. We also look at the
effect that genetic testing has on FAP and the possible implications for critical
illness insurance.
Adult Polycystic Kidney Disease (APKD) was originally on the list of genetic dis-
orders regarded by the ABI to be important to the insurance industry but was
removed as it is thought to no longer be of interest, in terms of genetic testing, due
to the use of ultrasound in its diagnosis. We look at APKD, but not in the detail
of the other three disorders.
Chapter 2 contains a basic introduction to genetics including a definition of DNA
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and a description of the relationship between genes, DNA and chromosomes. The
chapter then introduces possible methods of inheritance, including an outline of
Mendel’s laws of inheritance followed by a discussion of mutations, how they can
occur, and the problems they may cause. There is also a brief introduction to
pedigrees, the information that can be obtained to aid in genetics investigations,
and the problem of ascertainment bias.
We discuss insurance and how genetics impacts on insurance in Chapter 3. This
chapter starts by introducing the ideas behind insurance risk and illustrating how
insurance premiums are determined. We then discuss the moratorium, imposed by
the ABI, on the use of genetic testing in insurance and highlight GAIC’s role in
decisions made in relation to genetic testing. This chapter also includes a review
of previous studies concerning how the genetic disorders considered here affect life
and critical illness insurance.
Although work has previously been carried out to investigate the impact of three
of the above genetic disorders (APKD, HD and BRCA-related breast and ovarian
cancer) on insurance, these studies have had to rely on risk estimates published in
the epidemiological literature for their premium calculations.
Typically the distribution of the age at onset is used when determining insurance
premiums. The variances of the parameters of the distribution of age at onset,
however, are not usually published and the data are never published and, as a
result, a suitable measure of the reliability of the insurance premium cannot be
obtained.
Here we have data in pedigree form, obtained by Jacki Needs and Professor Lyndsay
Prior from the records of the Institute of Medical Genetics at the University of
Wales, Cardiff.
We will use this data to make parameter estimates of the distribution of age at
onset for each disorder and the variance matrix associated with these parameter
estimates. The estimates of variability will mean that, using Monte-Carlo methods,
we can estimate the reliability of the premium rates that would be charged to
mutation carriers.
In Chapter 4 we review epidemiological studies concerning the three genetic disor-
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ders of interest to us. This includes previous estimates of all quantities of interest
to insurers as well as details of the genetics for each disorder.
Chapter 5 reviews methods used to estimate onset rates of genetic disorders based on
families with a history of the associated disease. We describe the statistical methods
used and related issues, namely likelihoods, estimation of the sampling variances,
bootstrapping and ascertainment bias. Chapter 6 briefly discusses the actuarial
methods used to compute premium rates for persons with a known mutation.
The results obtained, both rates of onset of disease, and premium rates, are dis-
cussed for each disorder separately. Chapter 7 concentrates on Huntington’s Dis-
ease, while Chapter 8 on BRCA1-related breast and ovarian cancer.
We treat familial adenomatous polyposis (FAP) in a different way for two reasons;
(a) the disorder is no longer considered important by insurers; and (b) the infor-
mation available indicated that the likelihood methods used for the other disorders
were not suitable. Chapter 9 discusses the data available for FAP and the lim-
ited aims of the analysis carried out. A brief discussion of APKD, introducing
the epidemiology of APKD and previous insurance studies carried out, is given in
Appendix A.
Chapter 10 discusses the conclusions we reached and their possible applications to
insurance. We also discuss the possibilities for future work that can be carried out
using the data available here. The bibliography in this thesis gives a list of papers,
books and websites which I found useful in researching the subjects within this
thesis but have not referenced anywhere.
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Chapter 2
Genetics
2.1 An Introduction to Genetics
According to the Human Genome Project (HGP) the number of genes in the human
genome is much lower than previously thought. They estimate that every human has
approximately 20, 000 – 25, 000 genes (International Human Genome Sequencing
Consortium, 2004). These genes control the make-up of every part of the human
body from blood type to hair colour. In order to understand what genes do it is
important first to look at what genes are.
Genes are the units of inheritance for every living thing, carrying information from
one generation to the next. They are made up of strands of genetic material called
deoxyribonucleic acid (DNA) and are contained in the nucleus of every cell.
For more information on the basics of human genetics than we can give, we refer
the reader to Strachan and Read (1999) and Pasternak (1999).
2.1.1 DNA
Watson and Crick (1953) discovered that the DNA molecule is a double helix,
shaped like a twisted ladder, and that it is made up of three main parts:
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• Five-carbon sugars (deoxyribose).
• Phosphate molecules.
• Four nucleotide bases;
– Adenine (A)
– Guanine (G)
– Cytosine (C)
– Thymine (T).
The ‘sides’ of the ladder are made up of the sugars and phosphates, while the ‘rungs’
are made up of pairs of the bases linked to each other. A is always paired with T,
and G is always paired with C. These four letters, A, G, C and T are the alphabet
with which the message in DNA is encoded.
Through a process called transcription the DNA ‘ladder’ is split and a single strand,
one half of the ladder, of DNA is transcribed into a single-stranded Ribonucleic Acid
(RNA) polymer called mRNA (messenger RNA).
RNA is an important step between DNA and the manufacture of proteins. RNA,
like DNA, is made up of a chain of nucleotides and also consists of a four-letter
alphabet, but with thymine (T) replaced by uracil (U).
The mRNA may be thought of as a chain of three letter ‘words’ called codons. Each
codon provides the code for an amino acid which is added sequentially to a protein
chain. The resulting proteins control nearly all aspects of the human body.
There are 64 possible codons but only twenty possible amino acids so some amino
acids are coded for by more than one codon. The start codon (AUG), signals the
beginning of the coding sequence, while three stop codons signal the end (UAA,
UAG and UGA). Table 2.1 shows the possible codons and the corresponding one-
letter amino acid code. Table 2.2 shows what amino acid each one-letter code
represents.
Essentially, through transcription, a segment of the DNA ladder is translated into
a chain of 3-letter RNA words which, in turn, are translated into a chain of amino
acids to form a protein.
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Table 2.1: All possible codons and their corresponding amino acids (one-letter
code).
U C A G
U UUU (F) CUU (L) AUU (I) GUU (V)
UUC (F) CUC (L) AUC (I) GUC (V)
UUA (L) CUA (L) AUA (I) GUA (V)
UUG (L) CUG (L) AUG (M) GUG (V)
C UCU (S) CCU (P) ACU (T) GCU (A)
UCC (S) CCC (P) ACC (T) GCC (A)
UCA (S) CCA (P) ACA (T) GCA (A)
UCG (S) CCG (P) ACG (T) GCG (A)
A UAU (Y) CAU (H) AAU (N) GAU (D)
UAC (Y) CAC (H) AAC (N) GAC (D)
UAA (X) CAA (Q) AAA (K) GAA (E)
UAG (X) CAG (Q) AAG (K) GAG (E)
G UGU (C) CGU (R) AGU (S) GGU (G)
UGC (C) CGC (R) AGC (S) GGC (G)
UGA (X) CGA (R) AGA (R) GGA (G)
UGG (W) CGG (R) AGG (R) GGG (G)
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Table 2.2: The 1-letter codes for each amino acid as well as the name of each amino
acid and the corresponding 3-letter code used.
1-Letter Code Amino Acid 3-Letter Code
A Alanine Ala
C Cysteine Cys
D Aspartic acid Asp
E Glutamic acid Glu
F Phenylalanine Phe
G Glycine Gly
H Histidine His
I Isoleucine Ile
K Lysine Lys
L Leucine Leu
M Methionine Met
N Asparagine Asn
P Proline Pro
Q Glutamine Gln
R Arginine Arg
S Serine Ser
T Threonine Thr
V Valine Val
W Tryptophan Trp
Y Tyrosine Tyr
X Stop Codon
8
2.1.2 Chromosomes
DNA is organised into structures called chromosomes, each containing hundreds of
genes. Humans have 23 pairs of chromosomes, 22 of which (numbered 1 – 22) are
called autosomes while the 23rd pair are the sex chromosomes; one X and one Y
chromosome in males and two X chromosomes in females. One chromosome of each
of the 23 pairs is inherited from each parent.
Each pair of autosomes is similar in that they contain the same genetic information
in the same order. They can, however, differ in the specific form of the genes. These
different forms of a specific gene, given by different nucleotide sequences within the
gene, are called alleles.
The observed allele at a genetic locus is called the genotype, while the outward
appearance, characteristic or trait, influenced by the genotype is known as the
phenotype. Different genotypes can result in different phenotypes in individuals,
for example the different eye colour genotypes can give the phenotypes blue, green
and brown amongst others.
A person who has two different alleles at a genetic locus is known as heterozygous,
while a person with identical alleles at a genetic locus is known as homozygous.
The wild-type allele is the common form of the allele in the population, often
considered to be that which gives the ‘normal’ phenotype.
2.2 Inheritance
2.2.1 Cell Division and Reproduction
To understand how genes are inherited we need to look at the mechanisms of cell
division and reproduction, namely mitosis and meiosis.
Meiosis Everyone inherits one copy of each chromosome from their mother and
the other from their father. The make-up of the actual chromosomes inherited
from the parents is determined during meiosis.
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Meiosis is the process through which the chromosomes to be passed on are
installed in gametes (the reproductive egg cells, in the mother, and the repro-
ductive sperm cells, in the father). Each gamete contains 23 chromosomes,
instead of 23 pairs of chromosomes.
During meiosis a mixture of the genes from the maternally and paternally in-
herited chromosomes is produced. The resulting chromosomes in the gametes
contain genetic information from both the mother and the father of the parent
of the prospective child.
Mitosis Mitosis is the process of cell division. The division of the ‘mother’ cell,
through mitosis, leads to two ‘daughter’ cells, where each daughter cell has a
set of chromosomes identical to that of the mother cell.
This is the process through which the body grows, from the fertilised egg
(zygote), to a fully grown adult.
2.2.2 Mendel’s Laws of Inheritance
Gregor Mendel derived his laws of inheritance while conducting experiments on
plant hybrids (Mendel, 1866, in Peters, 1973). These laws relate to the transmission
of hereditary characteristics and traits from parents to their offspring.
The laws are as follows;
(1) Mendel’s Law of Dominance
When two people have a different trait, their offspring will only display the
dominant trait in the phenotype. For example, hair colour; if a child inherits
the blond genotype from one parent and the brown from the other, the child
will have brown hair as this trait is dominant.
(2) Mendel’s Law of Segregation
Each parent has two copies of each gene for each characteristic, inherited
from their parents, and one copy of each gene is passed on to their offspring,
through gametes.
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(3) Mendel’s Law of Independent Selection
The emergence of one trait will not affect the emergence of another.
As well as applying to the inheritance of characteristics such as eye colour, hair
colour and blood type, these laws also apply to the inheritance of mutations and
genetic disorders.
2.2.3 Mutations
A mutation is a change in the DNA which can cause changes in the make-up of a
person. These can be beneficial, neutral or harmful and can take many forms.
Here we will concentrate only on those mutations that are of interest to the insur-
ance industry, that is, those that result in a high risk of developing disease among
previously asymptomatic healthy adults.
Mutations can be classified in a number of ways:
(a) By effect on the structure of the protein
– Small scale mutations.
∗ Point Mutations – These cause a single nucleotide to be exchanged
for another.
· Missense mutations – These result in a change in the amino acid
coded for by that codon. The change to the protein may be
enough to cause it to be structurally abnormal or unstable.
· Nonsense mutation – This mutation alters an amino acid codon
to a stop codon resulting in a truncated protein. The change
either results in a protein with altered function or a very unstable
protein.
∗ Deletion or Insertion – The deletion or insertion of a number of
nucleotide bases.
· Frameshift mutation – This occurs when the number of deleted
or inserted base pairs is not a multiple of three. After the point
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of mutation all of the amino acids that follow will be different.
Either an abnormal protein or no protein is produced.
· In-Frame mutation – This occurs when the number of deleted or
inserted base pairs is a multiple of three. An unexpected amino
acid will appear in, or disappear from, the protein. The protein
may still be able to function.
– Large scale mutations.
∗ These mutations are normally associated with congenital birth de-
fects or can result in the foetus dying before birth.
(b) By effect on function
– Loss of function mutations – The resulting gene product has less or no
function. These mutations normally have recessive phenotypes.
– Lethal mutations – The resulting gene product gives a phenotype which
results in the development of a lethal disorder. This includes congenital,
early-onset and late-onset disorders.
(c) By aspect of phenotype affected
– Morphological mutations – Changes in the appearance of individuals,
such as, height, hair colour etc.
– Biochemical mutations – Disruptions or loss of biochemical functions.
A mutation in the pathway which converts amino acid tyrosine to skin
pigment melanin results in albinism.
Mutations can occur during meiosis or mitosis or can be caused by molecular decay
and can be induced through chemical action and radiation.
2.2.4 Disorders
Mutations can result in the development of disorders, from the relatively harmless
colour-blindness to late-onset lethal disorders such as Huntington’s Disease. These
disorders can be classified in the following way.
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(a) Monogenic (single-gene) disorders are those that are caused by a mutation in a
single gene, or pair of genes at a single locus. There are a number of ways in
which a monogenic disorder can be inherited, but here we will describe only
two, to highlight the differences and similarities:
• Autosomal Dominant Inheritance
– Only one copy of a disease allele is needed for a person to develop
the disease.
– There is a 50% chance of any offspring inheriting the mutation from
an affected parent.
– The proportion of affected males and females should be equal.
– An example of an Autosomal Dominant disorder is Huntington’s
Disease.
• Autosomal Recessive Inheritance
– Two copies of a disease allele are needed for a person to develop the
disease.
– The parents of an affected person are usually unaffected carriers.
– There is a 25% chance of a child, whose parents are unaffected carri-
ers, inheriting two copies of the mutation and having the phenotype.
– There is a 25% chance of a child, whose parents are unaffected car-
riers, inheriting no copies of the mutation.
– There is a 50% chance of a child, whose parents are unaffected car-
riers, inheriting one copy of the mutation and being a carrier.
– The proportion of affected males and females should be equal.
– An example of an Autosomal Recessive disorder is Cystic Fibrosis.
Genetic heterogeneity may exist in some monogenic disorders; this occurs
when mutations at more than one locus or different mutations at the same
locus can result in the development of the disorder.
(b) Polygenic (multifactorial or multi-gene) disorders are those that are caused by
variations in a combination of genes.
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• The inheritance of the mutations in several genes may make a person
more susceptible to a disease.
• Some environmental factors may combine with genotype to contribute
to the disease.
• An example of a possible polygenic disorder is Coronary Heart Disease.
It is to be expected that identifying disease-causing mutations will be easier in
respect of monogenic disorders than of polygenic disorders.
A number of genetic disorders do not develop until later ages, late-onset disorders.
These late-onset disorders are usually associated with mutations that cause tissue
deterioration over time, or with mutations in the DNA repair genes that can result
in cancer developing. The diagnosis of these disorders does not usually occur until
the deterioration has reached some limit and the symptoms become evident, as is
the case with Huntington’s Disease.
2.3 Pedigrees
In the context of hereditary disease the family tree is called a pedigree. The pedigree
enables the tracking of disease through generations of the family. Figure 2.1 shows
an example of a pedigree.
Most pedigrees are laid out in the same conventional way, with the youngest gener-
ation at the bottom and working back as far as possible to the pedigree founders.
Males are symbolised by squares while females are symbolised by circles. A slash
through either symbol indicates that that individual is dead and a filled symbol
indicates onset of the disease with which the pedigree is concerned.
The ideal pedigree would have dates of birth, death, onset and any genetic tests,
for every individual, but unfortunately this is often not the case in practice.
Pedigrees are compiled from information provided to geneticists or researchers.
Each pedigree usually comes to the attention of geneticists through one or more
affected people, often referred to as probands or index cases. In the case of HD it
usually only needs one person to be diagnosed with the disorder to highlight the
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pedigree as the disorder is rare and purely genetic.
The risk of developing breast or ovarian cancer, however, is associated with factors
other than the two mutations that have been identified so far. As a result it is often
the case that pedigrees which carry either mutation are only highlighted through
multiple cases of BC and/or OC occurring within them.
2.3.1 Information That Can Be Obtained From Pedigrees
Pedigrees are very useful to investigators of hereditary and genetic diseases. They
enable them to look at the patterns of inheritance of diseases and traits.
A number of quantities are important to clinicians and researchers investigating
genetic diseases, including; the onset rate, the post-onset survival rate and the
mode of inheritance. These quantities can be estimated through the examination
of pedigrees of families who display the disease.
Survival analysis usually aims to estimate probabilities of events such as; survival
from birth, survival after development of a disease, or survival after treatment. The
estimates can be used to compare the effect that different factors, such as different
treatments and different types of the disease, have on the probability that someone
lives to a certain age.
An onset rate is similar, but instead of survival to death, we can think of it as
survival to onset of the disorder. Many studies concerning onset of a disease pub-
lish estimates of the median age at onset and sometimes Kaplan-Meier curves for
survival to onset.
Often genetic and epidemiological studies publish an estimate of the penetrance
of the disease, equivalent to the onset rate. The penetrance at age x is defined
as the probability that onset has occurred by age x. Some genetic disorders are
completely penetrant, which means that everyone with the mutation will develop the
disease, if other decrements do not occur first. Other disorders may have incomplete
penetrance, meaning that not all people with the mutation will develop the disease
in their lifetime, even if all other decrements were absent.
A more detailed definition of onset rate and penetrance is given in Section 5.1, while
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Figure 2.1: Three generations of a sample pedigree. Squares are males, circles
are females, and a slash denotes death. Affected individuals are shown as filled
squares/circles. The year of birth, death and other relevant information for each
person is shown. Individuals are labelled X:Y, where ‘X’ (Roman) labels the gen-
eration and ‘Y’ (Arabic) the individual. xi represents the age of person i at onset
or censoring.
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Sections 5.3 – 5.6 describe the methods used in this investigation to estimate them.
Chapter 4 discusses previous work carried out concerning the genetic diseases of
interest here and, where relevant, gives estimates of the onset rates obtained in
these studies.
2.3.2 Ascertainment Bias
When carrying out investigations of rare autosomal dominant disorders it is not
sensible to attempt to obtain a study sample by sampling from the whole population
and testing for the associated mutations. What is more likely to happen is that,
as noted in Section 2.3, families who carry a mutation associated with a particular
disease will be identified by geneticists and researchers through one or more affected
people, namely ‘probands’.
Obtaining a sample in this way results in a bias, usually known as ascertainment
bias, as the pedigrees used were not selected at random from the population. As-
certainment bias is a major issue when carrying out studies concerning genetic
disorders and some attempt should be made to account for it.
Section 5.9 provides more detail on ascertainment bias and discusses some of the
possible methods that can be used to adjust for it. Some attempt is usually made
to adjust for ascertainment bias in epidemiological studies concerning genetic disor-
ders. However, there is often a lack of information about the effect of ascertainment
bias on the parameter estimates. Usually only the estimates, such as the penetrance
or the parameters of the distribution of age at onset, obtained after adjustment has
been made, are published.
It is often of interest in insurance studies to examine how ascertainment bias, and
any subsequent adjustment for it, may affect the resulting insurance premiums. As
the literature does not routinely publish estimates with and without adjustment for
ascertainment bias and, as the pedigree data used to obtain the estimates of pene-
trance etc are not given, some insurance studies attempt to adjust for ascertainment
bias by adjusting the penetrance estimates. Macdonald et al. (2003), for example,
reduced the onset rates by 50 and 70% so as to determine the possible effects of
ascertainment bias on premium rates by assuming that the effect of ascertainment
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bias on onset rates was very large.
As this study makes use of original pedigree data we can make some attempt to
adjust for ascertainment bias and, in turn, evaluate the effect the adjustments have
on the resulting premium rates. Section 5.9 identifies the method we use to adjust
for ascertainment bias.
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Chapter 3
Insurance
3.1 Insurance and Risk
When taking out motor insurance a number of questions will be asked to determine
how much risk a person and their car present. The main questions relate to age,
number of years’ driving experience and number of previous claims, as well as where
the applicant lives and how much their car is worth.
All of these are understandable; younger, less experienced drivers are known to be
more likely to have an accident, while home address and the location where the car
is parked may affect the risk of a car being stolen, and the value of a car will affect
how much might be paid out.
In respect of life and critical illness insurance the questions are mainly health related.
The main risk factors are age (the risk of death increases as an individual ages)
smoking status (smokers are at a higher risk of death than non- or ex-smokers) and
sex (males are at higher risk of death and disease at younger ages though their risk
at later ages does tend to be similar to that of females).
Also taken into account is the state of the applicant’s own health as well as that of
their family, called ‘family history’. Family history is information about the state of
the applicant’s family’s health including any cases of diseases such as heart disease,
stroke and cancer.
The insurer considers all relevant factors, estimates a person’s risk of death or of
19
suffering a critical illness and consequently determines the premium rate they should
pay. Normally in insurance there are three main categories of risk.
The main class is called the ordinary rates (OR) class. This accounts for about 97%
(Leigh, 1990) of applications for life insurance. The OR is the rate paid by people
who are in good health, although it does include some people who have slightly
poorer than average health. The OR class for life insurance is estimated to include
people with up to 130% to 150% of the average rates of mortality (Leigh, 1990).
If the applicant is estimated to have a higher rate of morbidity or mortality than
can be included in the OR class, because of poor health or adverse family history,
they may be charged a higher premium, usually expressed as a multiple of the OR
premium. This class accounts for about 2% of the life insurance population (Leigh,
1990). The final 1% of applicants are declined life insurance as the premium they
would be charged exceeds about 500% of the OR premium (Macdonald, 2000) for
life insurance. For critical illness insurance if the premium an applicant would be
charged exceeds 300% − 350% of the OR premium they would be declined cover
(Gutie´rrez & Macdonald, 2003). Dinani et al. (2000) states that 15% of all critical
illness insurance claims are declined, 22% of which are declined due to non-disclosure
and 70% due to the definitions of critical illness not being met.
3.2 Use of Genetic Information by UK Insurers
Genetic information can be defined as:
• A family history of a Mendelian disorder such as Huntington’s Disease.
• A family history of a complex non-Mendelian disorder such as heart disease.
• The results of tests such as those relating to blood, urine and ultrasound which
identify a genetic disease and as a result confirm the existence of a mutation.
• The result of a DNA-based test.
Since the development of DNA-based tests for some genetic disorders, concerns have
been raised about who should have access to the results. One of the main questions
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is whether insurance companies should be able to use presymptomatic genetic test
results to calculate premiums. It is thought that some people may be reluctant to
undergo presymptomatic testing because they are worried that an adverse result
will mean that they are uninsurable, or that people with an adverse result may not
attempt to buy insurance as they believe they would not be offered cover. These
problems have to be taken very seriously by the insurance industry.
In 1997 the Association of British Insurers (ABI), set out a code of conduct for
insurers to follow concerning the use of genetic information. They began by defin-
ing genetic tests as those that examine DNA or RNA only. They also imposed
a five year moratorium, which has since been extended until 2011, on the use of
presymptomatic genetic test results (ABI, 2005).
The most recent moratorium of the ABI stated that genetic test results should not
be used except, possibly, in respect of policies over £500,000 for life insurance and
£300,000 for CI insurance. Even if the applicant wishes to buy insurance above
these levels, they cannot be asked to take a presymptomatic genetic test and the
result of an existing genetic test can only be used if its use has been approved by
the Genetics and Insurance Committee (GAIC).
GAIC was formed by the UK Government in 1999 to oversee the use of genetic
testing in the insurance industry. It is GAIC’s job to decide whether a genetic test
result can be used by an insurer, following an insurer’s application. In practice
the ABI, rather than individual insurance companies, applies for permission to use
specific genetic tests. Applications are made for specific genetic tests and specific
insurance products and must contain the following information:
• Evidence that the genetic test is accurate and reliable.
• Clinical evidence that the the presence of a mutation leads to implications for
the health of an individual.
• Actuarial evidence that there is an increased probability of the insured event
occurring if the mutation is present.
GAIC’s annual report (2000) defines the evidence required in more detail. The
ABI developed a list of eight genetic disorders that their genetics adviser defined
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as important to insurers as part of their code of conduct (ABI, 1997). The eight
disorders are listed below along with a brief description of each disease and the
mutations that are known to cause them.
Huntington’s Disease (HD). HD is a progressive neurological disorder which
affects movement and speech. It is a fully penetrant, purely genetic, disorder
which is caused by a mutation in a single gene, the huntingtin gene.
Familial Adenomatous Polyposis (FAP). FAP is a disorder affecting the colon
and rectum, through the development of polyps which, if left untreated, may
become cancerous. A mutation in the APC gene is the main cause of FAP,
although it is believed that other mutations result in FAP, including an auto-
somal recessive mutation, MUTYH.
Breast Cancer & Ovarian Cancer (BC & OC). Mutations in two genes
have been found to cause breast and ovarian cancer, namely, BRCA1 and
BRCA2. These mutations do not account for all cases of BC & OC and it is
thought there are mutations still to be discovered. The presence of a mutation
increases the risk of developing BC and OC significantly.
Adult Polycystic Kidney Disease (APKD). APKD is a disorder that results
in cysts developing in the kidneys and leads to the need for dialysis and
subsequently kidney transplantation. Two APKD genes have been identified,
PKD1 and PKD2. These account for the majority of cases of APKD but it is
believed that a third mutation may exist.
Myotonic Dystrophy (MD). MD is a muscle wasting disease caused by a mu-
tation in the MDPK gene.
Multiple Endocrine Neoplasia (MEN). MEN results in the development of
endocrine tumours. There are two types of MEN associated with different
mutations. MEN1 is the only known gene associated with type 1, while RET
is the only known gene to be associated with type 2. The ABI only considered
the latter on their list.
Hereditary Motor & Sensory Neuropathy (HMSN). In this disorder the
nerves to the muscles, particularly in the lower legs and hands, do not work
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properly. There may be some effect on sensation in the affected areas as well.
There are a number of genes associated with HMSN but the most prevalent
is PMP22. The test for this gene was the only one considered by the ABI.
Early-Onset Alzheimer’s Disease (EOAD). EOAD is a disease which results
in progressive dementia. Three EOAD mutations have been identified, APP,
PS1 and PS2, although these do not account for all cases.
This list was later amended to include only seven disorders (APKD was removed
due to the use of ultrasound in its diagnosis).
To date only one application to GAIC, for Huntington’s Disease and life insurance,
has been successful. It was announced in October 2000 (Daykin et al., 2003).
The ABI intends to make other applications, concerning CI and income protection
(IP) insurance for HD and CI, IP and life insurance for BRCA-related Breast and
Ovarian Cancer.
The ABI has not yet considered applications to GAIC for the other disorders
(EOAD, FAP, MEN, MD and HMSN). They decided that, based on factors such
as age at onset and insurers’ experience of purchasing patterns, the tests for these
disorders may not be of practical value at the moment.
We give a more detailed discussion of the disorders which we consider (HD, FAP,
and BC & OC) in Chapter 4 (and discuss APKD in Appendix A).
3.3 Information Available About CI and
Life Insurance Risks
When a person applies for life or CI insurance they are asked questions about a
number of aspects of their life including; their health, their family history and
their lifestyle. It is then the job of the underwriter to examine the mortality and
morbidity risks associated with the information given and to determine whether the
applicant can be insured at the ordinary rate.
The underwriter may need more information in order to reach a conclusion. They
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may request a General Practitioner’s Report (GPR) or a Medical Examination Re-
port (MER) which will give them information about the applicant’s present health,
through physical measurements and non-DNA-based tests such as; height, weight,
blood pressure, blood and urine tests and X-rays.
The underwriter then uses all available information to determine whether or not
the risk presented by an applicant is acceptable, and to classify applicants with an
acceptable risk to be in the OR class or in a substandard class. The risk classification
is carried out so as to protect the insurer, by declining the people with severe risk
and charging those at significantly increased risk higher premiums. It also aims to
protect the other policyholders, who will ultimately lose out if the insurer admits a
significantly mis-priced group of risks.
The risk classification is usually carried out using data already available, such as
published epidemiological studies or life tables based on insurers’ own experience.
The data life insurers obtain through their own insurance experience is often more
reliable because of the size of the sample and because the insured population usually
has much lighter mortality than the general population.
There are currently no industry standard tables for CI insurance, as it is a rela-
tively new insurance product, but the Continuous Mortality Investigation (CMI),
who carry out research into mortality and morbidity experience, have begun an
investigation and have published a number of working papers on the subject. They
say that the CI insurance experience is, as yet, too immature for the data to allow
the construction of standard CI tables (CMI Working Papers 14 & 18).
When an insurer does not ask questions about a possible risk factor it is impos-
sible for it to base any assessment of the risk associated with that factor on their
own experience. As a result of the moratorium on presymptomatic genetic tests,
insurers have no information of their own about the risks associated with a positive
result. Insurers also have little information about the risks associated with positive
presymptomatic tests as genetic testing is relatively new and is not commonly used
yet. There are, however, epidemiological studies that provide estimates of the rates
of onset or death for some of the most important genetic diseases. Some of these
studies will be discussed in Chapter 4.
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3.4 Adverse Selection
Adverse selection occurs when a person attempts to buy insurance while knowingly
concealing some relevant information. The applicant may try to get more insurance
than they would normally, or even just try to get insurance when they would not
otherwise have considered it.
For example an applicant may know they have heart disease but may deliberately
not inform the insurer. This affects the insurer as they will evaluate the risk based
on the wrong information, thus the claim costs will be higher than expected and
the cost will be forced up for all policyholders.
A lot of the scope for adverse selection is eliminated through the insurer using
medical and family history information. Also, the fact that deliberate non-disclosure
may void an insurance policy should deter people from trying to defraud an insurer.
Now, however, insurance companies are worried that, with the increasing availability
of genetic tests, adverse selection will increase. It is possible that a person could buy
more insurance, given a positive result, or less insurance, given a negative result.
As the moratorium prevents insurers from asking about presymptomatic genetic
test results they can only determine the presence of genetic risk from family history
and, possibly, non-DNA-based medical tests. For example APKD manifests itself
through cysts in the kidneys and can be detected using ultrasound.
We would like to know whether adverse selection, related to genetic testing, actually
does occur, and if so how much effect it has. There has been some investigation of
adverse selection related to genetic testing in general, as well as some studies about
specific genetic disorders. Macdonald (1997) produced some crude estimates given
some very extreme assumptions about genetic testing. He stated that:
“If insurance companies refrain from using (or are forbidden to use) the
results of any genetic test in underwriting, additional mortality costs
are likely to arise. However, if adverse selection does not extend to
untypically large sums assured the magnitude of these costs is greatly
reduced; large sums assured is the costliest aspect of adverse selection”
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Macdonald (1999) concluded that if adverse selection involving higher sums assured
can be avoided then a reasonable order of magnitude for the additional costs of
adverse selection is 10%. He also demonstrated that it is unlikely that a separate
risk class will emerge for those undergoing genetic tests.
3.5 Research Concerning Genetics and Insurance
Some work has been carried out, using published epidemiological studies, to give
point estimates of premium rates for critical illness and/or life insurance. The
following is an outline of such work in respect of critical illness insurance, for the
genetic disorders that are of interest here.
Many of these papers discuss the effects on large and small insurance markets, where
the large insurance market defines insurers that are well established and conversely
the small insurance market defines insurers that are newer.
3.5.1 Breast and Ovarian Cancer
Figure 3.1 shows a multiple state model for critical illness insurance for BRCA1
and BRCA2 related breast and ovarian cancer based on the APKD CI insurance
model, introduced by Gutie´rrez & Macdonald (2003) and discussed in Appendix A.
The population is divided into sub-groups (usually three but sometimes more):
• Those with no family history, who are not at risk.
• Those at risk because of a family history but who do not carry a mutation.
• Those at risk because of a family history and who do carry a mutation.
The transition intensities in Figure 3.1 have to be estimated for each of these sub-
groups. The rates of onset of breast cancer, µ01(x), and ovarian cancer, µ02(x), are
usually based on estimates derived by epidemiological studies. The other intensi-
ties, µ03(x) and µ04(x) are estimated using a variety of medical and demographical
studies (discussed in more detail in Section 6.3)
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Figure 3.1: A multiple state model for BRCA1/BRCA2-related breast and ovarian
cancer in Critical Illness insurance.
Macdonald, Waters & Wekwete (2003a & 2003b)
Macdonald, Waters & Wekwete Part I (2003a) aimed to estimate the probability
of an applicant having a BRCA1 or BRCA2 mutation given their family history, or
more specifically, the structure of their family and the joint genotype of the family.
The population incidence rates of breast and ovarian cancer were estimated based
on cancer registrations in England and Wales in 1990–92 (O.N.S., 1999), and mid-
year population estimates in 1989–93. The breast and ovarian cancer onset rates
(µ01(x) and µ02(x)) among mutation carriers were determined from estimates in
Ford et al. (1998).
These intensities were then used to determine the probabilities of having a BRCA1
or BRCA2 mutation given the probability of different family structures (and allow-
ing for different mutation frequencies). The authors stated that risk estimates based
on studies of high-risk families should perhaps not be applied to other populations.
Part II (2003b) investigated a model of critical illness insurance which incorporates
breast and ovarian cancer as distinct causes of a claim, given the intensities and
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probabilities estimated in Part I.
The authors used their model to estimate the costs of critical illness insurance for
specific genotypes and found that level extra premiums were very high and that
most applicants would not have been insurable.
The critical illness insurance premiums given a family history of breast and ovarian
cancer were also estimated. The premiums were found to be significantly lower if
there is a family history but no known genetic test result. They also found that the
extra premiums varied depending on the age, term of policy, and what was known
about the family history and the family structure.
An attempt was made to adjust for ascertainment bias by reducing the penetrance
estimate. This was found to affect the costs of critical illness insurance significantly;
the extra premiums fell significantly for both the genotype-specific and family his-
tory models. The costs of adverse selection were found to be high in small CI
insurance markets. This estimate, however, was dependent on a number of extreme
assumptions, therefore the authors suggested that the costs they estimated could
be overstated.
Gui et al. (2006)
This study introduced family history into the life history of an applicant. This was
done by including the development of a family history as a transition between states
in the model. Most breast and ovarian cancers are caused by factors other than the
mutations that have been identified. Therefore the onset of either cancer alone does
not identify a mutation carrier and does not give information in a simple way about
the risks of family members being carriers. Also as being a mutation carrier does
not always result in the onset of BC or OC the model of onset for BRCA-related
BC and OC is more complex than that of fully penetrant, purely genetic genetic
disorders such as HD.
The post-onset mortality rates for breast and ovarian cancer were determined from
Coleman et al. (1999). The rates of onset of breast and ovarian cancer for BRCA1
and BRCA2 mutations were based on the meta-analysis of Antoniou et al. (2003).
Antoniou et al. (2003) used data from a number of studies to determine onset rates
of breast and ovarian cancer. They only used studies where the index case was
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identified independently of family history and had suffered breast or ovarian can-
cer. Adjustment for any possible ascertainment bias was made by maximising the
conditional likelihood of the pedigree given the phenotypic and genotypic informa-
tion of the index case.
The population was divided by Gui et al. (2006) into the following five sub-
populations to incorporate family history;
• Family with no BRCA1 or BRCA2 mutation carriers.
• BRCA1 mutation carrier family but applicant not a carrier.
• BRCA1 mutation carrier family and applicant is a carrier.
• BRCA2 mutation carrier family but applicant is not a carrier.
• BRCA2 mutation carrier family and applicant is a carrier.
The underwriting threshold for a family history was defined as two first-degree rel-
atives suffering onset of breast or ovarian cancer before the age of 50. Assumptions
about the family structure were also made; all the applicant’s siblings were supposed
to be the same age as she, and their mother was supposed to be 30 years older.
These assumptions meant that the family structure was defined by the number of
siblings. The rate of onset of a family history was then estimated for each of the
sub-populations.
The premium rates for life insurance for mutations carriers were, again, found to
be significantly lower when adjustment was made for ascertainment bias (by again
reducing the penetrance estimate). The life insurance premium rates for those with
a family history were below the underwriting threshold, of 400 − 500% of the OR
class.
It was found that the costs of adverse selection as a result of a moratorium on all
genetic test results would have the greatest impact on the small insurance mar-
ket. The percentage increases in premium rates, under severe adverse selection and
a normal rate of insurance purchasing, were estimated to be 0.000219 for small
insurance markets and 0.000510 for large insurance markets. A moratorium on ge-
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netic test results and family history would result in premium rates increasing by
0.013602% and 0.001677%, respectively.
They applied the model to CI insurance and found that the premium increases
were much higher than those for life insurance. Most mutation carriers would be
uninsurable, while all people with a family history would be insurable.
The adverse selection costs for critical illness insurance were slightly higher than,
but similar to, those for life insurance, under both moratoria.
Macdonald & McIvor (2006)
Although BRCA1 and BRCA2 mutations carry a very high risk of developing breast
and ovarian cancer they only account for about 25% of familial breast cancer. This
study made use of a model, proposed by Antoniou et al. (2002), that includes
BRCA1 and BRCA2 genes as well as a polygene.
The families used in the study by Antoniou et al. (2002) were ascertained through
two different methods; (a) cases of breast cancer diagnosed under the age of 55
and (b) families with 2 or more cases of breast cancer, with at least one diagnosed
under the age of 50. The maximum likelihood estimation allowed for bias occurring
from the use of the two ascertainment methods by (a) maximising the conditional
likelihood of observing the disease phenotypes and mutation status given the disease
phenotype of the index case, and (b) conditioning the likelihood on the disease
phenotypes of all of the family.
The polygenic component was used to attempt to represent the variations, both
adverse and beneficial, of alleles in several genes. It was acknowledged that this
polygenic component did not explain the remainder of the familial variation but it
was thought that it may explain a larger proportion of the variation than the major
genes that have already been identified. The polygenic component was assumed to
have both adverse and beneficial effects on risks of breast and ovarian cancer.
The premium rates obtained, for BRCA1 and BRCA2 mutations only, agree with
results obtained by both Macdonald, Waters & Wekwete (2003a, 2003b) and Gui
et al. (2006) and the effects of the polygenic component were shown to account for
much of the remaining variation.
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Macdonald and McIvor found that, for some BRCA1 and BRCA2 mutation carriers,
the premium was lower for those with a beneficial polygenotype than for non-
mutation carriers with an adverse polygenotype. Beneficial polygenotypes were
shown to reduce the premium significantly, and most mutation carriers with this
polygenotype were found to be insurable at most ages and for most policy terms.
The adverse polygenotype, however, resulted in premiums for carriers being even
higher than previously reported.
Through simulation, the premiums for an applicant with a family history were
estimated. The premiums, under the full polygenic model, did not increase by
much. It was suggested that this was due to the definition of family history, as
an increase in the number of affected first degree relatives, in the family history
definition, increased the premium rates.
Subramanian et al. (2000) and Lemaire et al. (2000)
Both of these studies investigated the effects on life insurance of possessing a family
history of breast and ovarian cancer.
Subramanian et al. (2000) found that the cost of adverse selection in life insurance,
in the case of breast and ovarian cancer, would be minimal if the insurer requested
information about the family history of cancer, including the age at onset for all
first degree relatives.
Lemaire et al. (2000) used onset rates from a study carried out by Claus et al.
(1994) to estimate premium rates for those with a family history of breast and
ovarian cancer. Based on results from epidemiological studies they stated that the
key underwriting factors associated with breast and ovarian cancer are: (a) how
closely related the affected relatives are; and (b) the ages at onset of the disease.
They found that many women with a family history of breast and ovarian cancer
can be insured at the standard rate, but that those with two family members with
cancer or those with one first degree relative who suffered onset at an early age
can only be accepted at substandard rates. They also stated that those with a
BRCA mutation will almost always be uninsurable at standard rates. They agreed
with Subramanian et al. (2000), saying that the insurer should gather as much
information as possible about family history in order to avoid adverse selection.
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The estimated onset rates used by Lemaire et al. (2000) may not be up to date, as
genetic testing had not been developed when the study by Claus et al. was published
in 1994.
3.5.2 Huntington’s Disease
Smith (1998)
Smith investigated life insurance for those with HD. He began by fitting Normal
penetrance curves to data from Newcombe (1981). Then, using results from Roos
et al. (1993), he estimated penetrance and post-onset mortality curves and the
resulting extra premiums for life insurance. He concluded that life insurance could
still be offered to healthy people who tested positive for HD mutations. He also
found that extra mortality associated with HD, as a proportion of normal mortality,
increased with increasing term of insurance and decreased with increasing age.
Gutie´rrez & Macdonald (2004)
As HD is a progressive illness the CI event can be difficult to define. Harper
(1996) outlined the progression of HD and categorised it into three stages, see
Table 4.1, where stage 1 is defined by manifestations of the disease being present
but not debilitating and stage 3 is defined by symptoms so severe that the sufferer
is completely dependent on others.
The CI event is usually taken to be at either stage 2 or stage 3 of Harper’s pro-
gression. The age at which these stages occur is usually taken to occur at about
5 or 10 years after onset respectively. Gutie´rrez & Macdonald (2004) interpreted
this delay after onset using an accelerated lifetime model, which will be explained
in more detail in Section 6.5.
The model of CI used is the same as in Guitie´rrez & Macdonald (2003), with the
addition of a separate state, onset of HD, with subsequent transition into the ‘CI
event’ state being possible, see Figure 3.2.
Another factor that is taken into account by Gutie´rrez & Macdonald (2004) is the
number of CAG repeats. The huntingtin mutation occurs because of extra CAG
repeats in the huntingtin gene. The number of CAG repeats is known to affect
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Figure 3.2: A multiple state model for HD in Critical Illness insurance.
the age at onset, an increase in the number of CAG repeats being associated with
a decrease in the age at onset (this is explained in more detail in Section 4.1.1).
Gutie´rrez & Macdonald split the mutation carrier group into categories by the
number of CAG repeats.
The rate of onset, as a function of age and CAG repeat length, and the distribu-
tion of CAG repeat lengths in the population were modelled using estimates from
Brinkman et al. (1997). Brinkman et al. (1997) carried out sensitivity analysis to
determine whether there was any bias introduced by using 2 or more individuals
from the same family by randomly selecting 2 individuals from each family and
carrying out the analysis based only on these people. They concluded that no obvi-
ous bias was introduced. The survival rates after onset of HD that were used were
based on estimates by Foroud et al. (1999).
The premium rates based on the CI event being stage 3 of Harper’s progression
showed that applicants would be insurable over a number of categories of age, term
and CAG repeat length, although there were a number of categories with a very
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high premium of over 1, 000% of the OR premium.
The CAG repeat length was found to affect the premium rate significantly; the
longer the CAG repeat the higher the premium. Using stage 2 of Harper’s pro-
gression as the CI event increased the premiums, as compared to stage 3. Basing
the calculation of premiums on a family history of HD only, most applicants are
insurable, with the exception of the very young and older persons.
Gutie´rrez & Macdonald (2004) found that a moratorium on genetic test results
would result in premiums increasing very slightly, for both stages of HD progression,
as would a moratorium on genetic test results and family history. They noted that
the latter would result in increased premiums caused by all high-risk people being
part of the standard risk group, not only as a result of adverse selection. Both
moratoria affect the small insurance market more than the large market, as found
previously.
Gutie´rrez & Macdonald (2004) also estimated the costs of adverse selection given
the two moratoria, assuming an extreme rate of adverse selection. They found that
the premiums increased by as much as 0.1%, given moratoria on genetic tests only,
and 0.35% under a moratorium on both genetic tests and family history. The costs
were higher assuming an extreme rate of adverse selection than when assuming a
moderate rate of adverse selection, but the costs were still found to be relatively
small.
The increase under a moratorium on family history was found to be so large because
those with a family history can buy insurance at the standard rate. They were
assumed to do this at a rate of 0.25 a year, which is high compared with the rate
of genetic testing.
All of these papers concluded that the costs of adverse selection were minimal for
each disorder; they did note, however, that although the costs were small taking
each disorder separately, the costs may add up when including all genetic disorders
for which testing will become available.
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3.5.3 General Discussion
The authors of the papers discussed here were not able to use original data to
estimate the required incidence rates, but instead had to derive onset rates and
penetrance curves through examination of published tables and plots. The authors
often had to use the estimates of the parameters, if given in the study that they used,
or to examine Kaplan-Meier plots and fit an appropriate curve to the values obtained
from the plots. Variances of parameter estimates are not routinely published in the
epidemiological literature and as the studies discussed here were not able to use
the original pedigree data they could not estimate the variances of any parameter
estimates themselves.
The parameters that are usually provided in published papers typically relate to the
distribution of the age at onset. As with all parameter estimation the distribution
of the age at onset is dependent on the data available, and as a result different data
may give different estimates of the parameters of the distribution. To determine
how reliable parameter estimates are their variances, or standard deviations, are
often used. This information would be valuable when using the distributions for
further work, such as the estimation of premium rates.
Applications to GAIC for the use of a genetic test for insurance purposes requires
that there is evidence that the genetic test is reliable in determining increased
risk. Having information available about the statistical reliability of the parameter
estimates should ideally form part of this evidence.
To determine the variance of the premium rates the variance and covariance of
the parameter estimates (the information matrix) is required, in the parametric
case. Using bootstrapping methods (Section 5.8) the sampling distribution of the
premium rates can be determined using the information matrix of the parameter
estimates.
Studies may sometimes publish the variance, or standard deviation, of the param-
eter estimates but the covariance of these estimates is not normally given. Lu et
al. (2006) investigated a possible approach to overcoming the lack of information
about the covariance of the parameter estimates. By investigating different corre-
lation structures of the parameter estimates they were able to obtain information
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about the sampling distribution of the premium rates.
The ideal scenario would be for genetic studies to publish the full covariance matrix
of the parameter estimates. This would enable the estimation of the variance of
the premium rates. As noted above, this is unfortunately not usually done. The
information matrix could be determined from the original data but pedigree data are
not normally available to those researching the effects of genetics on insurance. In
fact as far as we know no study concerning genetics and insurance has used original
pedigree data and resulting pedigree likelihoods to determine the distribution of
the age at onset. Gui and Macdonald (2002) used published pedigrees but they
used them to calculate Nelson-Aalen estimates of the incidence rates of early-onset
Alzheimers disease and discuss what information pedigrees should give.
The work to be undertaken here does use original pedigree data, provided by Jacki
Needs at Cardiff University, to estimate the onset rates. Likelihood methods are
used to estimate the parameters of the distribution of age at onset (See Section
5.3) and the information matrix. This information matrix can then be used to
determine the variance of the premium rates (using bootstrapping methods) and,
in turn, provide confidence intervals. We will also be able to show how estimated
extra premiums depend on the estimated onset rates and how this relationship
changes with age at application and term of policy.
The ability to make some adjustment for ascertainment bias and to gain an impres-
sion of the impact on critical illness insurance premiums is, as noted in Section 2.3.2,
another major advantage in having data from which to estimate the appropriate
parameters. The possible methods of dealing with ascertainment bias, including
the method which we use here, are detailed in Section 5.9.
Being able to use original pedigree data, rarely possible in genetics-related insurance
studies, will not only enable us to determine a measure of the reliability of the
premium rates estimated but will also enable us to see how much of an effect our
chosen method of ascertainment bias adjustment has on these results.
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Chapter 4
Epidemiological Review
Four autosomal dominant genetic diseases are considered here; Huntington’s Dis-
ease (HD), Breast and Ovarian Cancer (BCOC), Adult Polycystic Kidney Disease
(APKD) and Familial Adenomatous Polyposis (FAP). BCOC and HD are both on
the list of disorders important to insurers (see Section 3.2). APKD was on this list
but was removed due to the availability of ultrasonographic screening for diagnosis,
while FAP is no longer being actively considered by the ABI but is still of interest
to us. It is of interest to determine how the availability of genetic testing for these
disorders may affect premiums.
As discussed in Section 3.3, many epidemiological studies focus on these important
genetic diseases. The information obtained from these studies is important for use
in clinical settings, genetic counselling and further research. The quantities of most
interest are the age at onset of the disease, duration of survival after onset, the
penetrance of the disease and the prevalence of mutations.
Here we will review previous research into the four diseases of interest to us, looking
in particular at the quantities of interest mentioned above.
4.1 Huntington’s Disease
Huntington’s Disease (HD) is a rare inherited neurological disorder. The possible
symptoms of HD range from slurred speech and uncontrolled movements to depres-
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sion and immobility. As a result HD can be difficult to diagnose early as many of
these symptoms are common to other illnesses.
HD is an autosomal dominant disorder: it is passed from the parents to children
through what has become known as the huntingtin gene. Every person has two
copies of the huntingtin gene, one inherited from each parent. If there is a HD
mutation in either of the two copies, that copy produces a faulty version of the
huntingtin protein. It is this faulty protein that causes the deterioration of the
brain over time, specifically the control of motor and mental processes.
When a patient starts to suffer the symptoms of HD they are said to have suffered
onset of the disease, although there is the possibility of delayed diagnosis. Table 4.1
shows the progression of HD in three stages as defined by Harper (1996). In terms
of critical illness insurance stages 2 or 3 can be thought of as the insurable event,
depending on policy conditions. That is, it is a convenient proxy.
4.1.1 Genetic Testing and Penetrance
The Huntington mutation was identified on chromosome 4 (Gusella et al., 1983),
and later found to be specifically at locus 4p16.3 (The Huntington’s Disease Col-
laborative Research Group (HDCRG), 1993).
The faulty huntingtin protein is formed as a result of a trinucleotide expansion in
the Huntington gene. This means that extra ‘words’ are inserted in the gene, in
this case the extra word being the trinucleotide CAG. The CAG trinucleotide can
be repeated a number of times at a specific location in the gene, and it has been
shown that the number of CAG repeats affects the severity of the symptoms of HD
(Andrew et al., 1993, Illarioshkin et al., 1994, Furtado et al., 1996).
Most studies agree that those with the normal phenotype (unaffected) have fewer
than 36 CAG repeats (Stine et al., 1993, Masuda et al., 1995, Brinkman et al.,
1997, Alonso et al., 1997, Jakab et al., 1999 and Langbehn et al., 2004) although
some have disagreed. Barron et al. (1993) found a range of 35 − 62 CAG repeats
for affected subjects and Snell et al. (1993) found a range of 30− 70.
HD is fully penetrant (Roos et al., 1991), however, Rubinsztein et al. (1996) found
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Table 4.1: Stages of progression of Huntington’s Disease for a typical patient.
Source: Harper (1996). (Note: Chorea refers to brief, repetitive, jerky, or dancelike
uncontrolled movements caused by muscle contractions.)
Stage Clinical Features
1 Presentation with initial neurological or psychiatric symptoms
Main features remain similar to those at presentation
Chorea more prominent than other motor abnormalities
Patient largely independent for most activities
Burden on family mainly result of psychiatric problems
Death rare except for suicide
2 Motor disorders more generalised
Physical disability becomes major
Patient dependent on others for many activities
Burden on family both physical and psychological
Death often from unrelated causes
3 Severe generalised motor disorder
Physical disability severe to total
Patient completely dependent for all aspects of life
Burden on carers mainly physical
Death frequent at any point
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that HD was not fully penetrant for those with 36 − 39 CAG repeats. Brinkman
et al. (1997) found reduced penetrance for those with fewer than 42 repeats, while
McNeil et al. (1997) found reduced penetrance for 37− 39 repeats.
The U.S. Venezuela Collaborative Research Project (2004) found that persons with
fewer than 34 CAG repeats do not suffer symptoms, persons with 35− 39 repeats
have incomplete penetrance of HD and those with ≥ 40 CAG repeats show full
penetrance.
The different conclusions reached by these studies could possibly be caused by
different laboratory procedures for estimating CAG repeat length (Brinkman et al.,
1997). Rubinsztein et al. (1996) stated that the estimates made in previous studies
may not be reliable as the methods used to determine number of CAG repeats made
assumptions that were not valid.
The genetic test for the huntingtin mutation is ‘targeted mutation analysis’. This is
used because the huntingtin gene has been identified and there is no other cause of
HD, and mutations have a 100% detection rate. If a negative result is received then
the person will not develop HD, while a positive result, for a large enough number
of CAG repeats indicates that the person will develop HD if they live long enough.
The problem with HD is that although the test is accurate and reliable, a person
may be reluctant to know that they have the mutation as there is no cure. The
actual proportion of those at risk of HD that undergo testing is about 5 − 24%
(Craufurd et al., 1989, Tyler et al., 1992 and Maat-Kievit et al., 2000, Creighton
et al., 2003). Creighton et al. (2003) found that the uptake for the prenatal test is
approximately 2%.
Binedell et al. (1998) looked at the differences between two groups, test requesters
and non-requesters drawn from a HD register. They found that they differed in:
their knowledge of the availability of testing (people who knew more about testing
availability were more likely to take the test), their perceived attitudes of family
members to testing, their perceived stressfulness of being at risk and how they
thought they would cope with the results (non-requesters were more likely to say
that they could not cope). Taylor (2004) also investigated the decision-making
process undergone by people considering presymptomatic genetic testing for HD.
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She found that a person’s decision about whether to take the test or not depended
on their attitudes to a number of different factors including feelings about family
loyalty and feelings about the timing of the test.
4.1.2 Onset Rates
Much research has been undertaken to estimate the distribution of the age at onset
of HD for persons from HD families. Table 4.2 summarises a number of these
studies, in terms of the number of subjects, the mean age at onset and the standard
deviation of the age at onset. The mean age at onset ranges from 33.8 to 43.97
years. This variation may be because of various methods of analysis, as well as
geographical and temporal differences.
Newcombe (1981) stated that ascertainment bias was introduced in a number of
studies because they only used persons who had suffered onset, from the affected
families sampled, to estimate the age at onset. They did not include people who
had not suffered onset. He estimated the age at onset while attempting to remove
this bias. He found the mean age at onset to be 45.96 years, including all available
people and 48.86 years, when probands (those through which the pedigree was
identified) were removed. These mean ages are higher than those obtained from
other studies, in particular they are 4.6− 7.5 years greater than previous work that
did not attempt to remove this bias.
Myers et al. (1985) found that about a quarter of those affected by HD suffered
onset after age 50 and that the average age at onset for late onset sufferers was
57.5.
CAG Repeats
Table 4.3 shows the correlation between age at onset and number of CAG repeats
found in some studies. It is clear that higher numbers of CAG repeats are associated
with earlier ages at onset. Brinkman et al. (1997) also found that the relationship
between log(age at onset) and log(CAG repeat length) is strong, (correlation be-
tween them is −0.73).
Although the relationship is usually strong there has been some disagreement about
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Table 4.2: Mean age at onset of HD in published studies. N is the number of
subjects in the study, µ is the mean age estimated by that study and σ is the
standard deviation. Source: Gutie´rrez & Macdonald (2002a)
Reference N µ σ
Adams et al. (1988) 611 38.66 11.69
Andrew et al. (1993) 360 41.5 12.4
Bell (1934) 460 35.51 12.38
Bolt (1970) 265 42.7 13.2
Brackenridge (1971) 344 33.8
Brinkman et al. (1997) 728 41.0 13.0
Brothers (1964) 206 37.2
Dewhurst et al. (1970) 102 39.0
Farrer & Conneally (1985) 569 38.0 11.1
Feigin et al. (1995) 129 36.7 12.9
Folstein et al. (1987) 217 40.25 12.9
Foroud et al. (1999) 2,068 40.0 12.0
Marder et al. (2000) 960 40.8 12.4
Morrison et al. (1995) 143 43.6 13.5
Myers et al. (1985) 243 40.9
Panse (1942) 446 36.2 12.3
Reed et al. (1958) 262 35.3 9.8
Roos et al. (1991) 1,020 39.5 12.1
Stevens (1977) 162 43.43 10.26
Venters (1971) 123 38.8 10.11
Walker et al. (1981) 204 41.2 12.7
Wallace (1972) 144 39.5
Wendt et al. (1959) 762 43.97 10.9
Wendt & Drohm (1972) 802 43.39 10.08
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Table 4.3: Correlation between CAG repeat length and age at onset of Huntington’s
Disease in published studies. The Kehoe study published the results separately for
those that inherited the mutation from their mother (maternal transmission) and
father (paternal transmission).
Reference Correlation (ρ)
Andrew et al. (1993) −0.7
Brandt et al. (1996) −0.72
Kehoe et al. (1999) −0.771 (maternal transmission)
Kehoe et al. (1999) −0.751 (paternal transmission)
Kieburtz et al. (1994) −0.82
Myers et al. (2004) −0.81
Simpson et al. (1993) −0.58
Snell et al. (1993) −0.74
Stine et al. (1993) −0.65
whether this enables the prediction of age at onset based on the number of CAG
repeats. Brinkman et al. (1997) suggest that prediction based on CAG repeat length
alone is reliable and Penney et al. (1997) found that CAG repeat length accounts
for 78% of the variation in age at onset, while Andrew et al. (1993) states that the
number of CAG repeats accounts for less than 50% of the variation and is therefore
not reliable enough to be used for prediction.
Langbehn et al. (2004) developed a parametric model to predict age at onset given
the number of CAG repeats. The model suggested that there is a high probability
that a person with fewer than 40 CAG repeats will not suffer onset in their lifetime,
however long.
Sex of Affected Parent
The sex of the affected parent has been found to affect the age at onset of their
offspring, Jones & Phillips (1970) found that when all cases of onset at 21 years or
younger were removed there was no longer an effect of the sex of the transmitting
parent. Stevens (1977) found that there was also an effect of the sex of the affected
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grandparent and that if the mutation was transmitted from grandfather to father
to offspring then the age at onset would be much earlier; Newcombe et al. (1981)
agreed with these findings. Krawczak et al. (1991) found that the affected parent’s
age at onset and sex were significantly correlated with the age at onset of the
offspring.
4.2 Breast and Ovarian Cancer
Breast and ovarian cancer are serious diseases that affect women, though there are
also rare instances of male breast cancer. These cancers, as with most others, can
be fatal if not diagnosed early enough. Many investigations have been carried out
to determine what may cause breast and ovarian cancer.
The pedigrees of breast and ovarian cancer families suggest three possible patterns
of disease; sporadic, familial and hereditary.
A sporadic pattern occurs when there is no regular pattern of cancer in the family.
A familial pattern indicates there is family history of cancer but does not suggest
a Mendelian pattern of disease while a hereditary pattern suggests that there is a
Mendelian pattern of disease.
The existence of a family history of breast and ovarian cancer has been shown to
affect a person’s risk of developing breast and ovarian cancer.
Anderson et al. (1992) estimated the penetrance of breast cancer among first degree
relatives of breast cancer patients as 11.6%. Sutcliffe et al. (2000) found that the
penetrances of breast and ovarian cancer for people with more than 2 cases of
ovarian cancer in the family were 15% and 11%, respectively.
Claus et al. (1993) estimated the penetrance of developing breast cancer for a woman
with 1 or 2 first degree relatives with ovarian cancer as 13% and 31%, respectively.
They also found that a woman has a 40% risk of breast cancer by age 79 if she has
1 first degree relative with ovarian cancer and 1 with breast cancer, if the relatives
suffered onset in their 30’s.
The Collaborative Group on Hormonal Factors in Breast Cancer (2001) have shown
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that the risk of developing breast cancer increases as the number of relatives with the
disease increases. They found that a person with 1 affected first-degree relative was
1.8 times more likely to develop breast cancer than a person with no affected first-
degree relatives. This ratio increased as the number of affected first-degree relatives
increased, to 2.89 and 3.9 for 2 and 3 or more affected relatives, respectively.
Slattery and Kerber (1993) found that the risk of breast cancer decreased the more
distant the relative with breast cancer was. The odds ratio was 2.45 for women
with a first degree relative with BC, 1.28 for women whose nearest affected relative
was second degree and 1.35 when the nearest affected relative was third degree.
Through investigation of familial breast and ovarian cancer a number of studies
found evidence to suggest that there is an autosomal dominant allele that leads to
increased susceptibility to breast and ovarian cancer (Claus et al., 1991 & 1994;
Piver et al., 1993). These studies and others like them led to the search for breast
and ovarian cancer-causing genes.
4.2.1 Genetic Testing
A study using a large number of families with cases of early onset breast cancer
assigned the BRCA1 mutation, through linkage analysis, to chromosome 17 (Hall
et al., 1990). It was subsequently found to be at position 17q21 (Miki et al., 1994).
Although this mutation accounted for a high proportion of hereditary breast and
ovarian cancer, it was found that families with a high incidence of male breast cancer
did not carry this mutation (Stratton et al., 1994). This launched a further search
for other mutations which led to the discovery of a second mutation, BRCA2. It
was linked to chromosome 13 in 1994 (Wooster et al., 1994) and isolated one year
later at position 13q12.3 (Wooster et al., 1995).
The BRCA1 and BRCA2 mutations only account for a small proportion of all breast
and ovarian cancers. According to the Collaborative Group on Hormonal Factors
in Breast Cancer (2001), 7 − 10% of ovarian cancers (OC) and 5 − 10% of breast
cancers (BC) are due to BRCA1 and BRCA2 mutations.
There are many known mutations in BRCA1 and BRCA2 and some work has been
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carried out to determine if there are mutations that are unique to specific popula-
tions. It was found that there were three types of BRCA1/2 mutations that were
associated with Ashkenazi Jews, 185delAG, 5382insC on BRCA1 and 6174delT on
BRCA2 (Struewing et al., 1995, Tonin et al., 1995, Neuhausen et al., 1996) and
that if a Jewish woman does not carry one of these mutations then it is unlikely
that she will carry a different BRCA1/2 mutation (Narod & Foulkes, 2004).
There are two main types of genetic tests; mutation analysis and sequence analysis
(Petrucelli et al., 2005). Mutation analysis tests for the three Ashkenazi founder mu-
tations, while sequence analysis tests for BRCA1 and BRCA2 sequence alterations
as well as five specific large genomic BRCA1 rearrangements. Another available
test is the protein truncation test (PTT), developed by Hogervorst et al. (1995),
which, although inexpensive and quick, has been restricted to screening large exons
of BRCA1 and BRCA2 by many clinics (Narod & Foulkes, 2004).
Mutation analysis has a detection rate of 90% (Frank et al., 1998), while sequence
analysis has a detection rate of more than 88% in families shown to have a linkage
to BRCA1 or BRCA2 (Petrucelli et al., 2005). If a negative result is obtained by
mutation analysis for a person whose family is known to carry a mutation then the
person’s risk of developing breast or ovarian cancer is reduced but is still at least
the same as the risk of the general population. If the family is not known to carry
a mutation, sequence analysis may be recommended depending on the person’s
family history and their risk of having a mutation. If a positive result is obtained
a person’s risk of breast and ovarian cancer is greatly increased.
4.2.2 Prevalence
BRCA1 and BRCA2 are rare; the frequencies of BRCA1 and BRCA2 mutations
are estimated to be 0.051% and 0.068% respectively, (Antoniou et al., 2002). Anto-
niou et al. (2000) found the frequencies to be slightly higher, 0.128% and 0.172%,
respectively. They are found to be more common among families with histories of
breast and ovarian cancer.
In a study carried out using families with at least 4 cases of breast cancer, Ford et
al. (1998) found that 52% of familial breast cancer was due to BRCA1 and 35% was
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due to BRCA2. Therefore 13% was due to something else, perhaps another gene
or combination of genes. When using only families with four or five cases of breast
cancer, male or female, these proportions changed, 55% due to BRCA1 and 12%
due to BRCA2. When they considered only families with four or five cases of breast
cancer, female only, they found that only 32% were due to BRCA1 and 9% were
due to BRCA2. The Anglican Breast Cancer Study Group (2000) found that only
17% of breast cancer familial relative risk was attributable to BRCA1 and BRCA2.
A number of studies have estimated the proportion of people with breast and ovarian
cancer that carry either BRCA1 or BRCA2 mutations. One study stated that a
BRCA1 mutation was found in 16% of women with breast cancer, and in 14% of
women who suffered breast cancer before age 40. The mutation was also found in
40% of families with breast and ovarian cancer (Couch et al., 1997). Liede et al.
(2002) found that 6.7% of women with breast cancer and 15.8% of women with
ovarian cancer had one of the mutations (BRCA1 or BRCA2).
Malone et al. (1998) found a BRCA1 mutation in 6.2% of those diagnosed with
breast cancer before age 35 and in 7.2% of those diagnosed with breast cancer
before age 45, who had a first degree family history. A more recent study found
mutations in 9.4% of people diagnosed with breast cancer before age 35 (3.4% in
BRCA2 and 5.9% in BRCA1) and in 12.0% of those diagnosed before age 45 who
also had a first degree family history (4.9% in BRCA2 and 7.1% in BRCA1) (Malone
et al., 2000).
Another study found mutations (BRCA1 and BRCA2) in 5.9% of women with
diagnosis of breast cancer before age 36, and in 4.1% of women diagnosed between
ages 36 and 45. They also found a mutation in 11% of patients with a first degree
relative who was diagnosed with breast or ovarian cancer before age 60 and in 45%
of patients with 2 or more affected first or second degree relatives (Peto et al., 1999).
The prevalences of the Ashkenazi founder mutations among Ashkenazi Jewish wo-
men have been estimated to be 1.09%, 0.13% and 1.52% for the mutations 185delAg,
5382insC and 6174delT, respectively (Roa et al., 1996). Other studies estimated
similar prevalences, 1% for 6174delT, (Oddoux et al., 1996) and 0.9% for 185delAG,
(Struewing et al., 1995).
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It was also found that over 2% of Ashkenazi Jewish women carry a mutation in
BRCA1 or BRCA2 (Struewing et al., 1997) and that the mutations are present in
about 20% of Ashkenazi Jewish women with early onset breast cancer (Offit et al.,
1996).
With the exception of the studies concerning Ashkenazi Jewish women the estimates
of the proportion of people with breast or ovarian cancer who carry either the
BRCA1 or BRCA2 mutations are very similar. These values give a measure of the
prevalence of BRCA1 and BRCA2 amongst breast and ovarian cancer sufferers.
4.2.3 Penetrance
Carrying a BRCA1 or BRCA2 mutation confers a very high probability of devel-
oping breast or ovarian cancer. Table 4.4 shows penetrance estimates for breast
cancer, given the presence of BRCA1 or BRCA2 mutations, from a number of stud-
ies, and Table 4.5 shows the corresponding results for ovarian cancer. In both tables
the estimates in the right-hand column were obtained from studies which did not
differentiate between BRCA1 and BRCA2.
Another study carried out by Antoniou et al. (2005) estimated the penetrance for
the Ashkenazi founder mutations using the data from their 2003 study. They found
that the penetrance of breast cancer by age 70 was 64% for 185delAG, 67% for
5382insC and 43% for 6174delT. The penetrance of ovarian cancer was 14%, 33%
and 20% for 185delAG, 5382insC and 6174delT, respectively, while Struewing et al.
(1997) found that the penetrance of breast and ovarian cancer for those with the
Ashkenazi founder mutations was 56% and 16%, respectively.
These penetrance estimates vary widely and it is difficult to determine which is
the most reliable. However, comparing all of them with the population lifetime
risks of about 11% for breast cancer and 2% for ovarian cancer it is clear that the
probability of developing either cancer is greatly increased if a mutation in either
gene is present. In fact Claus et al. (1998) investigated the differences in penetrance
for both mutation carriers and non-mutation carriers and found that the penetrance
of breast cancer by age 80 was 63% and 9%, respectively.
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Table 4.4: Breast cancer penetrance in published studies. The penetrance is defined
at age 70 for all studies except for Claus et al. (1998), Risch et al. (2001) and
Anglican Breast Cancer Study Group (2000) where it is defined at age 80.
Reference BRCA1 BRCA2 BRCA1 or BRCA2
Lalloo et al. (2006) 84% 91%
Antoniou et al. (2006) 72% 75%
Marroni et al. (2004) 39% 44%
Antoniou et al. (2003) 65% 45%
Antoniou et al. (2002) 35.3% 50.3%
Risch et al. (2001) 68% 13.9%
Anglican Breast Cancer SG (2000) 48% 74%
Antoniou et al. (2000) 45%
Ford et al. (1998) 84%
Claus et al. (1998) 63%
Easton et al. (1995) 85%
Narod et al. (1995) 71%
4.2.4 Treatment
Surgery may be advised when breast or ovarian cancer is diagnosed, but it can
also be advised as a preventative treatment for mutation carriers. Prophylactic
surgery has been shown to reduce a carrier’s risk of developing breast and ovarian
cancer. Rebbeck et al. (2004) found that having a prophylactic oophorectomy and
mastectomy reduces the risk of breast cancer by as much as 95%; they also noted
that having a mastectomy alone reduces the risk of breast cancer by 90%. Rebbeck
et al. (2002) found that an oophorectomy reduces the risk of breast cancer by
approximately 50% and ovarian cancer by about 90%.
Schrag et al. (1997) stated that a 30-year old woman with a BRCA1 or BRCA2
mutation increases their life expectancy by between 2.9 and 5.3 years if they un-
dergo a prophylactic mastectomy and between 0.3 and 1.7 years if they undergo a
prophylactic oophorectomy. These gains were shown to decline with age and to be
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Table 4.5: Ovarian cancer penetrance in published studies. The penetrance is
defined at age 70 for all studies except for Claus et al. (1998), Risch et al. (2001)
and Anglican Breast Cancer Study Group (2000) where it is defined at age 80.
Reference BRCA1 BRCA2 BRCA1 or BRCA2
Lalloo et al. (2006) 60% 26%
Antoniou et al. (2006) 38% 49%
Marroni et al. (2004) 43% 15%
Antoniou et al. (2003) 39% 11%
Antoniou et al. (2002) 25.9% 9.1%
Risch et al. (2001) 36% 9.7%
Anglican Breast Cancer SG (2000) 22%
Antoniou et al. (2000) 66%
Ford et al. (1998) 27%
Easton et al. (1995) 63.3%
Narod et al. (1995) 42%
minimal at age 60. Armstrong et al. (2004) found that a prophylactic oophorec-
tomy lengthened the life expectancy by between 3.34 and 4.65 years depending on
age at surgery. Rebbeck et al. (1999) agreed, showing that a bilateral prophylactic
oophorectomy reduced the risk of breast cancer by about 50%. The risk of breast
cancer was only slightly reduced for those who underwent surgery after age 50.
Some investigation has been carried out to determine whether surveillance (ovarian
screening and mammography) is reliable. Meeuwissen et al. (2005) discovered that
ovarian cancer surveillance has limited sensitivity and gives a high number of false
positive findings. They recommended that a prophylactic oophorectomy is the
optimal risk-reducing strategy for women at high risk of breast and ovarian cancer.
Vasen et al. (2005) also found that surveillance for ovarian cancer was not effective
as all of the screen-detected tumours were advanced cancers. They did, however,
find that mammography was quite a reliable screening method for breast cancer as
only 20% of tumours detected had lymph node metastasis.
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Lynch et al. (2006) investigated the attitudes to genetic testing and prophylactic
surgery of people from hereditary breast and ovarian cancer families with BRCA
mutations. They found that before testing 23% had a prophylactic bilateral mas-
tectomy or oophorectomy or both, and of these 53% were subsequently found not
to have either mutation. After testing, 52.9% of mutation carriers and 0% of non-
carriers underwent prophylactic surgery.
4.2.5 Other Genes
As BRCA1 and BRCA2 account for only a small proportion of breast and ovarian
cancer it is clear that there may be other breast cancer susceptibility genes that
are, as yet, undiscovered. It is, however, unclear whether they are rare mutations
which confer a high risk or common low risk mutations.
It has been suggested that breast cancer families who do not have BRCA1 or BRCA2
mutations may carry mutations which act in a more complex manner. Peto (2002)
suggests that these genes may influence breast cancer susceptibility through gene-
gene or gene-environment interactions.
Antoniou et al. (2002) found that the best model for familial breast cancer was one
that incorporated BRCA1 and BRCA2 mutations as well as a polygenic component,
where the polygenic component affected BC but not OC. The polygenic component
represented a large number of low risk polymorphisms acting multiplicatively. They
also found that the presence of a third major breast cancer susceptibility gene
(BRCA3) was unlikely.
In Section 3.5.1 we discussed a paper investigating insurance costs based on the
assumption that there is a polygenic component in the model of breast cancer.
4.3 Familial Adenomatous Polyposis
Familial adenomatous polyposis (FAP), or familial polyposis coli (FPC), is a genetic
disorder in which polyps develop in the colon and rectum. There is a high risk
that, if nothing is done, the polyps will progress to colorectal cancer (CRC); the
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lifetime risk of colon cancer is nearly 100% (Ja¨rvinen, 2004). Other, less common,
manifestations of FAP include; osteomas, epidermoid cysts, retinal pigmentation,
gastric and duodenal polyps, desmoid tumors, brain tumors, periampullary adrenal
and thyroid carcinomas (Arvantis et al., 1990). Colorectal cancer is, however, the
main cause of death in people with FAP and is defined as the CI event for FAP.
Ja¨rvinen (1992) found that 0.53% of all colorectal carcinoma was associated with
FAP, while Bu¨low (2003) estimated this proportion to be 0.07%. The prevalence
of FAP, based on national registries, has been determined by a number of studies
whose estimates lie in the range 2.29− 4.65 per 100,000 (Burn et al., 1991, Bu¨low
1996, Ja¨rvinen 1992 and Bu¨low, 2003). Previous studies have provided a range
of estimates of the incidence of FAP, 0.62 − 2.38 per million (Ja¨rvinen, 1992 and
Bu¨low, 2003).
It has been shown that persons with affected first-degree relatives have an increased
risk of developing colon cancer. Those who have a first-degree relative who has
adenomatous polyps have an increased risk of colon cancer of 72, 74 or 78% (Fuchs
et al., 1994, Ahsan, 1998 and Winawer, 1996, respectively) while those who have a
first-degree relative who has had colon cancer have an increased risk of colon cancer
of approximately 218, 225 or 326% (Bonelli et al., 1988, Winawer, 1996 and Ponz
de Leon et al., 1987, respectively)
It has also been shown that as the number of affected first-degree relatives a person
has increases, the risk of colon cancer increases. St John et al. (1993) estimated the
odds ratio for colon cancer risk to be 1.8 given 1 first-degree relative and 5.7 given
2 first-degree relatives, compared to controls. Fuchs et al. (1994) estimated these
odds ratios as 1.72 and 2.75, respectively, while Winawer et al. (1996) found them
to be 1.78 and 3.25, respectively.
Mitchell et al. (2005) found that 9.4% of those with colorectal cancer had a first-
degree relative with colorectal cancer, while 28.8% had an affected first- or second-
degree relative.
A patient is diagnosed with FAP if they have more than 100 colorectal adenomatous
polyps (detected by sigmoidoscopy or colonoscopy), or have fewer than 100 polyps
and a relative with FAP. FAP is usually diagnosed using screening methods; how-
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ever, the availability of genetic testing brings a new dimension to the surveillance
and diagnosis of FAP.
4.3.1 Genetic Testing
The autosomal dominant gene associated with FAP has become known as the APC
(adenomatous polyposis coli) gene. It was linked to chromosome 5 in 1987 (Bodmer
et al., 1987), and subsequently found to be at location 5q21, (Groden et al. 1991,
Kinzler et al., 1991 and Nishisho et al., 1991). Until recently it was believed that all
cases of FAP were caused by the inheritance of mutations in the tumour-suppressor
APC gene (Chung, 2000). Now however, there is some evidence that points to a
proportion of FAP being due to autosomal recessive inheritance of mutations in
MUTYH, a DNA repair gene.
There are many mutations in the APC gene. Most of the mutations produce a
truncated APC protein through point substitutions or frameshift mutations (Arm-
strong et al., 1997). A person with FAP may have inherited one of these many
mutations in the APC gene or may have a de novo gene. The rate of new muta-
tions is estimated as between 4 and 9 mutations per million gametes per generation
(Bisgaard et al., 1994; Bjo¨rk et al., 1999). The same studies provided estimates of
the proportion of FAP cases that have a new mutation ranging from 11 to 25%.
Bertario et al. (2003) said that the site of the APC mutation is related to the
phenotype of FAP; in fact analysis of this relationship identifies subgroups of FAP
patients at high risk for major extracolonic disease.
Burt (2000) listed the genetic tests available for FAP as follows: protein truncation
testing, gene sequencing, known mutation in a family and linkage testing. The
genetic tests do not have 100% detection rate, in fact, Ja¨rvinen (2003) said that
the detection rate is 60− 95%, depending on the method used. Powell et al. (1993)
said that, given the technology available in 1993, APC mutations were detected in
80− 90% of FAP families.
Burt (2000) said that once it is known which APC mutation a person has their
family members can be tested for this mutation with sufficient accuracy. They can
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then be directed to appropriate screening and sometimes prophylactic surgery. If,
however, a mutation is not found in the proband then all family members should
undergo screening. It has been noted that a positive genetic test result should
be followed up by an annual sigmoidoscopy and that a negative result should be
followed up by a flexible sigmoidoscopy every 7 − 10 years, to account for any
potential error in the genetic testing (Powell, 1993).
4.3.2 Diagnosis of FAP
The two main methods of detection used for diagnosis of FAP, sigmoidoscopy and
colonoscopy, involve the examination of the colon and the large intestine. Although
family screening is recommended for those at 50% risk it has been shown that, apart
from those on FAP registers, the majority of patients are symptomatic at time of
diagnosis and that FAP is diagnosed based on clinical symptoms in 84% of sufferers
(Croner et al., 2005). They found that the commonest presenting features of FAP
are alteration of bowel habit (42%) and rectal bleeding (68%), but they stated
that both of these symptoms are found in many other conditions and therefore an
endoscopy is required to confirm diagnosis.
Family screening is recommended for those at 50% risk of having an APC mutation.
Family screening has been shown to be effective in diagnosing FAP earlier. Ja¨rvinen
(1992) found that the proportion of people with FAP diagnosed by family screening
has increased from 10%, between 1966 and 1970, to 56%, between 1986 and 1990.
Bernstein & Bu¨low (2005) found that the prevalence of colorectal cancer is reduced
by 55% by family screening.
In most studies the sample is split into two groups, probands and call-up patients.
The probands (or propositi) are those that are diagnosed through symptoms, while
the call-up patients are diagnosed through screening as they are known to be at
50% risk.
Bisgaard (1994) suggests that polyps nearly always develop by age 40, but Evans
(1993) suggested that without a specific genetic test, using genetic markers rather
than DNA, screening should be carried out well beyond the age of 40 as there is
evidence of some cases of late onset. Vasen et al. (1990) found that by age 40, 90%
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of the call-up FAP patients that were found to have a mutation, were diagnosed.
They suggested that screening should start at age 10 − 12 and continue until age
50, or age 60 for those with a family history of late onset.
Petersen et al. (1991) found that the probability of finding polyps in people who
had the FAP mutation was 15% at age 10, 82% at age 15, 94% at age 20 and 98%
at age 30 and that the probability a person at 50% risk has FAP after a negative
sigmoidoscopy was 49% at age 10, 20% at age 20 and 8% at age 30. They found
that, combined with linkage marker data, the 50% risk for relatives can be reduced
to below 0.5% by age 30 if there is a negative result on sigmoidoscopy and a negative
result from linkage analysis.
Age at Diagnosis
Vasen et al. (1990) estimated that the mean age at diagnosis of FAP was 24 years for
call-up patients and 35 years for propositi, while, Heiskanen et al (2000) estimated
these mean ages to be 22.8 and 36.8, respectively.
Petersen et al. (1991) estimated that the mean age at onset of polyps is 15.9. Bu¨low
(1986) found that the median age at development of polyps, for the call-up patients,
was 16, while the median age at first bowel symptom, for the propositi patients,
was 29. The median age at diagnosis of FAP was age 33, for the propositi group,
and 19 for the call-up group and the median age at diagnosis of CRC in the two
groups was at age 36 and 45.5, respectively.
This indicates that those who undergo family screening are diagnosed with FAP
earlier than probands, and that if CRC develops it develops later, due to early
surgery to remove pre-cancerous polyps.
4.3.3 Colorectal Cancer
Without surgery a person with FAP has a high risk of colorectal cancer (CRC); 7%
affected by age 21, 87% by age 45 and 93% by age 50 (Bussey 1975), with average
age 39 at diagnosis.
Table 4.6 shows the proportions of people in the two groups that already had col-
orectal cancer when they were diagnosed as having FAP. The proportion was very
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Table 4.6: Proportion of people with colorectal cancer at time of diagnosis, in the
call-up group and in the propositi group.
Reference Call-up Propositi
Ja¨rvinen (1992) 6.6% 65.5%
Bu¨low (1986) 3% 69%
Vasen et al. (1990) 4% 47%
Heiskanen et al. (2000) 4.2% 61%
Bu¨low (2003) 3% 67%
similar for all of the studies shown. These suggest that if diagnosed with FAP after
the development of symptoms, the risk of developing colorectal cancer is greater.
Bu¨low (2003) said that the prevalence of colorectal cancer in Denmark has decreased
and the prognosis has improved since the establishment of a Danish polyposis reg-
ister, and suggests that more registers be set up in order to attempt to eliminate
colorectal cancer in persons with FAP.
4.3.4 Other Manifestations of FAP
Congenital hypertrophy of the retinal pigment epithelium (CHRPE) is a symptom
associated with FAP. Burn et al. (1991) found that in a group of controls, 98% had
0, 1 or 2 small lesions in the eye, while in a group of FAP sufferers 7.6% had 0, 1,
or 2 lesions, 4.5% had 3 lesions and 87.8% had 4 or more. They concluded that
this could be used as a diagnostic tool for FAP; fewer than 3 lesions suggests a 1 in
13 carrier probability, more than 3 lesions suggests a 2 in 3 carrier probability, and
3 lesions is diagnostic. Tiret et al. (1997) agreed that CHRPE could be used as a
diagnostic tool. Their criteria were slightly different, however. The said that those
with at least 4 lesions or at least 2 lesions, of which one is large, were diagnosed as
having FAP. Their criterion had high sensitivity, 0.68, and maximal specificity of 1.
Bu¨low et al. (1995) found that 64% of those with FAP had histologically verified
duodenal adenomas, at a median age of 37, while, Bu¨low et al. (2004) found that
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65% had duodenal adenomas, at a median age of 38. The high incidence and the
fact that the severity of duodenal adenomatosis increased with age prompted them
to suggest that prophylactic gastrointestinal endoscopy was justified.
Clark & Phillips (1996) found that desmoid tumours (fibrous tissue tumours which
do not spread around the body but can invade nearby tissues) occur in 10% of
individuals affected with FAP, while Bertario et al. (2001) estimated that desmoids
developed in 11.9% of all FAP patients, and that the cumulative rate of desmoids is
20.6% at age 60. They found that females are at a higher risk of developing desmoids
than males (odds ratio 2.1), they also found that a family history of desmoids, (8.75),
a family history of osteomas, (2.9), and a family history of epidermoid cysts (1.8)
were significantly associated with occurrence of desmoids.
These other manifestations of FAP can also be used for diagnosis of FAP, even
though they are less prevalent in sufferers of FAP.
4.3.5 Treatment
Often patients with FAP have prophylactic surgery in the form of a colectomy
(removal of the colon), although other forms of surgery are available. Colectomy is
often performed in conjunction with other treatments; ileorectal anastomosis (IRA)
and ileal pouch-anal anastomosis (IPAA).
The IRA surgery involves the removal of the colon but all or most of the rectum
is left in place, with the small intestine being attached to the upper portion of the
rectum. IPAA involves the removal of the entire colon and most of the rectum with
an artificial rectum, a pouch, being made out of the lower end of the small intestine.
The IRA surgery will also involve life-long surveillance of the rectal stump as there
is still a risk of cancer of the rectal stump of up to 15% within 25 years (Bu¨low et
al., 2000).
Alarcon et al. (1999) found that endoscopic eradication is an appropriate initial
treatment for histologically advanced noncancerous neoplasms, or for patients who
are not surgical candidates. Pancreas-sparing duodenectomy may be the treatment
of choice for patients with carcinoma and those who have failed endoscopic therapy.
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The national polyp study found a 76−90% decrease in colon cancer incidence after
polypectomy (Winawer, 1996)
Ja¨rvinen (1985) said that the ideal treatment for FAP was prophylactic colectomy
and that it should be performed by age 20 − 25. Bu¨low et al. (2000) found that
colectomy with ileorectal anastomosis (IRA), with lifelong surveillance of the rectal
stump is a good treatment but there is still a 15% risk of rectal cancer.
Arvantis et al. (1990) found that the main cause of death for people with FAP is
colorectal cancer, 58.2% (colon 44.5% and rectal 13.6%), followed by desmoid tu-
mors, 10.9%, periampullary cancer, 8.2%, brain tumors, 7.3%, perioperative mortal-
ities, 4.5%, adrenal carcinoma, 0.9%, and carcinomatosis, 0.9%. After prophylactic
surgery (total proctocolectomy of total abdominal colectomy and ileorectal anas-
tomosis) the causes of death change significatly. The main cause of death is now
desmoid tumours, 30.6%, followed by periampullary cancer, 22.2%, perioperative
mortalies, 8.3%, rectal cancer, 8.3%, adrenal cancer, 2.8% and carcinomatosis, 2.8%.
It has been shown that there are no deaths caused by colon cancer after surgery
and that, while there is still a risk of rectal cancer, there are fewer deaths caused
by rectal cancer.
4.3.6 Survival
Heiskanen et al. (2000) estimated that for all of those with FAP, 91% of propositi
deaths are attributable to FAP, compared with 70% of call-up group deaths. They
found that the call-up group had a significant survival advantage after surgery
(colectomy or proctocolectomy). The mortality of the call-up group was found to
be very similar to a comparable group in the general population. The majority of
the deaths were due to colorectal cancer, 79%, with the second most common cause
of death in FAP patients being rectal stump cancer.
Ja¨rvinen (1992) has shown that the life expectancy of those diagnosed through
family screening is significantly better from the age of 31 years. Bu¨low (1986)
agrees, estimating the cumulative survival rates ten years after diagnosis to be 42%
for those diagnosed through symptoms and 97% for those diagnosed by way of
family screening, while he estimates the survival rates as 94% for call-up patients
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and 44% for probands in 2003.
4.4 Application to Insurance
Each of the quantities discussed above are of interest to the medical profession as
they can be used to provide sufferers with information about their disorder and also
to carry out further research.
These quantities are also of interest to the insurance industry and could have an
effect on the premiums that would be charged for different types of insurance;
The onset rate and the survival rate will affect the premium in different ways de-
pending on the age and the term of the policy sought. For example if the onset
of a disease is most likely to occur between ages 20 and 30, the CI premium, as a
percentage of the standard rate, would be higher at age 20 and 30 than at age 50,
as at age 50 they are past the age at which they are most at risk.
There are gender effects to be taken into account when determining standard rate
insurance premiums. If there is a gender effect on either the age at onset, severity
of the disease or the survival then this will result in the premium, relative to the
standard, being different for each sex.
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Chapter 5
Tools and Methodology —
Estimating Onset Rates
5.1 Onset Rate and Penetrance
As discussed, briefly, in Section 2.3.1 the intensity, or onset rate, is defined as the
rate at which onset of a disease is suffered and is defined as a function of age x and
denoted µ(x).
The penetrance is defined as:
F (x) = P (Onset has occurred by age x) (5.1)
and is related to the intensity by:
F (x) = 1− exp
(
−
∫ x
0
µ(t)dt
)
. (5.2)
When considering the effect of genetic testing on premium rates the onset rate
is an important item of information. The onset rate is often determined through
likelihood methods (discussed in Section 5.3).
5.2 Classical Survival Analysis
Survival analysis is based on the observation of a sample of N subjects, where each
subject’s lifetime is a random variable. We denote the lifetime from birth of the ith
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subject X i, and we assume that X1, ...., XN are iid, each with distribution FX(x)
and density fX(x).
The hazard function can then be written as:
µ(x) =
lim
h→0+
P [X i ≤ x + h|X i > h]
h
(5.3)
that is, the instantaneous probability of death per unit time having survived to age
x. It is the same as the intensity, or onset rate. The intensity is also given by:
µ(x) =
dFX(x)/dx
1− FX(x) =
fX(x)
1− FX(x) =
fX(x)
SX(x)
(5.4)
where SX(x) is the survival function, defined as SX(x) = 1− FX(x). Hence:
SX(x) = exp
(
−
∫ x
0
µ(t)dt
)
(5.5)
or S(x) = exp (−A(x)) where A(x) = ∫ x
0
µ(t)dt is defined to be the cumulative
hazard.
We can use these results to compile a likelihood by first defining the random vari-
ables:
X˜ i = highest age observed for the ith person, (5.6)
Z i =
⎧⎨
⎩ 1, Person i dies at age X˜
i
0, Observation of person i was censored at time X˜ i.
(5.7)
Then the likelihood of the data contributed by the ith person can be written as:
Li = SX(X˜
i)µ(X˜ i)Z
i
= exp
(
−
∫ X˜i
0
µ(t)dt
)
µ(X˜ i)Z
i
. (5.8)
See Chapter II of Andersen et al. (1993) for more details.
When the event of interest is the onset of a disorder and not death, as in the case
of critical illness insurance, lifetime can be defined as time free from the disorder.
Figure 5.1 illustrates the two-state model for critical illness insurance. A person
can be in two possible states in this model; state 0 if they are healthy or state 1
if they have suffered onset of disease, this is the most basic model of onset. Here
µ01(x) represents the transition intensity from state 0 to state 1. In this instance
we estimate the probabilities that a person is in state 0 or state 1, given whatever
information is known.
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State 0
Healthy
State 1
Onsetµ01(x)
Figure 5.1: The two-state model for critical illness insurance.
5.3 Pedigree Likelihoods
Suppose we have a pedigree with N members, that each suffered onset or censoring
at age xi, and that the ith member has phenotype zi = 1, affected, or zi = 0,
unaffected and has genotype ui. Suppose also that there are M alleles at a single
locus. Then the possible genotypes of the whole pedigree are the N -dimensional
vectors of the set U = {1, ....,M}N .
Also for pedigree genotype v ∈ U let P [v] = P [ui = vi : i = 1, ..., N ], where P [v]
is determined through the allele frequencies and the mode of transmission, and let
gvi(zi) be the probability that the ith person, with genotype vi, has phenotype zi.
The genotype probabilities, P [v], are determined by applying the genetic model
to the genotype probabilities of the founders. The genotype probabilities of the
founders are the population frequencies of the M alleles.
Supposing that age of onset is variable, we take it to have density function ϕu(x)
and survival function Φu(x), (where survival is defined here as absence of onset)
conditional on genotype u. Also let xi be the age at which the ith person’s genotype
zi is observed.
Then Elston (1973) writes the likelihood of a pedigree as:
L =
∑
v∈U
(∏
i
(zigvi (1)ϕvi (xi) + (1− zi) (((1− gvi (1)) Φvi (xi)))
)
P [v]. (5.9)
where gvi (0) = 1− gvi (1).
The pedigree likelihood is made up of contributions from each person within the
pedigree. There are four possible contributions a person can make to the likelihood:
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Table 5.1: Non-zero terms in the likelihood (5.9) for the pedigree in Figure 5.2.
Genotypes are ui = 1 = unaffected and ui = 2 = affected. f is the frequency of the
mutation within the population
Genotype Contribution to the Likelihood
(2,2,2,1,2,2,1,1) f 0.52 ϕ2(x1)ϕ2(x2)ϕ2(x3)Φ1(x4)Φ2(x5)Φ2(x6)Φ1(x7)Φ1(x8)
(2,2,2,2,2,2,1,1) f 0.52 ϕ2(x1)ϕ2(x2)ϕ2(x3)Φ2(x4)Φ2(x5)Φ2(x6)Φ1(x7)Φ1(x8)
(2,2,2,1,2,2,1,2) f 0.52 ϕ2(x1)ϕ2(x2)ϕ2(x3)Φ1(x4)Φ2(x5)Φ2(x6)Φ1(x7)Φ2(x8)
(2,2,2,2,2,2,1,2) f 0.52 ϕ2(x1)ϕ2(x2)ϕ2(x3)Φ2(x4)Φ2(x5)Φ2(x6)Φ1(x7)Φ2(x8)
A mutation carrier who has suffered onset of the disorder - ϕ2(xi)
A mutation carrier who has not suffered onset of the disorder - Φ2(xi)
A non-mutation carrier who has not suffered onset of the disorder - Φ1(xi)
A non-mutation carrier who has suffered onset of the disorder - ϕ1(xi)
The latter is not possible in the case of Huntington’s Disease but is possible for
other disorders.
5.3.1 Example
Using the pedigree in Figure 5.2 as an example we evaluate the likelihood above,
see Table 5.1. Here M = 2 and U = {1, 2}8.
When a person tests negative or positive for the mutation their genotype is deter-
mined to be 1 or 2, respectively.
Persons I:1, II:1 and II:2 have all suffered onset of Huntington’s disease, which
implies that they are mutation carriers, so their contributions to the likelihood are
ϕ2(x1), ϕ2(x2) and ϕ2(x3), respectively.
Persons II:4 and III:1 have both tested positive for the mutation but have not yet
suffered onset of the disease so their contributions are Φ2(x5) and Φ2(x6), respec-
tively.
Person III:2 has tested negative for the mutation and has not suffered onset giving
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




I:1 (x1)
1923–1980
Onset 1968
I:2
1925–
Well 2000


 
II:1 (x2)
1955–1999
Onset 1992
II:2 (x3)
1958–
Onset 1998
II:3 (x4)
1959–
Well 1999
II:4 (x5)
1961–
+Test 1998



III:1 (x6)
1978–
+Test 2000
III:2 (x7)
1981–
−Test 2000
III:3 (x8)
1986–
Well 2000
Figure 5.2: Three generations of a sample pedigree. Squares are males, circles
are females, and a slash denotes death. Affected individuals are shown as filled
squares/circles. The year of birth, death and other relevant information for each
person is shown. Individuals are labelled X:Y, where ‘X’ (Roman) labels the gen-
eration and ‘Y’ (Arabic) the individual. xi represents the age of person i at onset
or censoring.
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a contribution of Φ1(x7).
There are usually some people in the pedigree with unknown genotype. They are
dealt with by assuming every combination of possible pedigree genotypes. Taking
cases of onset and genetic tests into consideration, assuming here that onset implies
positive genotype, only members II:3 (age x4) and III:3 (age x8) have unknown
genotype. The four possible genotype combinations for these two members are:
Person II:3 negative and III:3 negative
Person II:3 positive and III:3 negative
Person II:3 negative and III:3 positive
Person II:3 positive and III:3 positive
These combinations result in the four possible likelihood contributions in Table
5.1. Summing over these possible combinations of the genotype gives the pedigree
likelihood as:
L = 0.52ϕ2(x1)ϕ2(x2)ϕ2(x3)Φ2(x5)Φ2(x6)Φ1(x7)
(
2∑
g=1
Φg(x4)
2∑
g=1
Φg(x8)
)
. (5.10)
5.4 Genetic Test Results
For those who are known to have a mutation the penetrance is taken as;
F (x) = 1− exp
(
−
∫ x
0
µ01(t)dt
)
(5.11)
where µ01(x) is the onset rate, or transition intensity, introduced in Section 3.5 and
shown in Figure 5.1 so
µ01(x) =
F ′(x)
1− F (x) . (5.12)
This gives the intensity for a person known to be a mutation carrier.
The survival function for a known mutation carrier (genotype u = 2) is:
Φ2(x) = exp
(
−
∫ x
0
F ′(t)
1− F (t)dt
)
= exp
(
−
∫ x
0
d
dt
log (1− F (t)) dt
)
= exp (log (1− F (x))− log(1− F (0))) = 1− F (x) (5.13)
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Figure 5.3: A multiple state model for HD in Critical Illness insurance.
and similarly the density of age at onset is:
ϕ2(x) = exp
(
−
∫ x
0
F ′(t)
1− F (t)dt
)(
F ′(x)
1− F (x)
)
= (1− F (x))
(
F ′(x)
1− F (x)
)
= F ′(x). (5.14)
5.5 Huntington’s Disease
5.5.1 Mutation Carrier
The Normal distribution is a good fit to the distribution of the age at onset of
Huntington’s Disease, as demonstrated by Newcombe (1981) and Smith (1998), so
we will use the Normal distribution for the penetrance here;
F (x) =
1√
2πσ
∫ x
−∞
exp
(
−(t−m)
2
2σ2
)
dt (5.15)
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Which gives;
ϕ2(x) =
1
σ
√
2π
exp
(
−(x−m)
2
2σ2
)
(5.16)
if onset occurs or;
Φ2(x) =
(
1− 1
σ
√
2π
∫ x
0
exp
(
−(t−m)
2
2σ2
dt
))
(5.17)
if it does not.
5.5.2 Non-Mutation Carriers
As non-mutation carriers (genotype u = 1) are not at risk of Huntington’s Disease
they do not contribute to the onset rate.
Here;
Φ1(x) = 1 and ϕ1(x) = 0 (5.18)
5.6 Breast and Ovarian Cancer
The likelihood is slightly more complex for breast and ovarian cancer. Here we have
to determine the onset rate for both breast and ovarian cancer. In order for us to
estimate the intensities we have to maximise the likelihood to estimate the parame-
ters of the distributions of the age at onset of both BC and OC simultaneously. We
use the idea of competing risks with independent lifetimes. We consider the time to
development of breast cancer and the time to development of ovarian cancer to be
bivariate random variables. We can then assume that the two random variables are
independent conditional on genotype, it is possible that some factors may influence
both, but this is not known. Therefore we can treat the probability of developing
breast or ovarian cancer as a product of the individual probabilities of developing
the disorders. While estimating the distribution of the age at onset for one disorder
we treat the onset of the other disorder as a censoring event.
The likelihood also has to be altered to allow for the fact that neither ovarian or
breast cancer are 100% penetrant. The penetrance values that will be used are
taken from published papers, rather than estimated as additional parameters.
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Figure 5.4: A multiple state model for BRCA1/BRCA2-related breast and ovarian
cancer in Critical Illness insurance.
Here we only determine the onset rate for BRCA1 carriers as the data is not suffi-
cient to enable us to estimate the onset rate for BRCA2 carriers.
5.6.1 Mutation Carriers
The distributions of age at onset of BRCA1/2 related breast and ovarian cancer
are skewed as the excess risk falls at later ages. Therefore we will use the Gamma
distribution for the age at onset distribution of both breast and ovarian cancer:
F j(x) = ρj
βj
αj
Γ(αj)
∫ x
0
tα
j−1e−β
jtdt, (5.19)
where j denotes the disorder, j = BC for breast cancer and j = OC for ovarian
cancer and ρj is the penetrance.
This gives;
ϕBC2 (x) = ρ
BC β
BCα
BC
Γ (αBC)
xα
BC−1e−β
BCx
(
1− ρOC β
OCα
OC
Γ (αOC)
∫ x
0
tα
OC−1e−β
OCtdt
)
,
68
(5.20)
if onset of breast cancer occurs, given mutation carrier status, and
ϕOC2 (x) = ρ
OC β
OCα
OC
Γ (αOC)
xα
OC−1e−β
OCx
(
1− ρBC β
BCα
BC
Γ (αBC)
∫ x
0
tα
BC−1e−β
BC tdt
)
,
(5.21)
if onset of ovarian cancer occurs, given mutation carrier status.
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If onset does not occur we have;
ΦBC2 (x) = Φ
OC
2 (x) =
(
1− ρBC βBCα
BC
Γ(αBC)
∫ x
0
tα
BC−1e−β
BC tdt
)
×
(
1− ρOC βOCα
OC
Γ(αOC)
∫ x
0
tα
OC−1e−β
OCtdt
) (5.22)
The parameters for both breast and ovarian cancer will be maximised simultane-
ously using the methods outlined in Appendix B.
5.6.2 Non-Mutation Carriers
People who are known or assumed not to carry mutations are still at risk of ovarian
and breast cancer so we need onset rates in respect of them. We take the following
rates from Macdonald, Waters & Wekwete (2003a).
µ01(x) =
1
Γ(8.7305)
0.07428.7305e−0.0742xx7.7305 0 ≤ x < 53
µ01(x) = 0.00012 + 0.00018(x− 35)− 0.000005(x− 35)2 x ≥ 53
+0.0000000529(x− 35)3
(5.23)
µ02(x) =
1
Γ(6.92)
0.0356.92e−0.035xx5.92 0 ≤ x < 45
µ02(x) = 0.0001554 + 0.000029(x− 45)− 0.00000048(x− 45)2 x ≥ 55
(5.24)
with linear interpolation between ages 45 and 55.
The contribution to the likelihood is then:
ϕBC1 (x) = exp
(
−
∫ x
0
µ01 (t) dt
)
µ01 (x) exp
(
−
∫ x
0
µ02 (t) dt
)
, (5.25)
if onset of breast cancer has occurred, and;
ϕOC1 (x) = exp
(
−
∫ x
0
µ02 (t) dt
)
µ02 (x) exp
(
−
∫ x
0
µ01 (t) dt
)
, (5.26)
if onset of OC occurs.
If onset is not suffered the likelihood contribution would be:
ΦBC1 (x) = Φ
OC
1 (x) = exp
(
−
∫ x
0
µ01 (t) + µ02 (t) dt
)
. (5.27)
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5.7 Variance of Parameter Estimates
The variances and covariances of the MLEs are found by taking derivatives of
the likelihood function.We will begin by outlining the method used for a twice-
continuously differentiable one-dimensional function, f(x).
Using Taylor’s expansion, where fx is the first derivative, fxx the second and so on:
f(x + h) = f(x) + hfx +
1
2
h2fxx +
1
6
h3fxx + ...... (5.28)
and
f(x− h) = f(x)− hfx + 1
2
h2fxx − 1
6
h3fxxx + ...... (5.29)
Then
f(x + h)− f(x− h)  2hfx + 1
3
h3fxxx. (5.30)
Therefore as h tends to zero, following the definition of the derivative:
fx  f(x + h)− f(x− h)
2h
. (5.31)
Applying the same method to fx we get:
fxx  f(x− h) + f(x + h)− 2f(x)
h2
. (5.32)
For a two-dimensional function, Taylor’s expansion gives the following approximate
derivatives:
fx  f(x + hx, y)− f(x− hx, y)
2hx
, (5.33)
fy  f(x, y + hy)− f(x, y − hx)
2hy
, (5.34)
fxy  [f(x + hx, y + hy) + f(x− hx, y − hy)]− [f(x + hx, y − hy) + f(x− hx, y + hy)]
4hxhy
,
(5.35)
fxx  f(x + hx, y) + f(x− hx, y)− 2f(x, y)
h2x
, (5.36)
fyy  f(x, y + hy) + f(x, y − hy)− 2f(x, y)
h2y
. (5.37)
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Using these derivatives the variance matrix can be estimated as
V =
⎡
⎣ V (x) Cov(x, y)
Cov(x, y) V (y)
⎤
⎦ = −
⎡
⎣ fxx fxy
fxy fyy
⎤
⎦
−1
(5.38)
from which we can construct confidence intervals or simulate values in the parameter
space consistent with the sampling distribution.
5.8 Bootstrapping
Maximising the pedigree likelihood using the simplex method (Appendix B) pro-
vides us with estimates of the parameters of the distribution of age at onset, and
of the variance matrix using the method outlined in Section 5.7.
The estimated onset rates will then be used in the calculation of premium rates.
As the premium rate is an estimate ultimately based on the data it would be useful
to know how reliable it is by looking at its sampling variance. Here we will use a
bootstrapping method. The procedure is as follows:
• Estimate the onset rates, using a parametric model:
Rate of Onset at age x = µ(x; θ) (5.39)
where θ is the (vector) parameter and θˆ is its estimate.
• Estimate the sampling variance matrix V ar(θˆ).
• Assume θˆ to have a multivariate normal sampling distribution and simulate
θ(1), θ(2),....,θ(S) as independently generated variates from the multivariate
normal distribution with mean θˆ and variance V ar(θˆ).
• Calculate the premium rate, g(θ)(i), for each simulated θ(i). Then the em-
pirical distribution of g(θ(i)) gives us the bootstrap estimate of the sampling
distribution of the premium rate.
Information about the variance of onset rate estimates is not routinely available
in published epidemiological studies and it is uncommon for data to be available
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for actuarial investigations of genetic disorders. As a result the variance of the
subsequent premium rates is often ignored. The availability of the data for this
investigation enables the reliability of the premium rate estimates to be evaluated,
in a robust statistical sense, which is one original contribution of this study.
5.9 Ascertainment Bias
Ascertainment bias arises through the fact that if a family is not identified as having
the disease by geneticists or researchers then there is no chance of them being in
the sample to be studied. The affected person, or persons, who first brought the
pedigree to the attention of geneticists or researchers is known as the proband, or
probands.
If the researcher chooses, or is aware of, only families with a higher number of cases
then the onset rates estimated using these cases will be too high.
Many methods have been suggested in the published literature concerning the best
way to deal with the problem of ascertainment bias. The general idea is that an
adjustment should be made to the likelihood to account for the fact that without
the proband, or probands being affected, it would be unlikely that the pedigree
would come to the attention of the researchers.
Sometimes a pedigree is identified through a number of people from the same family
being affected by the same disorder, called multiple ascertainment. This is often the
case for breast and ovarian cancer, where one affected family member alone would
probably not draw attention to the pedigree but a number of cases of the disorder,
especially cases of early-onset BC and OC, would do so.
In the case of disorders such as Huntington’s Disease, however, where genetic muta-
tion is the only cause, the pedigree of an affected family is often identified through
just one affected member, this is known as single ascertainment.
Thompson (1993) discusses adjusting for ascertainment by conditioning the likeli-
hood on the probability that the pedigree was ascertained. In the case of single
ascertainment, where there is only one proband, the probability that a pedigree is
ascertained is proportional to the number of affected individuals in the pedigree
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and the conditioning is equivalent to removing the proband from the likelihood.
Cannings and Thompson (1977) discuss ascertainment bias in sequential sampling.
They showed that ascertainment bias can be avoided if the decision of who, in a
pedigree, is to be examined next depends only on what has already been observed
and that all of the people who are examined are included in the analysis, regardless
of phenotype. This means that the decision to stop sampling from a particular
pedigree should be based solely on the people who have already been examined.
Hodge and Vieland (1996) defined single ascertainment as any ascertainment scheme
under which all pedigrees have the same probability of being ascertained indepen-
dent of the pedigree size or structure. Under this definition they showed that the
likelihood should be the probability of the data conditioned on the observed pedi-
gree divided by a function p(θ), whether the sampling is proband-dependent (PD)
or proband-independent (PI), where p(θ) is a function of the genetic parameters but
not the pedigree structure. They also showed that when p(θ) is the prevalence of the
trait being studied then the definition is equivalent to classical single ascertainment,
as defined by Thompson (1993).
Ewens and Shute (1986) illustrated adjusting the likelihood by conditioning only on
the part of the data which is relevant to ascertainment. They note that it may be
difficult to decide what part of the data that is, but no assumption is made about
how the probability of ascertainment is affected by data relevant to ascertainment.
The extension of the methods of Cannings and Thompson (1977) to multiple as-
certainment were discussed by Boehnke and Greenberg (1984). They have shown
that if ascertainment is complete then conditioning on the probands results in all
of the affected individuals being removed from the analysis, where complete as-
certainment is defined as when every individual has equal probability (100%) of
being ascertained. They showed that this method is not necessarily correct as the
resulting estimates may be asymptotically biased.
Epidemiological studies have used a variety of methods to adjust for ascertainment
bias. The methods of Cannings and Thompson (1977) were used by Antoniou et
al. (2006) who conditioned the likelihood of all of the phenotypic and genotypic
information given all of the disease phenotypes and genotypic information up to
74
the point at which the first carrier was identified.
Antoniou et al. (2003), Ford et al. (1998) and Anglican Breast Cancer Study Group
(2000) maximised the likelihood of the pedigree given the phenotypic and genotypic
information of the proband. Other studies have adjusted for ascertainment by
removing the proband from the data set, Bear et al. (1992), Bear et al. (1984) and
Churchill et al. (1984).
Newcombe (1981) tested three adjustment methods; (1) Not removing any pro-
bands; (2) Removing one proband per pedigree; and (3) Removing the proband
only when the pedigree was singly ascertained. They found that the resulting es-
timates of onset rates under (2) and (3) were very close, while estimates under (1)
were slightly lower.
In the case of the pedigree data available to us here no probands are identified, nor
do we know the ascertainment scheme. As a result we cannot adjust the likelihood
accurately using the aforementioned methods. We will therefore use a variation of
the ‘leave one out’ method to adjust for ascertainment bias.
For Huntington’s Disease we assume a pedigree is generally identified through a
single proband and as we are unsure of who may be the proband in each pedigree
we ‘choose’ one at random, as follows. For each pedigree, we identify all possible
probands as being those that suffered onset of HD before the first genetic test
was taken. After identification of all possible probands we will randomly remove a
‘proband’ from each pedigree and determine the parameters of the distribution of
the onset rate µ(x; θ). Repeating this random exclusion of probands D times leaves
us with a sample of θˆ and the corresponding variance matrix V ar(θˆ). For each
of these D parameter sets we then simulate E independently generated variates,
assuming θˆ has a multivariate normal samping distribution, as in Section 5.8.
We then have D ∗E estimates and we can, again, use these estimates to determine
the premium rates g(θ), then the empirical distribution of g(θ(i)) gives us a bootstrap
estimate of the sampling distribution of the premium rate, now given the adjustment
for ascertainment.
Comparing these values to those obtained through bootstrapping without the ran-
domly deleted proband, we will have a measure of how the chosen method of dealing
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with ascertainment bias affects the results. The variance of the premium rate will
incorporate the uncertainty about who the probands are as well as the uncertainty
about the age at onset.
In the case of breast and ovarian cancer pedigrees we first carry out the same
‘leave-one out’ method using randomly selected probands to adjust for single ascer-
tainment. However, breast and ovarian cancer are not caused solely by the BRCA1
and BRCA2 genes, so the way in which they come to the attention of the researchers
is often through multiple cases in one family. So to adjust for multiple ascertain-
ment we also randomly remove two of the possible probands from each pedigree.
This will result in estimated onset rates after approximately adjusting for single and
multiple ascertainment and will enable us to compare the results obtained through
both adjustment methods.
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Chapter 6
Tools and Methodology —
Estimating Premium Rates
We will first introduce the methods used to calculate the premium rates in respect
of breast and ovarian cancer. Some alterations have to be made to the model to
use it for HD, we will discuss these changes in Section 6.5.
There is usually a 28-day survival clause in a critical illness insurance policy so that
the insurer pays out only if a person survives 28 days after onset.
To define the actuarial model used we must first introduce the continuous-time
Markov model.
6.1 The Markov Model
The insurance model is defined in terms of states and the transitions between those
states, where the states usually include Healthy, CI event and Death, as illustrated
in Figure 6.1. The transition intensities and transition probabilities govern move-
ment between states j and k. The transition probability, pjk(x, t), is defined as the
probability that a person in state j at age x will be in state k at age x + t. The
transition intensity between states j and k at age x + t is denoted µjk(x + t).
If the transition is between the healthy state and the onset state then the tran-
sition intensity is the onset rate defined in Section 2.3.1, with j = 0 and k = 1.
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Figure 6.1: A multiple state model for BRCA1/BRCA2-related breast and ovarian
cancer in Critical Illness insurance.
For BRCA1-related breast and ovarian cancer these transition intensities would be
µ01(x) for breast cancer and µ02(x) for ovarian cancer (see Figure 6.1).
The transition probabilities and transition intensities are related by the Kolmogorov
forward equations:
∂
∂t
pjk(x, t) =
∑
l =k
pjl(x, t)µlk(x + t)−
∑
l =k
pjk(x, t)µkl(x + t) (6.1)
with boundary conditions pjk(x) = 1j=k.
We suppose that if a person is in state j at age x, then a premium is paid continu-
ously at an annual rate of bj(x) and on transition to state k a benefit of bjk(x) will
be paid, if k is a state that warrants a CI claim.
Denoting the force of interest as δ the Expected Present Value (EPV) of the future
discounted loss at age x + t, Vj(x, t), conditional on presence in state j is then
related to the benefit and premium through Thiele’s differential equations:
∂
∂t
Vj(x, t) = δVj(x, t)+ bj(x)−
∑
k =j
µjk(x, t) (bjk(x, t) + Vk(x, t)− Vj(x, t)) (6.2)
with boundary conditions Vjk(x, d) = 0 at expiry of the policy, at some age x + d.
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These equations can be solved numerically using methods found in any numerical
analysis textbook (we use a fourth-order Runge-Kutta method with step-size 0.0005
year and a force of interest of δ = 0.05 per annum).
Solving the Kolmogorov forward equations gives us the transition probabilities,
given all of the transition intensities. Then solving Thiele’s differential equations
gives the EPVs conditional on presence in any of the states.
6.2 The Model of Critical Illness Insurance
Given Genetic Information
Figure 6.1 shows the Markov model for breast and ovarian cancer. Each relevant
subgroup of the population will be represented by this model. As we concentrate
only on the incidence of breast and ovarian cancer related to BRCA1 mutations
there are three subgroups:
(a) Persons who are not at risk.
(b) Persons at risk, because of family history, but who do not have a BRCA1
mutation.
(c) Persons at risk, because of family history, who do have a BRCA1 mutation.
The mutation frequencies give the proportions in the starting state of each sub-
population at birth. Table 6.1 shows these proportions.
6.3 Intensities
For subgroup (c) we determine the onset rate, µ01(x) and µ02(x) using the methods
discussed in Chapter 5. The other transition intensities we use are those estimated
by Gutie´rrez & Macdonald (2004). These are as follows:
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Table 6.1: Proportions of the whole population who are in each of the three sub-
populations. Source: Gui et al. (2006).
Subpopulation Proportion
(a) Non BRCA1 carrier family 0.997671796
(b) BRCA1 carrier family, 0.001164102
applicant does not have mutation
(c) BRCA1 carrier family, 0.001164102
applicant has the mutation
6.3.1 Cancer
The intensities are based on cancer registrations between 1990 and 1992, from the
Office of National Statistics (ONS, 1999).
For males:
µ03c(x) = exp(−11.25 + 0.105x) x < 51, (6.3)
µ03c(x) = exp(0.2591585− 0.01247354x+ 0.000191691x2 − 8.952933× 10−7x3) x ≥ 60,
(6.4)
and between the ages of 51 and 60 linear interpolation is used.
For females:
µ03c(x) = exp(−10.78 + 0.123x− 0.00033x2) x < 53, (6.5)
µ03c(x) = −0.01545632 + 0.0003805097x x ≥ 53. (6.6)
CI policies typically include a clause stating that after a CI event occurs the policy
does not pay out until 28 days after diagnosis. The 28-day survival probability is
not taken into account here as death is very unlikely within 28 days of diagnosis of
cancer.
When considering BRCA1 mutation carriers we have to adjust the onset intensity
as the onset rate of breast and ovarian cancer is already included in the model
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through µ01(x) and µ02(x), respectively. We do this by removing the population
onset rate of breast and ovarian cancer given in Section 5.6.2:
µ01(x) =
1
Γ(8.7305)
0.07428.7305e−0.0742xx7.7305 0 ≤ x < 53
µ01(x) = 0.00012 + 0.00018(x− 35)− 0.000005(x− 35)2 x ≥ 53
+0.0000000529(x− 35)3
(6.7)
µ02(x) =
1
Γ(6.92)
0.0356.92e−0.035xx5.92 0 ≤ x < 45
µ02(x) = 0.0001554 + 0.000029(x− 45)− 0.00000048(x− 45)2. x ≥ 55
(6.8)
Then the onset intensity for cancer for BRCA1 mutation carriers, µ03cm(x), is then:
µ03cm(x) = µ03c(x)− µ01(x)− µ02(x). (6.9)
6.3.2 Heart Attack
The intensities were determined using numbers of first–ever cases of heart attacks
between September 1991 and August 1992, from the Morbidity Statistics from the
General Practice Survey (McCormick, Fleming and Charlton, 1995).
For males:
µ03h(x) = exp(−13.2238 + 0.152568x) x < 44, (6.10)
µ03h(x) = −0.001245109 + 0.000315605x x > 49, (6.11)
with linear interpolation between ages 44 and 49
and for females:
µ03h(x) =
0.598694
Γ(15.6412)
× 0.1531715.6412 exp(−0.15317x)x14.6412. (6.12)
6.3.3 Stroke
The intensities were determined from Stewart et al. (1999).
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For males:
µ03s(x) = exp(−16.9524+ 0.294963x− 0.001904x2 +0.00000159449x3), (6.13)
and for females:
µ03s(x) = exp(−11.1477 + 0.081076x). (6.14)
6.3.4 28–day survival probabilities
The probability a person survives for 28 days following a heart attack given that
they are aged x is denoted by s03h(x), similarly the probability of surviving 28 days
following a stroke is denoted by s03s(x).
The corresponding 28-day mortality probabilities are then defined as;
q03h(x) = 1− s03h(x) (6.15)
and
q03s(x) = 1− s03s(x). (6.16)
The values of the mortality rates that we use are taken from Dinani et al. (2000);
s03s(x) = (0.9− 0.002x)/0.9 (6.17)
for both males and females, while
q03h(x) = 0.21 (6.18)
at ages 20-80 for females only. Table 6.2 shows q03h(x) for males.
6.3.5 Other CI Illness Claims
It was assumed by Macdonald, Waters and Wekwete (2003b) and Dinani et al.
(2000) that other minor causes of CI claims amount to 15% of claims from heart
attack, stroke and cancer. Therefore, in total,
µ03(x) = 1.15(µ03c(x) + s03h(x)µ03h(x) + s03s(x)µ03s(x)) (6.19)
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Table 6.2: 28-day mortality rates after a heart attack for males. Source: Dinani et
al. (2000).
Age q03h(x) Age q03h(x) Age q03h(x) Age q03h(x)
20-39 0.15 58-59 0.21 47-52 0.18 65-74 0.24
40-42 0.16 60-61 0.22 53-56 0.19 75-79 0.25
43-46 0.17 62-64 0.23 57 0.20 80+ 0.26
6.3.6 Mortality
The mortality intensity, µ04(x), is determined from population mortality rates (En-
glish Life Tables No. 15 - O.P.C.S., 1991, 1993a & 1993b). These rates were
adjusted to exclude deaths from causes leading to CI claims.
6.4 Calculating Extra Premiums when
Genotype is Known
Using the intensities in Section 6.3 we calculate the level net CI premiums for a level
£1 sum assured for any age and term of policy. The premiums are calculated by
solving the equations in Section 6.1, using a fourth-order Runge-Kutta procedure
with a step size of 0.0005 year and a force of interest of δ = 0.05 per annum. We
then present the premium rate for mutation carriers as a percentage of the premium
rate for non-mutation carriers.
6.5 The Insurance Model for
Huntington’s Disease
The CI model for HD is shown in Figure 6.2, which now has a state ‘onset of HD’,
from which a person can suffer the HD CI event, another CI event or death. As
discussed previously the onset of HD is not a critical illness event. The clinically
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defined event of onset of HD is taken to be the time when the first symptoms appear.
These first symptoms can be hard to recognise, in fact time of onset may often be
ascertained retrospectively, and would not result in a CI insurance claim as they
are usually very mild. There is no data available to model the time at which the
symptoms reach a stage that they would trigger a claim. There is, however, data
available on the time to clinically defined onset of HD and time to death from HD,
after onset; a critical illness claim would occur between these two events.
Harper defined three stages of HD, as seen in Table 4.1, using his own observations
and suggested that these three stages may be equal in duration. Here we assume
that the CI claim occurs as disease progression moves into either stage 2 or 3 of
Harper’s progression, defined in Section 4.1. In Section 3.5.2 we discussed papers
concerning HD and insurance. In this section we note that Gutie´rrez & Macdonald
(2004) used an accelerated lifetime model to adjust for the fact that the HD CI
event does not occur until some time after onset and some time before death. The
time to CI claim is modelled as an acceleration of the time to death after onset.
We take the random variable X to be the time in years from onset until death,
FX(x) to be the duration-dependent distribution of the lifetime after onset and
µ14(x) to be the associated intensity.
We multiply the timescale by a constant, η ≥ 1, to obtain a new random variable,
Y with intensity µ12(x) such that:
FY (x) = P [Y ≤ x] = P [X ≤ ηx] = FX(ηx). (6.20)
The intensities associated with X and Y are then related through:
µ12(x) = ηµ14(ηx). (6.21)
As the median of Y is 1/η times the median of X it is clear that giving η a value of 1.5
or 3 will then correspond to the critical illness event occurring, and therefore claims
being paid, after 2/3 or 1/3 of the survival time, respectively. These values may be
taken to represent Stage 3 and Stage 2 of Harper’s progression, respectively, and
it is of interest to determine premiums at both of these stages as different insurers
may use different definitions of the CI event for HD.
The other intensities in the model are defined as follows;
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Figure 6.2: A multiple state model for HD in Critical Illness insurance.
We estimate the intensity µ01(x) using the data obtained from the pedigrees.
The estimates of the intensities µ03(x) and µ04(x) are the same as those for breast
and ovarian cancer, without the adjustment for non-BRCA breast and ovarian can-
cer.
It is assumed here that the intensity µ13(x) is the same as for those who have
not suffered onset of HD, µ03(x) as having HD would not significantly affect the
likelihood of developing other critical illnesses.
For the intensity µ14(x) we use the same model of post-onset mortality as Gutie´rrez
& Macdonald (2002a) where the probability of surviving e years after onset of HD
is S(e).
For age at onset 20 - 34:
1− S(e) = 0.1742194.11789
∫ e
0
t3.11789 exp−0.174219t dt. (6.22)
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For age at onset 35 - 49:
1− S(e) = 0.1772254.35046
∫ e
0
t3.35046 exp−0.177225t dt. (6.23)
For age at onset 50 or over:
1− S(e) = 0.1833724.1465
∫ e
0
t3.1465 exp−0.183372t dt. (6.24)
For HD we also have to make a further alteration to the model which leads on from
the accelerated lifetime model. Now that we are using duration-dependent survival
rates after onset of HD the model becomes semi-Markov but certain calculations
can be brought back into a Markov framework.
A reserve, V HD(0, x + t), has to be set up when a person moves from the insured
healthy state to the onset state at age x + t. If the insurer pays out V HD(0, x + t)
as a sum assured at age x + t, equivalent to rewriting the risk at this point, then
the policy value in all of the other states stays the same.
The final alteration is that the proportion of people from each sub-population is
obviously different for HD, Table 6.3 shows these values.
Table 6.3: Proportions of the whole population who are in each of the three sub-
populations. Source: Harper, Lim & Craufurd (2000)
Subpopulation Proportion
Non HD carrier family 0.9996250
HD carrier family, applicant does not have mutation 0.0001875
HD carrier family, applicant has the mutation 0.0001875
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Chapter 7
Huntington’s Disease
7.1 Data
The data used for our study of HD were obtained from 60 pedigrees. The pedigrees
were compiled by Jacki Needs and Professor Lindsay Prior from the records of the
Institute of Medical Genetics at the University of Wales, Cardiff.
The pedigrees included from two to six generations. In most cases, the most recent
generations contained persons too young to contribute any relevant information.
Apart from the blood relationships, we may have some or all of the following data,
in respect of pedigree members:
• Calendar year of onset of HD.
• Calendar year in which a genetic test was carried out, and the result.
• Calendar year in which a person was last observed to be free of symptoms,
called the age at censoring.
• Calendar year of death and cause of death.
We excluded those who suffered onset before the age of 20 or after the age of 60
for two reasons, one genetic and one actuarial. Juvenile HD (very early onset) is
associated with very large numbers of CAG repeats. Including these cases may
skew the estimated distribution of the age at onset. Their removal, and that of
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very late-onset cases, is acceptable for actuarial purposes as the usual age range for
insurance is 20 to 60.
In total we had data on 538 people from HD families. Eight of these people were sus-
pected of having HD; they were not diagnosed clinically but their family suspected
that they had suffered from HD. In respect of 74 people we had no information
except year of birth and it was not known whether these people suffered onset of
HD. These problems were dealt with in ways that will be discussed in Section 7.3.
7.2 An Example of a Pedigree
The best way to explain how the data were obtained from the pedigrees and to
demonstrate how they were used is to give an example. Figure 7.1 is an example of
a three-generation pedigree. This example is hypothetical and it is used to illustrate
the features of the real pedigrees available. Here xi represents the age at onset or
censoring of the ith pedigree member.
I:1 (x1) The grandfather, the founder of this pedigree, was diagnosed with HD
when he was 40. This confirms that he has the huntingtin mutation.
II:1 (x2) The most recent information available indicates that this male was well
and free from HD at age 60, so the observation was censored at that age.
II:2 (x3) This male was diagnosed with HD at age 44 and subsequently died at
age 51.
II:3 (x4) This female was diagnosed with HD at age 50.
II:4 (x5) This male received a positive genetic test result at age 49, this was also
their age at censoring.
II:5 (x6) This woman died at age 26 (cause unknown), so the observation was
censored at that age.
III:1 (x7) This male tested negative for the huntingtin mutation and was censored
at age 33.
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II:1 (x2)
1940–
Well 2000
II:2 (x3)
1943–1994
Diag 1987
II:3 (x4)
1945–
Diag 1995
II:4 (x5)
1949–
+Test 1998
II:5 (x6)
1950–1976

III:1 (x7)
1967–
-Test 2000
III:2 (x8)
1972–
+Test 2000
Figure 7.1: Three generations of a sample HD pedigree. Squares are males, cir-
cles are females, and a slash denotes death. Affected individuals are shown as
filled squares/circles. The year of birth, death and other relevant information for
each person is shown. Individuals are labelled X:Y, where ‘X’ (Roman) labels the
generation and ‘Y’ (Arabic) the individual and xi represents the age at onset or
censoring.
III:2 (x8) This woman tested positive for the huntingtin mutation and was cen-
sored at age 28.
7.3 Missing Data Problems
The main problem is that the dates of one or more of the key events may be missing
in respect of one or more pedigree members.
The pedigree in Figure 7.1 has no missing information. To highlight the possi-
ble items of missing data we will introduce the following four problems with the
pedigree:
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Problem 1. Assume that person II:2 was diagnosed with HD postmortem (age at
death was 51).
Problem 2. Assume that person II:2 suffered onset in their 40’s.
We therefore do not know at what age this person suffered onset of HD.
Problem 3. Assume that person II:1 was born in 1940 and no other information
is available. We therefore have no information about this person except their
year of birth.
Problem 4. Assume that the relatives suspected that person II:3 suffered onset of
HD at age 50. Therefore this person has not been diagnosed medically but
the family believe that they did suffer from HD.
Our approach is to deduce or postulate upper and lower limits for the missing dates,
and to estimate onset rates under each assumption to give a range of results. In
practice, the range of results so obtained is acceptably small.
(a) If evidence of onset was found only at a postmortem examination then the
age at death is an upper bound of possible onset times, and we will take ten
years before death to be a lower bound.
– Possible solution to Problem 1.
The upper and lower limits for the age at onset for Person II:2 would be
51 and 41, respectively.
(b) A person may only be known to have suffered onset between certain ages.
These ages are their own lower and upper bounds for the age of onset.
– Possible solution to Problem 2.
Upper and lower bounds for the age at onset for Person II:2 would be 40
and 50, respectively.
(c) If we know only the year of birth there are three ways to proceed.
(i) Assume that the person was alive and free from HD in the last calendar
year in which their pedigree was observed (Assumption A1).
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– Possible solution to Problem 3.
Assume Person II:1 alive and free from HD in the year 2000, age
60.
(ii) Exclude them from the sample (Assumption A2).
– Possible solution to Problem 3.
Exclude only Person II:1 from the analysis.
(iii) Remove the entire sibship of which they are a member (Assumption A3).
– Possible solution to Problem 3.
Exclude the whole pedigree from the analysis.
(d) In some cases HD had not been diagnosed by a medical practitioner but
relatives suspected that a pedigree member had developed HD. In this case
three assumptions are made:
(i) Assume that the pedigree member did develop HD at the time stated by
the family (Assumption B1).
– Possible solution to Problem 4.
Assume Person II:3 suffered onset of HD at age 50.
(ii) Assume that the pedigree member did not develop HD and observation
is censored at the time stated by the family (Assumption B2).
– Possible solution to Problem 4.
Assume Person II:3 was alive and free from HD at age 50.
(iii) Exclude the pedigree member from the sample (Assumption B3).
– Possible solution to Problem 4.
Exclude Person II:3 from the analysis.
Table 7.1 shows how each assumption should affect the estimated rate of onset.
Making assumptions A1 and B1 together will have little or no effect on the estimated
age at onset. Making assumption A1 will result in an overestimate while B1 will
underestimate the age at onset, which implies that making both assumptions should
result in an estimate very close to the one which would be achieved if there were
no missing data.
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Table 7.1: The assumptions made about missing or indeterminate data and how
each assumption should affect the rate of onset. A1–A3 and B1–B3 are the labels
referred to in Section 7.3.
Assumptions Effect on Age at Onset
A1 & B1 Not significant
A2 & B1 Underestimate
A3 & B1 Underestimate
A1 & B2 Overestimate
A1 & B3 Overestimate
7.4 Results — Onset Rates
Table 7.2 shows the results under all the assumptions given in Table 7.1.
The first row of the table illustrates the maximum likelihood estimates of the mean
m and standard deviation σ of the Normal distribution of age at onset, using all
available data, excluding only those who suffered onset before age 20 and after age
60 and making Assumptions A1 and B1. The remainder of the table shows the
results obtained under the assumptions defined in Section 7.3.
The table is presented in two parts, based on assumptions of ‘earliest possible age at
onset’ and assumptions of ‘latest possible age at onset’ when dealing with missing
data. It is clear that the assumptions have the expected effect on the estimated age
at onset distribution.
The estimates for mean age at onset obtained here, when assuming ‘earliest age
at onset’ lie in the interval (42.64, 43.98) and fall in the range of estimates from
the studies in Table 4.2. The estimates obtained assuming ‘latest possible age at
onset’ lie in the interval (43.71, 45.42) and are, for the most part, slightly higher
than those estimated in previous studies.
All of our estimated means are lower than the estimate of 45.96 years obtained by
Newcombe (1981).
Our age at onset distributions, although slightly higher than most previous studies
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Table 7.2: The Normal model and sensitivity analyses. The parameters mˆ and σˆ
are the mean and standard deviation of the age at onset, respectively, and N is
the sample size. The sampling variance of each estimate is shown in parentheses.
Assumptions A1–B3 are described in Section 7.3.
‘Earliest Possible Age At Onset’
Assumption N mˆ σˆ Cov(mˆ, σˆ)
A1 & B1 538 43.67 (0.982) 13.26 (0.509) 0.229
A2 & B1 538 43.09 (0.962) 13.21 (0.502) 0.197
A3 & B1 397 42.64 (1.113) 13.27 (0.581) 0.212
A1 & B2 538 43.98 (1.062) 13.43 (0.551) 0.264
A1 & B3 538 43.84 (1.052) 13.40 (0.546) 0.257
‘Latest Possible Age At Onset’
Assumption N mˆ σˆ Cov(mˆ, σˆ)
A1 & B1 538 45.04 (1.166) 14.52 (0.603) 0.275
A2 & B1 538 44.41 (1.149) 14.47 (0.596) 0.238
A3 & B1 397 43.71 (1.350) 14.64 (0.704) 0.263
A1 & B2 538 45.42 (1.275) 14.80 (0.660) 0.320
A1 & B3 538 45.27 (1.266) 14.76 (0.655) 0.312
have estimated, are plausible. For the calculation of premium rates we will use the
mean and standard deviation estimated under assumptions A1 and B1, assuming
both ‘earliest’ and ‘latest’ ages at onset, that is; 43.67 and 13.26, and 45.04 and
14.52, respectively (all in years).
Figure 7.2 shows the distribution of age at onset assuming earliest and latest age at
onset. Also shown in the figure are the distributions obtained assuming a Normal
distribution for the mean and standard deviations found by Reed et al. (1958) and
Wendt et al. (1959). These two studies represent the highest and lowest mean age
at onset in Table 4.2, 35.3 and 43.97, respectively. The shape of the distributions of
age at onset obtained through maximising the pedigree likelihood (assuming both
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‘earliest’ and ‘latest’ age at onset) is very similar to that of both Bell (1934) and
Wendt et al. (1959). There are slight differences in the position of the distributions,
resulting from differences in the estimates of the mean parameter mˆ.
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Figure 7.2: Distribution of age at onset of Huntington’s Disease estimated from
the pedigree data, assuming both ‘earliest’ and ‘latest age at onset’. The figure
also shows the distributions of age at onset of HD obtained assuming a Normal
distribution for the mean and standard deviation found by Bell (1934) and Wendt
et al. (1959).
7.5 Results – Premium Rates
As described in Section 5.8 we carried out bootstrapping using the estimates ob-
tained in Section 7.4 to obtain the distribution of the premium rate, expressed as a
percentage of the OR premium rate.
Simulated values of m and σ were obtained from the multivariate normal distribu-
tion, MN(a, b), where a is the mean vector and b is the covariance matrix.
For ‘earliest possible age at onset’ we used:
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a = (43.67, 13.26) and b =
⎛
⎝ 0.982 0.229
0.229 0.509
⎞
⎠ ,
and for the ‘latest possible age at onset’
a = (45.04, 14.52) and b =
⎛
⎝ 1.166 0.275
0.275 0.603
⎞
⎠ ,
Given the 1, 000 bootstrapped estimates of the premium rate we then obtained
estimates of the standard deviation of the sampling distribution of the premium
rate estimate using the methods outlined in Section 5.8.
Estimates of these quantities for ‘earliest age at onset’, for a combination of ages
and terms, are shown in Table 7.3 and Table 7.4, with the CI event defined as
progression to Harper’s Stage 2 and Stage 3, respectively. Table 7.5 and Table 7.6
show the same results for ‘latest age at onset’.
The bootstrap-estimated sampling distributions of the premium rates obtained for
an insurance policy term of 10 years are illustrated in Figures 7.3 and 7.4 (assuming
‘earliest’ and ‘latest’ ages at onset, respectively). The figures show the premium
rate sampling distributions of both males and females, with the CI event defined as
either Stage 2 or Stage 3 of Harper’s progression.
Figures 7.5 and 7.6 also show the sampling distributions of the premium rates but
for a variety of policy terms, assuming the age at which the person purchased the
insurance policy was 20 years. The four plots shown in each figure have differing
scales as the actual ranges of the sampling distributions of the premium rate differ
so much, depending on the definition of the CI event and the sex of the applicant.
We make the following comments:
(a) The definition of the CI event affects the insurance premium significantly.
Figures 7.3 and 7.4 show that, although the sampling distributions of the
premium rate are very similar in shape for both Stages 2 and 3, there is a big
difference in the average premium rate. When Stage 3 of Harper’s progression
is defined as the CI event, the premium is significantly reduced.
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(b) Figures 7.5 and 7.6 show that the definition of the CI event and the sex of the
applicant have a significant effect on the sampling distribution of the premium
rate, particularly for shorter policy terms.
(c) Given that a premium of about 300− 350% of the standard rate will result in
an applicant being declined insurance it is clear that insurance would only be
offered to those at age 50 for a term of 10 years, when the CI event is defined
as Harper’s Stage 3.
(d) Gutie´rrez and Macdonald (2003) estimated the premium, as a percentage of
the standard rate, for different CAG repeat lengths (36−50). Their estimates
for those with 50 CAG repeats are slightly lower than ours but they follow
the same pattern. They found, however, that insurance could be offered for a
number of combinations of CAG repeat lengths, terms and ages. Comparing
their results for different CAG repeat lengths with our results highlights the
fact that those with a lower number of CAG repeats would pay lower insurance
premiums than if they were underwritten on the basis of family history alone.
(e) The estimates of the standard deviation of the bootstrapped premium rate
estimates give us an idea of the sampling variability of the estimated insurance
premium. It is clear, from both the tables and the plots, that there is more
variance in the premium rate for the lower ages and terms. This variance
decreases as the term of the policy and the age when insurance is purchased
increases.
(f) Whether we take the ‘earliest’ or ‘latest’ possible age at onset does not make
a big difference to the resulting sampling distributions of the premium rate,
seen by comparing Figures 7.3 and 7.4, and Figures 7.5 and 7.6.
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Figure 7.3: Sampling distribution of the premium rate for a range of ages, assuming
‘earliest possible age at onset’ and an insurance term of 10 years. The scales of the
x and y axes are not the same for all four plots.
Top Left: Female with CI event defined as Harper’s Stage 3.
Top Right: Male with CI event defined as Harper’s Stage 3.
Bottom Left: Female with CI event defined as Harper’s Stage 2.
Bottom Right: Male with CI event defined as Harper’s Stage 2.
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Figure 7.4: Sampling distribution of the premium rate for a range of ages, assuming
‘latest possible age at onset’ and an insurance term of 10 years. The scales of the
x and y axes are not the same for all four plots.
Top Left: Female with CI event defined as Harper’s Stage 3.
Top Right: Male with CI event defined as Harper’s Stage 3.
Bottom Left: Female with CI event defined as Harper’s Stage 2.
Bottom Right: Male with CI event defined as Harper’s Stage 2.
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Figure 7.5: Sampling distribution of the premium rate for a range of policy terms,
assuming ‘earliest possible age at onset’ and the age at which the policy is taken
out is 20 years old. The scales of the x and y axes are not the same for all four
plots.
Top Left: Female with CI event defined as Harper’s Stage 3.
Top Right: Male with CI event defined as Harper’s Stage 3.
Bottom Left: Female with CI event defined as Harper’s Stage 2.
Bottom Right: Male with CI event defined as Harper’s Stage 2.
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Figure 7.6: Sampling distribution of the premium rate for a range of policy terms,
assuming ‘latest possible age at onset’ and the age at the which policy is taken out
is 20 years old. The scales of the x and y axes are not the same for all four plots.
Top Left: Female with CI event defined as Harper’s Stage 3.
Top Right: Male with CI event defined as Harper’s Stage 3.
Bottom Left: Female with CI event defined as Harper’s Stage 2.
Bottom Right: Male with CI event defined as Harper’s Stage 2.
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7.5.1 Ascertainment Bias
The range of estimates of m obtained after adjusting for ascertainment bias, by
randomly removing one proband from each pedigree are shown in Table 7.7. The
range of the estimated m values is quite small and they are very similar to the es-
timates used for obtaining the premium rate without adjustment for ascertainment
bias, (Section 7.4). There are some differences, however, in the covariance matrices
associated with the estimates, in particular the variance of m ranges from 0.8 to 1.3
and the variance of σ ranges from 0.4 to 0.7, when assuming ‘latest age at onset’
and 0.8 to 1.0 and 0.4 to 0.5, respectively, when assuming ‘earliest age at onset’.
We then simulate from each of these estimated normal distributions, as explained
in Section 5.9. The range of the estimates of m and σ, being used for estimation of
the premium rates, is wider than when no ascertainment adjustment is carried out,
see Table 7.8.
Table 7.7: The minimum and maximum bootstrapped values of m when adjusting
for ascertainment bias, where m is the mean of the age at onset.
‘Earliest Possible Age At Onset’ ‘Latest Possible Age At Onset’
Min m Max m Min m Max m
42.7 44.4 45.0 46.8
Table 7.8: The minimum and maximum of the bootstrapped values of m carrying
out the random sampling from the multivariate normal distributions, where m is
the mean of the age at onset.
‘Earliest Possible Age At Onset’ ‘Latest Possible Age At Onset’
Min m Max m Min m Max m
39.1 47.6 41.2 50.6
Tables 7.9 – 7.12 show the premium rates, as a percentage of the standard rate,
when the onset rate is adjusted for ascertainment bias.
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The estimated premiums when an ascertainment adjustment is made, given as per-
centages of the OR premium, are slightly lower than when no adjustments are made.
The only exceptions to this occur for those taking out the policy at age 50 for a
term of 10 years, with the rate being slightly higher or equal after adjusting for
ascertainment bias. The estimated mean age at onset, after adjustment for ascer-
tainment bias, seems to be slightly higher than when no adjustment is made. For
most of the ages and policy terms this would, and does, result in a lower premium
rate. However, when no adjustment is made the risk begins to fall at a slightly
earlier age than when adjustment is made and this results in the premium rate for
age 50 being slightly higher when adjusted for ascertainment bias.
The standard deviation of the premium rate is higher when adjusted for ascertain-
ment bias, this will be partly due to the fact that the variance in the estimates of
the parameters of the distribution of age at onset is a lot higher after ascertainment
adjustment.
When Harper’s Stage 2 is defined as the CI event, the premium rate follows the
same pattern as when no adjustment is made for ascertainment bias (Tables 7.3
and 7.5) .
When Stage 3 is used as the CI event the only insurable cases are still those at 50
years of age for a term of 10 years, but a number of cases have a premium closer to
the 350% limit.
Figure 7.7 illustrates the difference that adjusting for ascertainment bias can make
to the premium rate sampling distributions. These are shown for females only as,
although the actual premium rate values for males are quite different, the relation-
ship between the estimated sampling distributions with and without adjustment for
ascertainment bias is very similar. For the same reason we show only the results
obtained assuming ‘latest possible age at onset’. The plots show that there are
big differences in the the sampling distributions of the premium rates, with little
overlap between the distributions with and without ascertainment adjustment. Al-
though for HD this difference has no effect on the overall conclusions it is clear that
it is important to adjust for ascertainment bias as it does have a large effect on the
premium rate sampling distributions.
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Figure 7.7: The sampling distributions for the premium rate assuming either
Harper’s Stage 2 or Stage 3 as the CI event, with and without adjustment for
ascertainment bias. The scales are not the same for both plots. Left: The distribu-
tions for Females of age 20 for a policy term of 40 years. Right: The distributions
for Females of age 30 for a policy term of 30 years.
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7.6 Conclusions
A number of factors will determine whether or not a person with a known HD
mutation would be offered critical illness insurance.
Although insurance would not be offered for the majority of ages and policy terms
the possibility of being able to take out insurance is greatly affected by the definition
of the CI event used by the insurer. If Stage 2 of Harper’s progression is the CI event
used by an insurer then an applicant would not be offered insurance, regardless of
age and the term of the policy they were seeking. If, however, Stage 3 of Harper’s
progression is defined as the CI event a person may be offered insurance for a policy
term of 10 years when taking out insurance at 50 years old only.
Adjusting for ascertainment bias, by removing randomly selected ‘probands’ from
each pedigree, has an effect on the sampling distribution of the premium rate. There
are differences in the location and shape of the distribution with the distributions
after adjusting for ascertainment bias having a slightly lower mean than when no
adjustment was made and a higher standard deviation. This difference appears to
be slightly greater when the CI event is defined as Stage 2 of Harper’s progression
rather than Stage 3. Although the effect of adjusting for ascertainment bias does
not make any difference to the overall conclusions concerning insurance for those
known to carry HD mutations there is a clear effect on the premium rate sampling
distributions.
As described in Section 3.2, an application to GAIC for a specific genetic test and
specific insurance product must include evidence of the actuarial significance of the
genetic test. The results obtained here allow us to conclude that there is indeed
a high probability that carriers of the HD mutation suffer onset of Huntington’s
Disease and that the critical illness event, either Stage 2 or 3 of Harper’s progression,
will occur at such an age that the premium rate that would be charged would result
in the carrier being declined critical illness insurance at almost all ages and policy
terms. However, as demonstrated by Gutie´rrez and Macdonald (2003), using the
extra information of CAG repeat lengths, not available for the pedigrees in this
investigation, could result in insurance being offered at more ages and policy terms.
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The main advantage of the work carried out here is that determining premium rate
sampling distributions and adjusting for ascertainment bias, using actual pedigree
data, results in the strengthening of any conclusions made. This will have significant
relevance to GAIC, in terms of the evidence needed for any future applications to
use a genetic test result to calculate insurance premiums, especially in the case of
disorders which are less penetrant, and not as clear-cut as Huntington’s Disease.
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Chapter 8
Breast and Ovarian Cancer
8.1 Data
Thirty of the BRCA1/2 related breast and ovarian cancer pedigrees were obtained
from the records of the Institute of Medical Genetics at the University of Wales,
Cardiff. The other twenty-four were obtained from Southampton by our collabora-
tors Jacki Needs and Professor Lindsay Prior.
Ten of the pedigrees were known to have the BRCA2 mutation while the rest were
known to have BRCA1 mutations. As there was not enough data to estimate
the onset rate of breast and ovarian cancer for BRCA2 carrying pedigrees we will
consider only those with the BRCA1 mutation. This leaves us with 44 pedigrees.
For both breast and ovarian cancer we are using the Gamma distribution for the
distribution of the age at onset and we will therefore have four parameters to esti-
mate.
From the 44 BRCA1 pedigrees there were 270 people for whom sufficient data
were available. Males were not included in the analysis unless they were known to
have a BRCA1 mutation. As with HD there were a number of people for whom all
information was missing with the exception of their year of birth. When all sibships
containing any of these people were removed (Assumption A3 in Section 7.3) we
were left with only 172 people.
The information obtained from these pedigrees was the same as for HD:
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• Calendar year of onset.
• Calendar year in which a genetic test was carried out, and the result.
• Calendar year in which a person was last observed to be free of symptoms,
called the age at censoring.
• Calendar year of death and cause of death.
8.2 Results – Onset Rates
As noted in Section 5.6 we will use previously published penetrance estimates for
breast and ovarian cancer in the likelihoods to estimate the distribution of age at
onset. So as to assess the effect of the assumed penetrance on the estimated age at
onset distribution we will use results from three studies, see Table 8.1.
Table 8.1: The penetrance estimates that we use in the estimation of the onset rates
of breast and ovarian cancer and the studies they were obtained from.
Reference Breast Cancer Ovarian Cancer
Lalloo et al. (2006) 84% 60%
Antoniou et al. (2006) 72% 38%
Antoniou et al. (2003) 65% 39%
Tables 8.2 – 8.4 show the results for all of the assumptions given in Section 7.3
for each set of penetrance estimates. Here we use assume that both ovarian and
breast cancer follow a Gamma distribution with parameters α and β. The first row
of each table illustrates the results using all of the available data. The Gamma
distribution obtained using the parameter estimates in the tables will be multiplied
by the corresponding penetrance estimates to obtain the distribution of the age at
onset. In this dataset the people for whom no further information is available are
assumed to be alive and still at risk in the last calendar year in which the sibship
was observed.
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The estimates of α and β obtained for breast cancer are consistently higher than for
ovarian cancer regardless of the penetrance estimates used. There is no significant
difference in the results obtained under either assumption A1 or A2 although car-
rying out the analysis under assumption A3 does increase the parameter estimates
significantly.
For the estimation of the premium rates we will use the parameters, and variances,
obtained through assumption A1 at both ‘earliest’ and ‘latest’ possible year. To
obtain the actual distribution of the age at onset we multiply the gamma distri-
bution by the corresponding penetrance estimates. As the results obtained using
the penetrance estimates of both Antoniou et al. (2003) and Antoniou et al. (2006)
are practically the same for ovarian cancer and quite close for breast cancer we will
carry out the premium rate estimation using Antoniou et al. (2006) and Lalloo et al.
(2006) only. Figures 8.1 and 8.2 show the estimated distributions of the age at onset
for breast and ovarian cancer given the three different penetrance estimates, under
assumption A1, and demonstrate how close the estimated distributions actually are.
Figure 8.3 shows the estimated distributions of age at onest for both breast and
ovarian cancer, using the penetrance estimates of Lalloo et al. (2006) as well as the
distributions obtained by Macdonald et al. (2003a) by fitting truncated Gamma dis-
tributions to the estimated incidence rates of Ford et al. (1998) for BRCA1 carriers.
For both breast and ovarian cancer the distribution of age at onset estimated here is
very similar in shape to that used by Macdonald et al. (2003a). There are, however,
differences in the location. The study used by Macdonald et al. (2003a) found that
breast and ovarian cancer were diagnosed slightly later, on average, (about 48 and
55, respectively) than we have in our data (44 and 46, respectively).
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Table 8.2: The Gamma model and sensitivity analyses using the penetrance esti-
mates of Lalloo et al. (2006). α and β are the parameters of the Gamma distribution
and N is the sample size. The variance of each estimate is shown in parentheses.
Assumptions A1–A3 are described in Section 7.3.
‘Earliest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 BC 270 16.36 (0.93) 0.41 (0.0007) 0.0224
A2 BC 270 16.42 (0.38) 0.41 (0.0003) 0.0091
A3 BC 172 19.28 (0.57) 0.48 (0.0005) 0.0137
A1 OC 270 14.66 (1.11) 0.37 (0.0008) 0.0269
A2 OC 270 14.69 (0.89) 0.37 (0.0006) 0.0215
A3 OC 172 17.23 (1.09) 0.43 (0.0008) 0.0261
‘Latest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 BC 270 18.35 (0.43) 0.45 (0.0004) 0.0102
A2 BC 270 18.40 (0.84) 0.45 (0.0006) 0.0120
A3 BC 172 22.94 (0.44) 0.55 (0.0004) 0.0102
A1 OC 270 16.42 (0.51) 0.40 (0.0004) 0.0122
A2 OC 270 16.45 (0.67) 0.40 (0.0005) 0.0159
A3 OC 172 20.49 (2.83) 0.50 (0.002) 0.0665
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Table 8.3: The Gamma model and sensitivity analyses using the penetrance es-
timates of Antoniou et al. (2006). α and β are the parameters of the Gamma
distribution and N is the sample size. The variance of each estimate is shown in
parentheses. Assumptions A1–A3 are described in Section 7.3.
‘Earliest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 BC 270 15.56 (0.33) 0.38 (0.0003) 0.0078
A2 BC 270 15.59 (1.86) 0.38 (0.0012) 0.0442
A3 BC 172 18.72 (1.05) 0.46 (0.0008) 0.0249
A1 OC 270 14.71 (0.85) 0.36 (0.0006) 0.0202
A2 OC 270 14.73 (0.85) 0.36 (0.0006) 0.0203
A3 OC 172 17.55 (1.06) 0.43 (0.0004) 0.0252
‘Latest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 BC 270 17.34 (0.67) 0.41 (0.0005) 0.0158
A2 BC 270 17.38 (0.97) 0.41 (0.0007) 0.0228
A3 BC 172 21.73 (2.10) 0.52 (0.0013) 0.0489
A1 OC 270 16.38 (1.31) 0.39 (0.0008) 0.0306
A2 OC 270 16.40 (0.53) 0.39 (0.0004) 0.0123
A3 OC 172 20.50 (1.50) 0.49 (0.0010) 0.0351
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Table 8.4: The Gamma model and sensitivity analyses using the penetrance es-
timates of Antoniou et al. (2003). α and β are the parameters of the Gamma
distribution and N is the sample size. The variance of each estimate is shown in
parentheses. Assumptions A1–A3 are described in Section 7.3.
‘Earliest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 BC 270 15.70 (5.86) 0.38 (0.0025) 0.1319
A2 BC 270 15.75 (0.53) 0.38 (0.0004) 0.0125
A3 BC 172 18.56 (0.54) 0.45 (0.0005) 0.0127
A1 OC 270 14.77 (0.35) 0.36 (0.0002) 0.0053
A2 OC 270 14.79 (2.17) 0.36 (0.0014) 0.0517
A3 OC 172 17.51 (0.74) 0.43 (0.0006) 0.0176
‘Latest Possible Age At Onset’
Assumption Disorder N α β Cov(α, β)
A1 OC 270 17.52 (1.71) 0.42 (0.001) 0.0401
A2 OC 270 17.56 (0.32) 0.42 (0.0003) 0.0076
A3 OC 172 21.97 (0.85) 0.52 (0.0006) 0.0199
A1 OC 270 16.47 (0.70) 0.39 (0.0005) 0.0165
A2 OC 270 16.48 (0.84) 0.39 (0.0006) 0.0197
A3 OC 172 20.59 (0.26) 0.49 (0.0003) 0.0061
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Figure 8.1: Distributions of age at onset for Breast Cancer obtained using the
penetrance estimates of Antoniou et al. (2006), Antoniou et al. (2003) and Lalloo
et al. (2006); Left: Assuming ‘Earliest age at onset’ and Right: Assuming ‘Latest
age at onset’.
8.3 Results – Premium Rates
As for HD we carried out bootstrapping using the estimates obtained in Section
8.2 to obtain the distribution of the premium rate. As in Section 7.4 we simulated
values of α and β using a multivariate normal distribution, MN(a, b) where a is
the mean vector (αBC , βBC , αOC, βOC) and b is the covariance matrix.
Antoniou et al. (2006)
For ‘earliest possible age at onset’ we used:
a = (15.56, 0.38, 14.71, 0.36) and b =
⎛
⎜⎜⎜⎜⎜⎜⎝
0.3300 0.0078 0.0000 0.0000
0.0078 0.0003 0.0000 0.0000
0.0000 0.0000 0.8500 0.0202
0.0000 0.0000 0.0202 0.0006
⎞
⎟⎟⎟⎟⎟⎟⎠
and for ‘latest possible age at onset’ we used:
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Figure 8.2: Distributions of age at onset for Ovarian Cancer obtained using the
penetrance estimates of Antoniou et al. (2006), Antoniou et al. (2003) and Lalloo
et al. (2006); Left: Assuming ‘Earliest age at onset’ and Right: Assuming ‘Latest
age at onset’.
a = (17.34, 0.41, 16.38, 0.39) and b =
⎛
⎜⎜⎜⎜⎜⎜⎝
0.6700 0.0158 0.0000 0.0000
0.0158 0.0005 0.0000 0.0000
0.0000 0.0000 1.3100 0.0306
0.0000 0.0000 0.0306 0.0008
⎞
⎟⎟⎟⎟⎟⎟⎠
Lalloo et al. (2006)
For ‘earliest possible age at onset’ we used:
a = (16.36, 0.41, 14.66, 0.37) and b =
⎛
⎜⎜⎜⎜⎜⎜⎝
0.9300 0.0224 0.0000 0.0000
0.0224 0.0007 0.0000 0.0000
0.0000 0.0000 1.1100 0.0269
0.0000 0.0000 0.0269 0.0008
⎞
⎟⎟⎟⎟⎟⎟⎠
and for ‘latest possible age at onset’ we used:
a = (18.35, 0.45, 16.42, 0.40) and b =
⎛
⎜⎜⎜⎜⎜⎜⎝
0.4300 0.0102 0.0000 0.0000
0.0102 0.0004 0.0000 0.0000
0.0000 0.0000 0.5100 0.0122
0.0000 0.0000 0.0122 0.0004
⎞
⎟⎟⎟⎟⎟⎟⎠
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Figure 8.3: Distribution of age at onset for Breast Cancer (left) and Ovarian Cancer
(right). Both ‘earliest age at onset’ and ‘latest age at onset’ are shown, assuming
the penetrance estimates obtained by Lalloo et al. (2006). The distributions used
by Macdonald et al. (2003) were obtained by fitting truncated Gamma distributions
to the estimated incidence rates of Ford et al. (1998) for BRCA1 carriers.
Tables 8.5 and 8.6 show the bootstrapped estimates of the premium rate, obtained
using the penetrance estimates of Antoniou et al. (2006), for the ‘earliest age at
onset’ and ‘latest age at onset’, respectively, while Tables 8.7 and 8.8 show the
equivalent results using the penetrance estimates of Lalloo et al. (2006). We only
calculate premium rates for females as male breast cancer is extremely rare in the
population.
Based on Tables 8.5 – 8.8 and the chosen combinations of age, policy term and
penetrance estimates illustrated in Figures 8.4 and 8.5 we make the following com-
ments:
(a) The results are affected by the penetrance estimates, and therefore the esti-
mated distribution of age at onset. Using the penetrance estimates of Lalloo
et al. (2006) results in consistently higher premiums. As the penetrance es-
timates of Lalloo et al. (2006) are higher than that of Antoniou et al. (2006)
this is to be expected, the higher the penetrance of a disorder the higher the
probability of a mutation carrier developing the disorder. An increase in the
probability of developing a disorder will result in an increase in the insurance
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premiums.
(b) The assumed age at onset, earliest or latest, does not affect the result signif-
icantly. The premium rates would be slightly higher for insurance taken out
at ages 20 and 30 if the ‘earliest age at onset’ was assumed, and higher at
ages 40 and 50 if we assumed ‘latest age at onset’.
(c) An applicant known to carry a BRCA1 mutation would be refused insurance
for any age or term, regardless of the assumed age at onset for the missing
data or the penetrance estimates used as the premium is higher than 350%
of the ordinary premium rate. Again, regardless of the assumptions made,
the only age at which an applicant would have a possibility of being offered
insurance, though unlikely, would be at age 50 for a term of 10 years.
(d) Although very high at age 20 the standard deviation of the estimated per-
centage of the OR premium does decrease as the term of policy increases.
(e) From Figure 8.4 we can see that the percentage of the ordinary premium rate
is highest at age 30, for a term of ten years. The ordinary premium rate at
age 30 would not be very high as the risk of CI at this age would be low in
the general population. The risk of CI for BRCA mutation carriers, however,
would be very high at age 30, giving a high% of the OR. The risk at age 20
would be also low in the general population but the excess risk associated
with being a mutation carrier would not have come into effect at age 20. At
age 40 and 50 the excess risk of mutation carriers would be high but not as
high, in comparison to the risk in the general population, as at age 30.
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Figure 8.4: Sampling distribution of the premium rate for a range of ages, for an
insurance policy term of 10 years.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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Figure 8.5: Sampling distribution of the premium rate for a range of policy terms,
given the age at which insurance was taken out was 20 years old.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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8.4 Ascertainment Bias
We adjust for ascertainment, as we did for Huntington’s Disease, by randomly re-
moving one proband from each pedigree, as we do not know which pedigree member
is the proband and then simulating values from the multivariate normal distribution
with the mean being each set of parameter estimates in turn and the variance being
the corresponding covariance matrix. However, as discussed in Section 5.9, in the
case of breast and ovarian cancer the pedigrees are not usually ascertained through
one proband alone. Therefore we also adjust for ascertainment bias by randomly
removing two probands from each pedigree and maximising the likelihood using the
remaining data. It is of interest to see whether the removal of an extra proband
makes any difference to the resulting premium rate estimates.
Tables 8.9 and 8.10 illustrate the premium rate results using the penetrance esti-
mates of Antoniou et al. (2006) and randomly removing one proband from each
pedigree, for ‘earliest’ and ‘latest’ age at onset, respectively. Tables 8.11 and 8.12
show the corresponding results when two probands were randomly removed from
each pedigree.
Tables 8.13 – 8.16 show the same results using the penetrance estimates from Lalloo
et al. (2006).
We make the following comments:
(a) Adjusting for ascertainment bias, by removing randomly selected probands,
does not significantly affect the premium rate.
(b) The premium rate is, however, higher without any ascertainment adjustment
than when any probands are removed for the majority of the policies and
terms. As with HD, the exception to this occurs at age 50 when the premium
rate is lower when no adjustment is made for ascertainment bias.
(c) The standard deviation of the premium rate estimates are higher when 2
probands are removed as compared to when only one proband was removed.
(d) The standard deviation when no proband is removed is consistently lower
than when any adjustment is made for ascertainment bias.
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(e) Even after adjustment for ascertainment bias applicants would still be refused
insurance at all ages and for all policy terms.
Figures 8.6 - 8.9 illustrate the differences in the sampling distributions of the pre-
mium rates for a variety of policy terms, ages and methods of adjustment for as-
certainment bias. The average premium rate is reduced, though not significantly
when adjusting for ascertainment bias, evident in the plots. The differences in the
plots represents the differences in estimated % of the OR premium and differences
in the standard deviation of these estimates.
Although an effect of ascertainment adjustment is evident it does not appear to
significantly affect the resulting premium rates. One explanation for a lack of effect
could be the due to the use of published penetrance estimates in the distributions of
age at onset for both disorders, rather than obtaining estimates for the penetrance
as two more parameters in the maximum likelihood estimation.
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Figure 8.6: Sampling distributions of the premium rate, for a female aged 50 seek-
ing an insurance policy term of 10 years with; (a) no adjustment for ascertainment
bias, (b) adjusting for ascertainment bias by removing one proband from each pedi-
gree and (c) adjusting for ascertainment bias by removing two probands from each
pedigree.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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Figure 8.7: Sampling distribution of premium rate, for a female aged 40 seeking an
insurance policy term of 20 years with; (a) no adjustment for ascertainment bias, (b)
adjusting for ascertainment bias by removing one proband from each pedigree and
(c) adjusting for ascertainment bias by removing two probands from each pedigree.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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Figure 8.8: Sampling distribution of premium rate, for a female aged 30 seeking an
insurance policy term of 30 years with; (a) no adjustment for ascertainment bias, (b)
adjusting for ascertainment bias by removing one proband from each pedigree and
(c) adjusting for ascertainment bias by removing two probands from each pedigree.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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Figure 8.9: Sampling distribution of premium rate, for a female aged 20 seeking an
insurance policy term of 40 years with; (a) no adjustment for ascertainment bias, (b)
adjusting for ascertainment bias by removing one proband from each pedigree and
(c) adjusting for ascertainment bias by removing two probands from each pedigree.
Top Left: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘earliest age at onset’.
Top Right: Using the penetrance estimates of Antoniou et al. (2006) and assuming
‘latest age at onset’.
Bottom Left: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘earliest age at onset’.
Bottom Right: Using the penetrance estimates of Lalloo et al. (2006) and assuming
‘latest age at onset’.
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8.5 Conclusions
Based on the distributions of the age at onset for breast and ovarian cancer, for
BRCA1 carriers, estimated using the pedigrees available to us, it would be very
unlikely for a female to be offered critical illness insurance at any age or for any
policy term.
As would be expected the estimate of the penetrance used affects the estimated
distribution of age at onset and the resulting premium rate sampling distributions;
using higher penetrance estimates results in higher premium rates. As critical illness
insurance would not be offered at any age or term, however, it does not make any
difference to the conclusions reached in this investigation although it is something
that should be thought about in any future studies. Using reliable penetrance
estimates when estimating the distribution of the age at onset will result in more
reliable premium rate estimates.
As with Huntington’s Disease the choice of whether to use ‘earliest’ or ‘latest’ age
at onset for those whose age at onset was missing does not make any real difference
to the resulting premium rates.
Adjustment for ascertainment bias, either by removing one or two randomly selected
probands from each pedigree, increases the standard deviation of the estimated
premium and reduces the mean premium rate slightly. This is an interesting result
illustrating that, although there is some change in the sampling distribution of the
premium rates depending on whether ascertainment bias is adjusted for or not, it is
small and does not result in any change in the conclusions reached about whether
a person would be insured given that they were known to be a BRCA1 mutation
carrier. It would be interesting to see if this were still the case if we estimated the
penetrance of breast and ovarian cancer rather than using published estimates.
As with HD there is evidence that the premium rates that a BRCA1 mutation carrier
would be charged would result in them being declined critical illness insurance for
most ages and policy terms. This suggests that there is evidence that the genetic
test for BRCA1 has actuarial significance.
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Chapter 9
Familial Adenomatous Polyposis
9.1 Data
We have data from 40 FAP pedigrees supplied by Cardiff University, including 152
persons with FAP. Some had to be excluded because of lack of information about
year of birth, leaving 132 with known age at onset. Of these, 107 were diagnosed
by screening, and 25 were not identified as having FAP until they were diagnosed
with CRC or until they died.
The discussion of the analysis of the FAP data deserves a chapter to itself, as the
FAP data and FAP disease take on a slightly different form than the other disorders
considered.
9.2 How Might Screening Affect Insurance Risk
Here we are interested in how the availability of screening, and now genetic testing,
for FAP may affect life and critical illness insurance. We ask: (a) does screening
reduce the risk of CRC and death? and (b) does better targetted screening based
on genetic tests reduce that risk yet further?
For now insurers are able to make use only of family history of FAP when determin-
ing premiums. A person with a family (parental) history of FAP has a 50% chance
of also developing FAP and this is reflected in the premium calculation. However if
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insurers were able to use the results of genetic tests, a person known to be at high
risk of developing FAP, following a genetic test, would be likely to have a higher
premium.
If genetic tests can be used by insurers, people with a family history of FAP may
be unwilling to be genetically tested and screened as these results would have to
be disclosed and would be detrimental to their insurance premium. On the other
hand people may get tested and screened but not attempt to buy insurance as they
believe that they would not be successful or that their premiums would be too high
for them.
Here we aim to show that in the case of FAP the use of genetic testing and screening
can be very beneficial to possible FAP sufferers and therefore there may be no need
for insurers to consider FAP to be a problem when calculating premiums, as long as
the possible sufferers get genetically tested and follow a regular screening program.
Ideally, we would carry out a standard survival analysis to estimate rates of onset
of FAP. However, this is ruled out because we have almost no information about
those who did not suffer onset, that is, censored observations. Therefore we are
limited to analysing those whose age at onset was observed, for the same reasons
we are also limited in the analysis that can be carried out. Although this ‘sample’ is
obtained retrospectively, we may legitimately ask questions about its composition
conditioning on the fact of onset. We will look at three factors: calendar year of
onset; year of birth; and method of detecting FAP.
9.3 Year of Onset of FAP
Affected persons were divided into two groups, those who had suffered onset before
a given calendar year Y and those who had suffered onset in or after year Y . Figure
9.1 shows the empirical survival functions (‘survival’ meaning free of FAP) for these
two groups, on the left with Y = 1990, and on the right with Y = 2000. The
former shows little difference between the two groups; the latter suggests there is a
slight difference but only 13 people suffered onset after 2000. Formally, using the
Wilcoxon Mann-Whitney (WMW) test of equal medians, there is no difference in
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Figure 9.1: Left: Probability of survival given ‘onset occurred before 1990’ and
probability of survival given ‘onset in or after 1990’.
Right: Probability of survival given ‘onset occurred before 2000’ and probability of
survival given ‘onset in or after 2000’.
either case (Y = 1990, p = 0.616 and Y = 2000, p = 0.798).
9.4 Year of Birth
The earliest year of birth in the data is about 1900 and the latest about 2000. We
compared two groups, those born before calendar year B and those born in or after
year B. Figure 9.2 shows, on the left, empirical survival functions for B = 1950, and
on the right for B = 1970. There is a clear difference but the maximum possible age
at onset is different for each group; we are not comparing like with like. Specifically,
for each choice of B we are comparing the random variables X1 and X2 where:
X1 = Age at onset given Born before year B (9.1)
X2 = Age at onset given Born in or after year B. (9.2)
However, since we are viewing these data retrospectively from the present time T ,
X1 and X2 have different ranges: X1 ranges over all human lifetimes whereas X2
cannot exceed T −B. To compare like with like, we must exclude those born before
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Figure 9.2: Left: Probability of survival given ‘born before 1950’ against the prob-
ability of survival given ‘born in or after 1950’.
Right: probability of survival given ‘born before 1970’ against the probability of
survival given ‘born in or after 1970’.
year B whose age at onset exceeds T − B. In other words, compare X∗1 and X∗2
where:
X∗1 = Age at onset given Born before B & not exceeding T − B (9.3)
X∗2 = Age at onset given Born in or after year B. (9.4)
Figure 9.3 shows the results with X∗1 limited to age 50 (B = 1950) and age 30
(B = 1970). A difference remains in both cases. This suggests that those born in
or after 1950 were diagnosed earlier than those born before 1950
9.5 Method of Diagnosis
Finally, we stratify by the method of diagnosis, whether by screening or in some
other way (death, onset of cancer and so on). Figure 9.4 suggests that the curves
are different until they cross at nearly age 60. The hypothesis test of equal medians
shows a difference (p < 0.001). Screening does seem to result in an earlier diagnosis
of FAP and reduced cancer risk.
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Figure 9.3: Left: Probability of survival given ‘born before 1950 and onset before
age 50’ against the probability of survival given ‘born in or after 1950 and onset
before age 50’.
Right: Probability of survival given ‘born before 1970 and onset before age 30’
against the probability of survival given ‘born in or after 1970 and onset before age
30’.
9.6 Screening and Cancer Risk
Figure 9.5 illustrates how screening and now genetic testing have altered substan-
tially the cancer risk associated with FAP. It presents three alternative life histories.
At the top is the most likely life history in the absence of screening: the first event is
the diagnosis of CRC followed by post-onset diagnosis of FAP. In the middle is the
life history of someone who undergoes screening because of a family history of FAP.
The screening allows treatment to follow the diagnosis of FAP, with fewer cases
proceeding to CRC. At the bottom is the identification of high-risk individuals by
genetic testing, making screening more effective.
In our sample, 152 people fall into the three groups; 26 suffered CRC without
any previous diagnosis of FAP (top), 90 were diagnosed with FAP through family
screening (middle), and 36 were determined to be at high risk through genetic
testing (bottom). (Note that year of birth was not needed here so more individuals
could be included here than above.)
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Figure 9.4: Time to onset for those diagnosed through screening compared with
those diagnosed through other methods.
Of the 152 people who have FAP 17.1% developed CRC without any diagnosis of
FAP, 6.6% developed CRC after being diagnosed through family screening while
no-one so far has developed CRC after genetic testing. Of course, genetic testing
is relatively recent. the latter may be because it is too soon for these people to
have developed CRC, or because their risk of suffering CRC after early treatment
is genuinely very low.
Screening and genetic testing does enable earlier diagnosis. The average ages at di-
agnosis of those diagnosed through having CRC, those diagnosed through screening
and those diagnosed through screening as a result of genetic testing is 42, 32 and
19 respectively. Since most people have surgery as soon as FAP is diagnosed (88%
of people in the pedigrees used here) this also reduces the risk of developing CRC.
Ja¨rvinen (1992) determined that those diagnosed through symptoms alone have a
65.5% risk of colorectal cancer, whereas those diagnosed through family screening
have a 6.6% risk. This is only slightly higher than the population lifetime risk of
CRC, 2−5%. Evans (1993) says that screening at risk patients with a combination
of genetic markers, screening for congenital hypertrophy of the retinal pigment ep-
ithelium and a negative bowel investigation may reduce initial risk of cancer from
50% to well below 1%.
Both Bu¨low (2003) and Heiskanen (2000) say that the use of screening improves
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the survival of FAP sufferers. Bu¨low found that the survival rate is 44% for people
diagnosed with FAP through symptoms (probands) and 94% for those diagnosed
through screening based on family history (call-up). Heiskanen found that there was
a significant increase in survival for the call-up patients compared to the probands
after colectomy or proctocolectomy.
9.7 Conclusions
Here we address the questions: (a) does a family history of FAP, or a genetic test
result, indicate significantly increased life and critical illness insurance risk? and (b)
is there any reason for a person in a high-risk family to be deterred from undergoing
testing and screening because of the insurance implications?
The results above show that the age of diagnosis of FAP is even lower when screening
follows genetic testing than when screening is used alone. As the risk of CRC is
reduced to almost the population level (3 − 5%; Evans, 1993) by screening alone
(6.6%; Ja¨rvinen, 1992) it is plausible that genetic testing will reduce the risk further;
how much further we cannot yet say. It may be that earlier treatment, through
better targetted screening, will eliminate the excess risk.
The risk of CRC need no longer be significantly higher for those at risk of FAP, hence
insurance premiums need not be significantly higher either, provided the individual
is actively following a screening program. Those at risk should not be deterred from
being tested and screened because of any perceived implications for life and critical
illness insurance. We suggest that, in this case, insurance and clinical interests are
aligned instead of in opposition. However, this leaves open the question of how
an insurer should respond in case a person exercises their autonomy over medical
decisions, and chooses not to be tested or screened.
The findings here suggest that co-operation between those with a family history
of FAP and insurers would result in benefits for both parties. FAP sufferers could
get tested, screened and treated without worrying about how it will affect their
insurance and insurers can cross FAP off their list of genetic disorders to worry
about.
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Chapter 10
Conclusions and
Recommendations for Future
Work
In this investigation we have determined the premium rates that would be charged
to known mutation carriers for two specific genetic disorders, Huntington’s Disease
and BRCA1-related breast and ovarian cancer, in order to see the possible effects
that knowing the result of a genetic test for either of these disorders would have.
However, as we had pedigree data available for both of these genetic disorders, we
were able to do more than just determine the premium rate appropriate for a known
mutation carrier.
Very few studies concerning genetic disorders and insurance have been able to de-
termine the sampling distribution of the premium rate as neither the variability of
the parameters of the distribution of the age at onset nor the data behind these
estimates are routinely available. Here we used the available pedigree data to de-
termine the variance matrix for the parameters of the distribution of age at onset.
As a result we were then able to estimate not only the premium rate but also the
variance, and therefore a measure of reliability, of the premium rate.
Another area of interest when examining genetic disorders is the effect of ascer-
tainment bias on the distribution of the age at onset and the resulting premium
rates. Again, as we had the pedigree data available, we were able to adjust for
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ascertainment bias while estimating the distribution of age at onset and determine
the sampling distribution of the premium rate after adjustment for ascertainment
bias was carried out.
Being able to use actual pedigree data allows the investigation of genetic disorders
and the premium rates associated with them to move a step further.
10.1 Huntington’s Disease
10.1.1 Onset Rates
The distribution of age at onset for HD was assumed to follow a Normal distribution.
The estimated parameters of the distribution of the age at onset were higher than
those estimated by the majority of previous epidemiological studies (see Table 4.2).
A plot of the estimated distributions of age at onset and the distribution of age at
onset of two published studies showed that the differences were relatively small (see
Figure 7.2).
The different assumptions made about the data missing from the pedigrees made
little overall impact on the parameter estimates. The decision of whether to assume
‘earliest’ or ‘latest age at onset’ resulted in small, insignificant differences in the
estimates.
10.1.2 Premium Rates
As HD is a fully penetrant genetic disorder it is unlikely for a mutation carrier to
not suffer onset of the disorder if they live long enough. This, coupled with the low
mean age at onset, obtained from the pedigree data, of about 44 years old, results
in there being very few instances where a known HD mutation carrier would be
offered critical illness insurance.
The definition of CI event used by insurers, represented here by Stage 2 or Stage 3
of Harper’s progression, makes little difference to whether a known mutation carrier
would be offered insurance or not, with the only exception being that using Stage 3
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as the CI event would result in mutation carriers being able to take out insurance
at age 50 for a term of 10 years.
The estimated sampling distribution of the premium rates show that there is more
variance in the estimated premium rate at lower ages and policy terms. Any confi-
dence intervals, based on the sampling distributions, would not include 500% of the
standard premium, with the exception of a policy taken out at age 50 for 10 years
given the CI event being Stage 3 of Harper’s progression. It is also clear that even
charging the minimum bootstrapped premium rate would result in an insurance
application being denied.
There is sufficient actuarial evidence, in the case of CI insurance, that the premium
rates are increased for known mutation carriers to such a level that they would
not be offered insurance. This, in itself, is not new but the methodology that
we have used here, based on data from real pedigrees, parametric modelling and
bootstrapping provides a robust criterion for any approach that GAIC might take
to applications in future, which in general may not be as clear-cut as that of HD
(see Section 10.4).
10.2 BRCA1 related breast and ovarian cancer
10.2.1 Onset Rates
For BRCA1-related breast and ovarian cancer it was assumed that the distributions
of age at onset followed Gamma distributions. The parameters that were estimated
using the pedigree data, and assuming the penetrance to be that estimated in a
selection of previous studies, were very similar for both breast and ovarian cancer.
As with HD, the different methods used to deal with the missing data in the pedi-
grees did not have a significant effect on the resulting parameter estimates, with
the exception that whether the ‘earliest’ or ‘latest age at onset’ was used makes a
small difference to the estimated parameters, but no significant difference to the
actual distribution of age at onset.
The penetrance estimates used did not significantly affect the estimates of the pa-
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rameters, but made a difference to the overall age at onset distribution (see Figures
8.1 and 8.2). The estimated distribution of the age at onset for both breast and
ovarian cancer are very similar to that used by Macdonald et al. (2003a), see Figure
8.3.
10.2.2 Premium Rates
BRCA1-related breast and ovarian cancer are highly penetrant disorders so it is
therefore not a surprise that the premium rates that would be charged to a known
BRCA1 mutation carrier would mean that they would not be offered insurance for
the majority of ages and policy terms.
The choice of penetrance estimates used when estimating the distributions of age
at onset has an effect on the sampling distributions of the premium rates, with the
rates resulting from using the higher penetrance estimates of Lalloo et al. (2006)
being higher than when using the penetrance estimates of Antoniou et al. (2006).
However, due to the high penetrance of both breast and ovarian cancer, regardless
of which penetrance estimates were used, the resulting sampling distribution of the
premium rates would not affect the overall conclusions.
Again the investigation carried out here suggests that the result of a genetic test
for BRCA1 would be of interest to insurers as the premium rates that would be
appropriate for a known mutation carrier would result in them not being offered
critical illness insurance. The standard deviations of the premium rates add to the
evidence, in that although there is a lot of variability in the estimated premium
rates, especially for lower ages and policy terms, the variability is not so high that
an applicant would be offered insurance at a premium rate in the plausible range.
10.3 Effect of adjusting for ascertainment bias
Adjustment was made for ascertainment bias by removing a proband from each
pedigree, where the proband was randomly selected from the possible probands in
each pedigree. In addition to this, for breast and ovarian cancer, an adjustment
for ascertainment bias was also made by removing two randomly selected probands
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from each pedigree as BRCA1-related breast and ovarian cancer families are likely
to have been identified due to multiple cases.
Carrying out adjustment for ascertainment bias for BRCA1-related breast and ovar-
ian cancer resulted in slight differences to the distribution of the premium rates,
specifically removing one proband increased the standard deviation and removing
two increased it further. As noted in Section 8.4 the lack of a significant effect of
ascertainment bias on the location of the sampling distribution of the premium rate
for BRCA1-related breast and ovarian cancer could be due to the fact that, instead
of estimating the penetrance of both disorders within the likelihood maximisation,
we used published penetrance estimates.
In contrast, although the adjustment for ascertainment bias for HD did not make
any difference to the overall conclusions concerning whether an applicant would
be insurable or not, there was a significant difference in the estimated sampling
distributions of the premium rate after adjusting for ascertainment bias. The pre-
mium rate was reduced significantly after adjusting for ascertainment bias and the
standard deviation was increased. As HD is fully penetrant, and is an extreme ex-
ample of a genetic disorder, it is not surprising that ascertainment adjustment does
not alter the fact that a known mutation carrier would be declined critical illness
insurance.
The difference in the sampling distributions of the premium rate for known HD
mutation carriers with and without ascertainment bias adjustment highlights the
importance of adjusting for ascertainment bias and the effect it has on the premium
rate. For a less penetrant disorder the adjustment for ascertainment bias may sig-
nificantly affect the decision on whether to sell a known mutation carrier insurance
or not.
10.4 Implications for GAIC criteria
As discussed in Section 3.2 it is up to GAIC to decide whether a genetic test result
can be used by an insurer. Applications are made to GAIC, by the ABI, in relation
to a specific genetic test and a specific insurance product. Each application must
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include:
1 Evidence that the genetic test is accurate and reliable.
2 Clinical evidence that the the presence of a mutation leads to implications for
the health of an individual.
3 Actuarial evidence that there is an increased probability of the insured event
occurring if the mutation is present.
Evidence in support of both points 1 and 2 can be obtained from epidemiological
and genetic studies. The investigations carried out here relate to possible evidence
for point 3 of GAIC’s criteria list, for critical illness insurance.
It has been shown here, for both Huntington’s Disease and BRCA1-related breast
and ovarian cancer, that the probability of developing the critical illness event is
greatly increased when the related mutation is known to be present. In fact, for
both disorders, the probability is increased to such an extent that the premium
rates appropriate for a known mutation carrier would result in them being declined
critical illness insurance at almost all ages and policy terms.
The results obtained in this thesis confirm the already well-known fact that for both
disorders known mutation carriers would not not be offered critical illness insurance.
For the first time though we are able to provide an estimate of the reliability of the
conclusion, using the sampling distributions of the premium rates. Being able to
assess the reliability of the premium rate estimates will be of even more importance
when considering disorders that do not have such extremely high penetrance.
10.5 Familial Adenomatous Polyposis
Examination of the FAP pedigrees illustrated that genetic testing, in addition to
screening, results in possible FAP mutation carriers being diagnosed earlier. The
risk of colo-rectal cancer is reduced to almost the population level by screening
alone so it is plausible that genetic testing will reduce the risk further
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We would conclude that a known FAP mutation carrier should not be put off seeking
critical illness insurance. Rather we would say that co-operation between those with
a family history of FAP and insurers would result in benefits for both parties. Those
with a family history of FAP could then undergo genetic testing, follow the resulting
screening program and be treated, in the event that FAP develops, in such a way
that the risk of developing colo-rectal cancer as a result of being an FAP carrier
would be minimised, or perhaps even eliminated. Insurers would then be able to
remove FAP from the list of genetic disorders to worry about in terms of insurance.
10.6 Further Work
For both breast and ovarian cancer and Huntington’s Disease the estimation of the
distributions of age at onset would benefit from using data from more pedigrees, if
it was available.
10.6.1 Breast and Ovarian Cancer
Although we found evidence of an effect of ascertainment adjustment on the esti-
mated sampling distribution of the premium rate it would be interesting to see if
this was affected by the fact that we used published penetrance estimates. It would
be of interest to carry out the parameter estimation for BRCA1-related breast and
ovarian cancer again, but to also estimate of the penetrance of both breast and
ovarian cancer based on the data.
By estimating the penetrance estimates, instead of using published estimates, the
effect of ascertainment bias adjustment could be investigated in more depth. In
particular if the estimation of the penetrance of breast and ovarian cancer resulted
in there being an effect of either method of ascertainment bias adjustment then the
relationship between the adjustment used and the resulting sampling distributions
of the premium rate could then be looked at.
The likelihood maximisation could be extended to include the penetrance of both
breast and ovarian cancer as unknown parameters. This would result in a total
of six parameters being estimated which would substantially increase computation
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time. The increase in the number of the parameters being estimated is also likely
to result in more variation in the estimates, unless more data is used.
The distributions of age at onset for breast and ovarian cancer were only esti-
mated for BRCA1 mutation carriers as there were not enough pedigrees available
for BRCA2 carriers. Identifying more BRCA pedigrees, especially those families
carrying BRCA2, would enable the estimation of the distributions of age at onset
of both breast and ovarian cancer for both BRCA1 and BRCA2 mutation carriers.
The premium rates could then be compared for BRCA1 and BRCA2 carriers and
it could be determined whether there was a significant difference in the effect of
BRCA1 and BRCA2 and also to investigate whether the sampling distributions of
the premium rates after adjusting for ascertainment bias behaved differently for the
two mutations.
Another possibility for future work in the case of BRCA1/2-related breast and
ovarian cancer is to consider the model of Antoniou et al. (2002). They modelled
the effects of BRCA1, BRCA2 and a polygenic effect, finding that their polygene
accounted for a large proportion of familial breast cancer. Using the pedigree data
available here we could attempt to obtain the sampling distributions after allowing
for the polygene effect.
10.6.2 Huntington’s Disease
If it was possible to determine the CAG repeat lengths for each known mutation
carrier within the pedigrees then it could be possible to incorporate this CAG repeat
length into the estimation of the age at onset distributions and any subsequent
estimation of the premium rate. It would be very difficult and time-consuming to
get this data, however, and to be able to estimate the age at onset distribution for
a number of CAG repeat lengths it is highly likely that significantly more pedigrees
would be required.
In this investigation we adjusted for ascertainment bias by removing randomly
selected probands from each pedigree; this was done as we did not know who the
actual proband was in each pedigree. With more investigation into the medical
records it may be possible to find out which member of each pedigree was actually
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the proband. It may also be possible to investigate the effect that different methods
of ascertainment adjustment would have on the premium rates and determine how
the method used here compares.
10.6.3 Familial Adenomatous Polyposis
As noted in Section 9.2, due to a lack of information about the people who had not
suffered onset of FAP, we could not carry out any parametric testing. Although it
may be of interest if more information could be found about all members of the
pedigrees, perhaps through further investigation of the records or perhaps contact
with the families, it would not enable us to investigate FAP in any more depth than
has been done here.
As the risk of an FAP mutation carrier developing colo-rectal cancer (CRC), the
critical illness event associated with FAP, appears to be decreasing, especially when
screening is carried out, any investigation of the age at onset of CRC in FAP carriers
would require data from significantly more pedigrees than are available here.
Also as a result of the changes in detection and treatment, the younger generations of
families known to carry the FAP mutation are diagnosed, and subsequently treated,
earlier. This could result in being unable to treat the older and younger generations
of the pedigrees as the same when carrying out modelling and estimation.
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Appendix A
Adult Polycystic Kidney Disease
A.1 Epidemiological Review
Adult polycystic kidney disease (APKD) is a genetic disorder that primarily affects
the kidneys. Cysts develop in the kidneys causing them to enlarge, often leading
to kidney failure. The first symptom of APKD is often high blood pressure as the
cysts squeeze the blood vessels. Many other symptoms may follow including fatigue,
headaches, frequent urination, blood in the urine, kidney stones and urinary tract
infections (Milutinovic et al., 1984).
Serious problems can occur as a result of these symptoms. These include brain
aneurysms, enlargement of the heart, cysts in the pancreas and liver as well end-
stage renal disease (ESRD). According to the PKD Foundation over 60% of people
with APKD develop ESRD, where the kidneys can no longer function and can only
be treated through renal replacement therapy (RRT), which consists of dialysis
and/or kidney transplantation.
Robinson & Hawkins (1981) estimated that APKD accounts for 6 − 9% of ESRD
in Europe, while Davies et al. (1991) estimated that this proportion was slightly
higher in Wales, 10.4%. In a study carried out in the US it was found that 6.5% of
all transplants following ESRD were because of APKD (Fitzpatrick et al., 1990),
while Abbott & Agodoa (2002) carried out a study in the US over 10 years later
and estimated the proportion of all those with ESRD because of APKD to be 1.5%.
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Garcia Iglesias et al. (1983) stated that because of improvements in medical care
and diagnostic techniques APKD has been diagnosed earlier and more frequently in
recent decades and this, along with therapeutic advances, explains the improvement
in kidney and patient survival.
A.1.1 Genetic Testing
APKD is a single-gene autosomal dominant disorder, passed on from one or other
parent through a faulty APKD gene. At present two genes have been identified as
causing APKD to develop, PKD1 and PKD2. Reeders et al. (1985) showed that
the PKD1 locus was closely linked to the α-globin locus on chromosome 16 and it
was later fully sequenced and isolated to location 16p13.3-13.1 by the International
Polycystic Kidney Disease Consortium (1995) and Hughes (1995).
Romeo et al. (1988) reported a family with APKD but with an absence of linkage
between disease mutation and α-globin, indicating that there is a second mutation.
Wright et al. (1993) found most APKD families to be due to mutations at the PKD1
locus, but not all. Wright et al. (1993) estimated the likelihood that there are 2
APKD loci to 2,514.9 times the likelihood that there is a single locus for APKD.
Peters et al. (1993) linked the second APKD gene, PKD2, to chromosome 4. This
was later isolated to 4q21-23 (Mochizuki et al., 1996).
Torra et al. (1996) found that PKD1 mutations account for approximately 85−90%
of all people with APKD, while PKD2 accounts for the majority of those that do
not carry PKD1. They also noted that there is a possibility of a third gene, PKD3,
which has yet to be identified, as Daoust et al. (1995) agreed.
The identification of the PKD1 and PKD2 genes enables presymptomatic genetic
testing. Linkage analysis is available but is not always suitable as it relies on a
large number of affected family members to determine which of the mutations the
family carries. If there are enough affected relatives to identify the mutation linkage
analysis is very accurate (Harris & Torres, 2006). Sequence analysis is also used to
identify PKD1 and PKD2 mutations and the detection rate for this test is found to
be about 85% (Rosetti et al., 2001 & 2002).
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Sujansky et al. (1990) investigated the attitudes of those with APKD and those
at risk of APKD to genetic testing. They found that both groups had a good
knowledge of APKD and that both groups were concerned about health problems
and passing the gene on to children. 97% of the at-risk group said that they would
use genetic linkage in order to define their own gene status.
A.1.2 Ultrasonographic Scan (USS)
APKD can also be diagnosed without the use of genetic testing. An ultrasono-
graphic scan (USS) is a test that uses ultrasound to examine the kidneys and
determine whether cysts are present and if so the extent of them. Using USS a
person is diagnosed as having APKD if there are cysts in both kidneys and one of
the kidneys has two or more of these cysts present.
In people with APKD the growth of cysts is age related, therefore the reliability
of USS should be age related also. In fact Parfrey et al. (1990) and Bear et al.
(1992) found that the sensitivity of USS is very close to 100% after the age of 30.
Demetriou et al. (2000) said that although USS was not recommended as a routine
diagnostic procedure for those under 14 for people with PKD2, it was 100% reliable
in excluding PKD2-related APKD in family members at 50% risk over the age of
30.
Dobin et al. (1993) found that the age at diagnosis follows a Normal distribution
with mean 20 and standard deviation 15.94. They also found that the penetrance
of cysts was over 70% by age 30, over 95% by age 50 and 99% by age 55.
Bear et al. (1984) estimated the probability of clinical diagnosis of APKD for those
at 50% risk as 0.011, 0.041, 0.115, 0.299 and 0.404 at age 10, 20, 30, 40 and 50
respectively. The probability of ultrasonographic detection of asymptomatic APKD
is estimated as 0.222, 0.657 and 0.855 at age 5, 15 and 25, respectively, while the
probability of having APKD following a normal ultrasonogram is 0.46, 0.28 and
0.14, respectively, for people at 50% risk, in their 1st, 2nd or 3rd decade.
Age at Diagnosis Through Ultrasound
USS screening is recommended to those at 50% risk of having APKD as it is so
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reliable in detecting the cysts produced in people with APKD. One study found
that those diagnosed through USS due to family screening had a mean age at
diagnosis of 23 years while those diagnosed due to symptoms had a mean age of 40
at diagnosis (Davies et al., 1991).
Torra et al. (1996) found that the age of diagnosis using USS was lower for those
with PKD1 than those with PKD2, 27.4 years versus 41.4 years, while Wright et al.
(1993) estimated the age at diagnosis for those with PKD1-related APKD was 25
years compared with 37 years for non-PKD1 related APKD. Other studies found
the mean age at diagnosis through USS to lie between 31 and 45.9 years (Sujansky
et al., 1990, Gonzalo et al., 1990 and Roma˜o et al., 2006).
Ravine et al. (1992) stated that non-PKD1 linked APKD had a much milder phe-
notype than that of APKD linked to PKD1. Iglesias et al. (1997) agreed saying
that there is a milder APKD phenotype for those with PKD2 rather than PKD1.
A.1.3 Age at Onset of ESRD
Most of the epidemiological studies that have been carried out have concentrated
on the age at onset of ESRD. Table A.1 shows some of the estimates obtained from
these studies. Some of the studies in the table have estimates for PKD1 and non-
PKD1; these studies were carried out before PKD2 was located and the non-PKD1
group is likely to be the same as the PKD2 group in other studies. This research
indicates that the mean age at onset of ESRD is earlier for those with PKD1 rather
than PKD2.
Churchill et al. (1984) found that the probability of a person with APKD being alive
without ESRD was 77% by age 50, 57% by age 58 and 52% by age 73. Gonzalo et
al. (1990) estimated this probability to be 74% by age 50, 51% by age 58 and 37%
by age 70, and Gabow et al. (1992) estimated it to be 71% by age 50, 53% by age
58 and 23% by age 70.
Milutinovic et al. (1984) found ESRD present in 5% of APKD patients younger
than 40 years old, in 33% of patients aged 40− 49 and in 47% of patients aged 50
years or older.
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Table A.1: Mean age at onset of ESRD for people with APKD.
Reference PKD1 non-PKD1 PKD2 APKD
Parfrey et al. (1990) 56.7 69.4
Bear et al. (1992) 56.3 68.7
Torra et al. (1996) 53.5 72.7
Hateboer et al. (1999) 54.3 74
Roma˜o et al. (2006) 45.4
Roscoe et al. (1993) estimated the mean age at onset of ESRD to be 54.4 for those
with APKD and 50.4 for those without APKD, while Abbott & Agodoa (2002)
estimated these ages to be 55.24 and 60.56, respectively. It is unclear whether
persons with APKD suffer onset of ESRD earlier or later than those without.
Wright et al. (1993) estimated that 75% of non-PKD1 related APKD patients had
not had ESRD by age 54 compared with 35% of those with PKD1 related APKD.
Gabow et al. (1984) found that a number of factors related, independently, with
worse renal function at a given age; namely PKD1 gene, younger age at diagnosis,
male gender and hypertension.
A.1.4 Survival
The survival of those with APKD depends on what form of treatment they undergo,
transplant or dialysis, and the form of treatment they undergo depends on their
health at the time of ESRD. It was found that, among those that suffer ESRD,
healthier people are put on the transplant waiting list (Wolfe et al., 1999). Whether
on the waiting list or not people who have ESRD usually underwent dialysis. It
was found that the long-term survival was better for those on the waiting list that
eventually undergo transplant than for those that did not have a transplant.
Rabbat et al. (2000) found that factors associated with the death of patients on
the waiting list and the death of patients that underwent transplant were older age
and diabetes. Longer time on the waiting list before transplant was also associated
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with those that died after transplantation.
Port et al. (1993) found that the risk of dying increased early after transplant but,
given survival to 365 days, then decreased to a beneficial long-term effect of 60%
risk reduction compared with similar patients on dialysis. Meier-Kriesche et al.
(2001) found that the risk of death decreased by 30% for those that underwent
transplantation and by 23% for those that were on the waiting list for transplanta-
tion compared with those on dialysis but not on the waiting-list at the time of the
study.
McDonald et al. (2002) found that cadaveric transplant was associated with an
increase in mortality during the first 3 months after the operation, compared with
those undergoing dialysis. There was then a reduction in risk of death of 73% at 6
months and 81% at 12 months after the operation.
Murphy et al. (2000) studied the differences between hemodialysis and peritoneal
dialysis and found that the risk of death was reduced by 17% for those on hemodial-
ysis after 6 months.
Fick et al. (1995) found that the main causes of death for those with ESRD were
infection (30%) and uremia (28%) before 1975 and cardiac disease, (36%) and in-
fection (24%) after 1975. Roscoe et al. (1993) agreed, finding that 34% died from
cardiac disease and 20% died from infection, while Harris & Brown (1998) found
that 57% died from cardiac disease and 14.3% died from infection.
As with age at onset of ESRD, there have been mixed results from investigations
into the differences in survival between those with APKD and those without APKD.
Perrone et al. (2001) found that those with APKD had a significantly better survival
than non-APKD patients, while, Fitzpatrick et al. (1990) found that the survival
was similar for both APKD and non-APKD groups.
Ravine et al. (1992) found the survival to be better for non-PKD1 related APKD
patients than for PKD1-related APKD patients, the median survival times being
71.5 and 56.0 years, respectively. Johnson & Gabow (1997) found that those with
PKD2 survived longer than those with PKD1 (68 versus 53 years), women had
better survival than men (56 versus 52 years), people diagnosed before 30 had
worse survival (49 versus 59 years) and those with hypertension before age 35 had
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worse survival (51 versus 65 years).
A.1.5 Gender Difference
Gretz et al. (1989) found the median age at ESRD was 52.5 years for men and 58.0
years for women, while Ishikawa et al. (2000) found that men with APKD started
hemodialysis earlier than women, at age 55.9 compared with age 57.2.
Magistroni et al. (2003) estimated the mean age at onset of ESRD for females to
be 76 years and for males to be 68.1 years and the median age at CRF (Chronic
Renal Failure) to be 72.5 for females and 63.7 for males. Here ESRD is defined as
severe chronic renal failure while CRF is defined as moderate chronic renal failure.
Hateboer et al. (1999) found that there was a gender difference for those with PKD2
but not for those with PKD1. The median survival with PKD2 was estimated as
71.0 for women and 67.3 for men.
These all suggest that there is some evidence of a gender difference for APKD, with
men suffering onset of ESRD earlier than women.
A.1.6 Hypertension
It has been found that the most important treatable factor associated with faster
progression to ESRD in APKD patients is hypertension; the average age of entry
into ESRD is 12 years earlier for hypertensive patients than normotensive APKD
patients (Gabow et al., 1992). Gonzalo et al. (1996) found that prior to renal insuf-
ficiency a high arterial pressure makes a significant contribution to renal function
deterioration.
A.2 Critical Illness Insurance Studies
Gutie´rrez & Macdonald (2003) This study introduced a model for critical illness
insurance which has, subsequently, been used in a number of other studies. Figure
A.1 shows the CI insurance model, where the CI event for APKD is end-stage renal
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disease (ESRD).
The population is divided into three sub-groups:
• Those with no family history, who are not at risk.
• Those at risk because of a family history but who do not carry a mutation.
• Those at risk because of a family history and who do carry a mutation.
The transition intensities in Figure A.1 have to be estimated for each of these
subgroups.
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Figure A.1: A multiple state model for APKD in Critical Illness insurance.
This study used data from two sources; Churchill et al. (1984) and the U.S. Renal
Disease System (USRDS) (1999) to estimate the age-dependent rate of onset of
ESRD, µ01(x). The Churchill study, unusually, published the numbers of events,
censored cases and persons at risk, which enabled a function to be fitted to the
intensity µ01(x). The USRDS study published numbers of cases of ESRD that
were due to APKD. These values were used to estimate the onset rates and to fit
a function to represent the distribution of age at onset. Churchill et al. (1984)
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adjusted for any possible ascertainment bias by removing the probands from the
analysis.
The estimation of the other intensities, µ02(x) and µ03(x), is discussed in Section
6.3
Given all of these intensities the authors calculated level net premiums for a level
unit sum assured under a CI insurance contract for a number of ages and policy
terms.
In accordance with insurance practice, the level net premiums for mutation carriers
were given as a percentage of the level net premiums for non-carriers. This study
found that carriers would be uninsurable as the premiums charged would be above
500% of the OR premium rate.
This study also extended the CI insurance model to account for moratoria and ad-
verse selection. They found that if a moratorium covers only genetic test results
and not family history, the costs of adverse selection (in terms of increased premi-
ums) are very small. If the moratorium is extended to include family history, the
premiums were found to increase slightly.
A.3 Available Data and Problems
There were 46 pedigrees available for APKD noting any available information on
whether each person underwent ultrasonographic screening (USS), the result of any
genetic testing, when they were diagnosed as having APKD and whether either
dialysis or transplantation was required.
The critical illness event for APKD is end-stage renal disease (ESRD) where the
kidneys fail and can only be treated through dialysis and transplantation. The
problem with the APKD pedigrees is that, although a number of people received a
transplant or underwent dialysis, it was not usually noted when a person actually
suffered ESRD. For this reason we have not carried out an investigation into the
age at onset of ESRD.
Further investigation of the medical notes could be carried out to identify the age at
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which ESRD was actually reached. Although knowing that a person has undergone
treatment, either transplant or dialysis, indicates that a person is likely to have
suffered onset of ESRD it is not conclusive. So, although we could investigate the
age at onset of ESRD using the age at which either dialysis or transplant as a
surrogate for onset of ESRD, we could not be certain that the results would be
plausible.
The other aspect of the pedigrees which could present a problem is that the PKD
mutation associated with each family, PKD1 or PKD2, is only known, or noted, for
a small number of pedigrees.
Although investigating the critical illness insurance premiums for those known to
carry an APKD mutation would be interesting it would have no relevance in the
discussion of genetic testing and insurance as APKD has been removed from the
list of genetic disorders which are of interest to insurers due to the use of USS and
the treatments available.
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Appendix B
Maximum Likelihood Estimation
B.1 Maximising the Likelihood
The Nelder-Mead downhill simplex method was used to compute the maximum
likelihood estimates by minimising the minus log-likelihood.
The method is outlined here, for more details see Nelder and Mead (1965).
P is defined as a (n + 1)× n array containing the points of a (n + 1)-dimensional
simplex, where n is the number of parameters to be estimated.
The first row of P , P0, is the set of initial parameter estimates, chosen intuitively.
The ith row of P is calculated as Pi = Po + λei, i = 1, ..n, where e is the set of
unit vectors and λ is chosen to reflect the probable scale of the parameters, usually
λ = 1.0.
If yi is the value of the likelihood at point Pi then we define yh = max(yi) and
yl = min(yi).We also define P¯ , a 1× n array, as P¯i = 1n
(∑n+1
j=1 Pij
)
, for j = h
and
∆ = 2
|yh − yl|
|yh|+ |yl|+ 1.0e− 10 . (B.1)
The minimisation then follows the steps below, with the function being the minus
log-likelihood:
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A new point, P ∗, is calculated;
P ∗ = (1 + δ) P¯ − δPh. (B.2)
If the value of the function at this new point, y∗, is less than yh and more than yl
the highest point of the simplex, Ph, then becomes P
∗.
If, however, y∗ is less than yl a new point is determined;
P ∗∗ = (1− ω) P¯ + ωP ∗. (B.3)
If the value of the function at this new point, y∗∗, is less than yl then the highest
point of the simplex becomes this new point Ph = P
∗∗.
If, however, y∗∗ is bigger than yl then the highest point of the simplex Ph becomes
P ∗.
If the value of the function at point P ∗ is higher than at all other points of the
simplex except for at Ph then Ph = P
∗. A new point is then determined
P ∗∗∗ = (1− η) P¯ + ηPh. (B.4)
If the value of the function at this new point, y∗∗∗, is less than the minimum of yh
and y∗ then Ph becomes P ∗∗∗ otherwise new points are calculated Pi = (Pi + Pl) /2.
These steps are repeated until ∆ is less than some specified value. At this point the
optimal values for the parameters are those at the lowest point of the simplex, Pl.
The optimisation used here is based on a function from Numerical Recipes in C:
The Art of Scientific Computing.
B.1.1 Example
To explain the simplex method in more detail we will follow an example for a
one-parameter function over two-dimensional space.
We begin with the simplex, in this case a triangle, obtained from the points P0 =
(0, 0), P1 = (0, 1), and P2 = (1, 0), (a) in Figure B.1, where λ = 1. Suppose the
point which gives the maximum value of the function, Ph, is P2.
Then P¯1 = (P01 + P11) /2 = (0+0)/2 = 0 and P¯2 = (0+1)/2 = 0.5, so P¯ = (0, 0.5).
With δ = 1 we then get P ∗ = (−1, 1).
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If yl < y
∗ < yh P ∗ becomes the new Ph and a new triangle is made consisting of
points P0, P1 and P
∗, (b) in Figure B.1.
If, however, y∗ is less than yl, with ω = 2, P ∗∗ = (−2, 1.5). If y∗∗ is less than yl,
P ∗∗ replaces P2, (c) in Figure B.1, otherwise P ∗ does, (b) in Figure B.1.
If y∗ is greater than the value of the function at all points except Ph, then Ph
becomes either P ∗ or the old Ph whichever gives the lowest value of y.
Then with η = 0.5, if y∗ is less than yh then Ph = P ∗ and P ∗∗∗ = (−0.5, 0.75) (e)
in Figure B.1. Otherwise Ph = Ph and P
∗∗∗ = (0.5, 0.25), (d) in Figure B.1.
If y∗∗∗ is less than the minimum of yh and y∗ then Ph = P ∗∗∗, otherwise new points
are calculated, Step 4.4. These steps are repeated until ∆ reaches some specified
value.
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Figure B.1: Example of the Simplex Method for a one parameter function, in
two dimensions. (a) is the original simplex. (b) is the ‘reflection’ step, (c) is the
‘expansion’ step and (d) and (e) are ‘contraction’ steps.
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Appendix C
Other Tools Used
C.1 Numerical Integration
The main problem occurs when determining the value of the integral. This was
overcome by using numerical integration. Two of the methods that could be used
are the trapezium method and an acceleration of the Simpson’s method.
Trapezium Method:
∫ x0+∆x
x0
f(x)dx =
1
2
(f(x0) + f(x0 +∆x))∆x + O(∆x
3)
Milne’s (or Booles) Method:
1
90
[
7f (x0) + 32f
(
x0 +
∆x
4
)
+ 12f
(
x0 +
∆x
2
)
+ 32f
(
x0 +
3∆x
4
)
+ 7f (x0 +∆x)
]
Both methods are good approximations to the integral.
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C.2 Polynomial Approximation
C.2.1 Normal Distribution
There is a polynomial approximation to the Normal available when q follows a
Normal distribution. This is obtained from
P (Z < z) = 1− P (Z > z) ≈ 1− 1√
2π
exp
(
−z
2
2
) 5∑
j=1
bj
(1 + pz)j
Where
p = 0.2316419, b1 = 0.31938153, b2 = −0.356563782, b3 = 1.781477937,
b4 = −1.821255978, b5 = 1.330274428
This approximation has absolute errors of 7.5x10−8. Giving values very close to
the true Standard Normal distribution values.The actual values of the integral were
calculated by standardising the time, x:
z =
x− µ
σ
,
then using z to obtain an estimate of integration of the Normal distribution at time
x.
C.2.2 Gamma Function
Polynomial approximation was also used to determine Γ(α) when q follows a Gamma
distribution as it can be difficult to calculate for values of α that are not small whole
numbers.
Γ(z) =
(√
2π
z
(
p0 +
∑6
i=1
pi
z+i
))
(z + 5.5)z+0.5 e−(z+5.5)
Where
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p0 = 1.000000000190015, p1 = 76.18009172947146, p2 = −86.50532032941677,
p3 = 24.01409824083091, p4 = −1.231739572450155, p5 = 0.1208650973866179e−2,
p6 = −0.5395239384953e− 5
The function used to calculate Γ(z) in the program is based on a function from
Numerical Recipes in C.
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